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ABSTRACT
The synthesis of a series of polyfunctional Ca,Ca-disubstituted glycines is 
described. The lysine-like amino acid analog, Api, was prepared by regioselective 
hydrolysis of a triBoced hydantoin intermediate, followed by N“-protection to yield the 
first orthogonally protected ionizable Ca,Ca-disubstituted amino acid which is alicyclic 
in nature.
The synthesis of three orthogonally protected tetrafimctional amino acids, Bap, 
Bglu, and Basp was envisioned by the mild alkylation of the common organic synthon 
ethyl nitroacetate. Subsequent regioselective modification should allow for the 
isolation of the first synthesized tetrafimctional amino acid derivatives suitable for 
solid-phase synthesis. These amino acids are designed to induce peptide secondary 
structure by salt-bridge stabilization.
A series of peptides, incorporating 80% Ca,Ca-disubstituted glycines were 
synthesized to establish the helix stabilizing effect of amphipathicity in short helices. 
The peptides were prepared as the following permutation isomer pairs, Pi-10 & Ipi-10; 
Ach-lOa & Ach-10; and Cyh-10 & Ich-10. The peptides within each pair contains the 
same amino acid content, but with different sequences, each designed to preferentially 
adopt a 3 to- or a-helix. Circular dichroism studies confirm that amphipathicity is a 
significant factor in shifting the 3io-/a-helix equilibrium, notably so in micellar 
environments which mimic biological membranes.
The bioactivity of the aforementioned peptides was established by minimum 
inhibitory concentrations (MICs) against representative Gram-positive and Gram-
xix
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negative bacteria. The more hydrophobic peptides showed higher levels of cytotoxicity 
than the less hydrophobic peptides. In addition, in vitro studies using a strain of 
Brucella abortus expressing Green Fluorescent Protein (GFP) show that all of the 
peptides exhibit moderate to high selectivity towards the destruction of murine 
macrophages infected with the intracellular pathogen.
The spectroscopic properties of the o-nitrobenzenesulfonyl (oNBS) group have 
been established to confirm the practical use of this protecting group in solid-phase 
synthesis. Synthesis of the deprotection product, resulting from treatment of the oNBS- 
protected amino acid with mercaptoacetic acid / DBU, shows a linear correlation 
between concentration and absorption at 390nm. The molar absorptivity, £ 3 9 0  was 
determined to be 2950 cm*lM'[. This number was verified by solution-phase cleavage 
of several oNBS-protected Ca,Ca-disubstituted amino acids, which were synthesized by 
a modified Bolin procedure to allow for synthesis under non-aqueous conditions.
xx
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CHAPTER 1 
AN INTRODUCTION TO PEPTIDE CHEMISTRY
1.1. INTRODUCTION
Proteins, along with carbohydrates, lipids and nucleic acids, make up the 
cornerstones upon which life is based. Yet the structural, functional and catalytic
presumably due to the incredible ubiquity and complexity of proteins in nature. As 
structural molecules they provide much of the cytoskeletal framework of cells, as 
enzymes they act as biocatalysts for innumerable physiological functions, and as motile 
structures, they provide movement to cells and cell structures. They stabilize and 
control the activity of nucleic acids, forming active parts of ribosomal processes, and 
play a key role in membrane transport and recognition. The ability of these molecules 
to adopt such a broad spectrum of functional and structural properties is due to the 
ingenious design scheme by which these molecules are structured. Proteins are 
composed of as many as 50,000 individual amino acid residues (Figure 1.1). The
Figure 1.1. Basic structure of the amino acid. Stereochemistry about the C“-carbon is 
not specified, but exists overwhelmingly as the L-isomer in nature. All common amino 
acids vary only by the R-group side chain, which distinguishes the amino acids from 
one another.
mechanisms, by which proteins function, are just beginning to be understood. This is
o
R
l
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presence of the 20 commonly occurring ammo acids, and the more than 300 less 
common variants which have been found to exist in nature, make an almost endless 
variety of proteins possible. A relatively small protein of only 50 amino acid residues 
in length, in which any of the naturally occurring amino acids may occupy any position 
along the sequence, allows for 2050 permutation isomers, without modifying any 
individual amino acid. This number is roughly equivalent to the number of grams of 
matter in the known universe.1'1 Considering the huge spectrum of protein size, the 
large number of modified amino acids, the recent rise in the number of synthetic amino 
acids, and the conformational and quaternary structural interactions which are possible, 
the numbers of possible proteins and protein conformations are essentially infinite. 
However, every change in sequence and/or composition can result in distinctly different 
functions and properties. It is the ability to understand the structure and function of 
protein fragments, or peptides, as a result of primary amino acid sequence which is the 
very dogma of peptide chemistry. This introduction will present an overview of the 
basic principles of peptide chemistry and introduce some of the vital contributions made 
to this field in recent years.
1.2. THE AMINO ACID
Amino acids are the building blocks of all proteins. There are 20 commonly 
occurring amino acids in nature that are encoded by the genome, and hundreds of post- 
translationally modified amino acid derivatives which are used to synthesize the 
countless proteins which provide structure and function to the biological world. The 
first natural amino acid to be discovered in proteins was asparagine, in 1806, the last of 
the common 20 was threonine, which was not identified until 1938.1-2 Since then, a
2
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
multitude of synthetic amino acids have emerged to complement the naturally occurring 
20. A list o f the commonly occurring amino acids is presented in Table 1.1. Once 
released from the ribosome, proteinogenic amino acids can be post-translationa lly 
modified by processes such as acetylation, amidation, glycosylation, methylation, 
hydroxylation, halogenation and phosphorylation.1’3 These alterations provide endless 
possibilities in terms of final form and function of the resulting peptide.
In addition to the 20 naturally occurring amino acids and their post- 
translationally modified analogs, several synthetic amino acids and amino acid analogs 
have been reported within the past twenty years. A particularly interesting group of 
these synthetic amino acids are the Ca,Ca-disubstituted amino acids (oocAAs), whose 
most common member, 2-aminoisobutyric acid (Aib) or Ca-methylalanine, is illustrated 
in Figure 1.2. Ca,Ca-disubstituted amino acids are characterized by substituting the 
hydrogen at the Ca-carbon with an alkyl group. Most aaAAs are achiral, although 
synthesis and application of chiral aaAAs, where the amino acid side-chains are 
different, has become more common in recent years.
2-Aminoisobutyric acid was first discovered as a strongly helix promoting 
residue in the channel-forming peptide alamethicin. Alamethicin was found to be more 
helical than would have been predicted by the helix forming propensities of the 
proteinogenic amino acids which encompass the peptide.1'4 Since, it has been shown 
that Aib, and several other disubstituted amino acids, are strongly helix promoting.1,5*6 
The additional R group at the C“-carbon sterically restricts the possible conformations 
of the peptide, and in the case of Aib and alicyclic Ca,Ca-disubstituted amino acids, 
favors the formation of a helix. It has also been shown that amino acids with extended
3
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Table 1.1. The twenty commonly occurring amino acids.
Amino Acid Code R Amino Acid Code R
Alanine Ala (A) H3< H Leucine Leu (L)
Arginine Arg(R) H N ^.N H2
HNnXV ^I
Lysine Lys (K)
Asparagine Asn (N) Methionine Met(M)
Aspartic Acid Asp (D)
H O ^ ^
Phenylalanine Phe (F) Q u
Cysteine C ys(Q Proline Pro (P) <3T
Glutamic Acid Glu(E) 0
HO,^ SsXV' |
Serine Ser(S) HOv/|
Glutamine Gln(Q) O Threonine Thr(T) H e y }
CHj
Glycine Gly (G)
•A*1X Tryptophan Trp (W)
Histidine His(H) O u
H
Tyrosine Tyr(Y) “X u
Isoleucine ne(I) h3c^ Y ^
c h 3
Valine Val (V)
4
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h2n^ C 0 2h 
h3c  ch 3
Figare 1.2. 2-aminoisobutyric acid 
w-alkyl side chains larger than a methyl group, i.e. diethylglycine and dipropylglycine, 
favor extended conformations.1'7 ocaAA influences on peptide structure is discussed in 
more detail in chapter 3 of this document.
Since most Ca,Ca-disubstituted amino acids are hydrophobic in nature, peptides 
rich in these derivatives are generally restricted to study in organic solvents due to their 
low solubility in aqueous media. There have been very few examples of side-chain 
functionalized Ca,Ca-disubstituted amino acids which would allow for the synthesis of 
highly water-soluble peptide rich in C°,Ca-disubstituted amino acid content.1'8 This is 
primarily due to difficulty of synthesis. Since poly-functionalized C°,Ca-disubstituted 
amino acids have the ability to induce branching and side-reaction at their side-chain 
functionality, they must be orthogonally protected to allow for incorporation into solid- 
phase peptide synthesis. Thus, we present the syntheses of new orthogonally protected 
polyfunctional amino acids in Chapter 2 of this text. These synthetic schemes include 
two Ca,C“-disubstituted amino acid analogs of lysine, the alicyclic 4-aminopiperidine-
4-carboxylic acid (Api) and 2,2-bis(3-aminopropyl)gIycine (Bap), and two Ca,C“- 
disubstituted amino acid analog of glutamic/aspartic acid, 2,2-bis(3- 
carboxyethyl)glycine (Bglu) and 2,2-bis(3-carboxymethyl)glycine (Basp). The 
structures of these amino acid targets are shown in Figure 1.3. The incorporation of 
these new residues should allow for the development of short peptides, with highly 
stabilized secondary structures.
5
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Fmocv
O O O
OtBu BuOt
Fmoc
O^OtBu
O
Fmoc-Api(Boc)-OH Fmoc-Bap(Boc)rOH Fmoc-Bglu(/Bu)j-OH Fmoc-Basp(/Bu)rOH
Figure 1.3. Target Ca,Ca-disubstituted amino acids Api, Bap, and Bglu and Basp in 
their fully protected forms.
1.3. PRIMARY STRUCTURE AND SOLID-PHASE PEPTIDE SYNTHESIS.
Amino acids are joined to produce peptide segments by linking them together 
via a condensation reaction to make a chain of intramolecular amides known as "peptide 
bonds", as is illustrated in Figure 1.4. All peptides have this fundamental substructure 
and vary only in the composition of amino acids and the sequence in the polypeptide 
backbone, which is referred to as the primary structure of the peptide. The process by 
which peptide bonds are formed synthetically are very different from those performed 
by biological processes. There have been numerous methods developed to synthesize 
peptides chemically. However, none of them have been as revolutionary for the field of 
peptide chemistry as solid-phase peptide synthesis (SPPS), introduced by Merrifield in 
the 1960s.1'9 Merrifield's method is founded on anchoring an amino acid to an insoluble 
polymeric support and "growing" the peptide off of the polymer until it has reached it's 
final sequence. The peptide is then cleaved from the resin and purified. The advantage 
of using solid-phase methods is the ability to utilize large accesses o f reagent without 
encountering difficulties in purification. These accesses drive the equilibrium
6
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towards completion and thus provide greater yield and purity o f the targeted product 
SPPS has grown into a prominent application in chemistry since the first seminal 
publications, and is now a major driving force behind discovery sciences such as
The theory and practice of solid-phase peptide synthesis, coupling methods for peptide 
linkage formation and protection schemes are reviewed in further detail in chapter 5.
Figure 1.4. Condensation of two amino acids to generate a peptide bond.
As with N-alkylated amino acids, C^C^-disubstituted amino adds offer a 
significant challenge in their ability to couple under solid phase peptide synthesis 
conditions.*'30'31 The difficulty in coupling C^.C^disubstituted amino adds stems 
primarily from the steric repulsion that arises between residues being coupled;01 
Although some Ca,Ca-disubstituted amino adds, such as 2-aminoisobutyric add, are 
found extensively in nature and are easily coupled under solid-phase peptide conditions, 
couplings of larger and more sterically hindered residues are tedious and require long 
coupling times under harsh reaction conditions.1'47 The need for a newer, more efficient 
coupling method for the incorporation of Ca,Ca-disubstituted amino adds and other
combinatorial chemistry,1'10 the incorporation of synthetic amino acid derivatives and 
the synthesis of other biomolecules.111'19 SPPS has, in turn, enabled peptide structure- 
function studies, such as those presented in chapters 3 and 4 of this dissertation.1'20*28
peptide bond
O R*
NHa^COzH NH2^ C 0 2H
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sterically hindered residues into synthetic peptides led to the development of the o- 
nitrobenzenesulfonyl (oNBS)/acid chloride coupling scheme which is presented in 
chapter 5. This method is designed to utilize the higher reactivity of protected amino 
acid chloride derivatives1'29'31 as activated coupling agents, which has so far been 
impossible with the use of Fmoc chemistry due to high levels of competing oxazolone 
formation by intramolecular cyclization. Use of the less nucleophilic o- 
nitrobenzenesulfonyl protecting group should allow for the synthesis of this highly 
active species without competing side-reactions. Successful application of these 
derivatives should dramatically increase coupling yields and lower reaction times 
required for the coupling of Ca,Ca-disubstituted amino acids. We have shown that the 
protecting group is easily incorporated into proteinogenic amino acids and aaAAs 
under non-aqueous conditions (Figure 1.5) and is quantitatively cleaved under 
nucleophilic conditions to yield a chromophore that can be detected by UV- 
spectroscopy, allowing for on-resin monitoring of coupling efficiency.
1.4. PEPTID E SECONDARY STRUCTURE
Biological function of peptides and/or proteins is dependent on two factors: 1) 
bonding interactions with the substrate (usually hydrogen bonding or coulombic 
effects), and 2) overall peptide structure. Protein structure is divided into four levels of 
complexity, primary, secondary, tertiary and quaternary (see chapter 3), where primary 
structure is the description of amino acid sequence and composition. The chemical 
characteristics of the primary sequence allow the peptide to establish internal hydrogen 
bonding patterns along the amino acid backbone. This bonding pattern, in turn, induces 
the next level of structure in the peptide, secondary structure. Factors that determine
S
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h3c. ,CH3 „  TUOJ-, / = \  9  H^ ,cv ° \ H 1) diea, tms-ci / = \  ?
: " Y H 2)oNBSCI J
.OH
A .  ( 1 H  ' '  -  - m  .>— <2----- M Y
H2N'
°  N 02
1) DIEA, TMS-CI
2) oNBS-CI
Boc
OHO  1) DIEA, TMS-CI _  / = \  §  kl.
? Y 0H  2) oN B S-d---------- ^  t "O
n o 2
NHZ
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NHZ
2) oNBS-CI o  H O
N 02
Figure 1.5. Synthesized oNBS-C® Ca-disubstituted amino acid adducts.
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which secondary structure will be adopted and the characteristics of secondary structure 
are discussed further in the introduction of chapter 3. The secondary structure of 
peptides can be divided into four general categories: 1) the extended conformation, 2) 
helices, 3) (3-sheets and 4) (3-tums. Of these four, the helical configurations are of most 
interest for the work presented in this dissertation. Figure 1.6 illustrates several helical 
secondary structures of peptides. Using fundamental chemical principles and a few 
experimental observations, Linus Pauling and Robert Corey elucidated the two most 
prominent secondary structures, the a-helix and (3-sheet, as early as 1951, years before
a-helix 3io-heiix x-helix
Figure 1.6. Helical secondary structure conformations. Of these structures, the a-helix 
is by far the most common. The 3to-helix makes up less than 10% of all peptide 
structure. The x-helix is not found in nature.
10
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the first crystal structure of a protein was ever defined.1*32 Of the known helical 
secondary structures, the a-helix is the most thermodynamically stable and is the most 
common secondary structure in nature.
Recently, the 3io-helix has gained attention as a significant helical motif in 
peptides, making up nearly 10% of all peptide helices.1*33 The delicate equilibrium 
between the 3 to- and a-helix, which is thought to be significant in protein folding 
processes, has not been fully explored. In addition, it is not known what factors 
stabilize one helix over the other. To gain understanding of this process, we prepared a 
series of short peptides rich in Ca,Ca-disubstituted amino acids. The peptides were 
designed to be perfectly amphipathic as a result of adopting either an a - or 3to-helical 
conformation. Since the peptides are paired as permutation sequence isomers, the 
adopted conformation is based purely on the peptides’ preference to adopt an 
amphipathic cross-section, not induced by their amino acid composition. The structures 
of the peptides were deduced by electronic circular dichroism spectroscopy (ECD)1*32 3S. 
ECD, along with crystallographic methods and NMR, are the primary methods of 
obtaining information of peptide secondary structure. The results of these structural 
studies are presented in chapter 3 o f this dissertation.
IS . AM PHIPATHIC PEPTID ES
Amphipathic peptides are predominantly hydrophilic along one side of the helix 
axis and predominantly hydrophobic in character on the other side (Figure 1.7). The 
tendency of these structures to self-associate and interact with bi-lipid membranes result 
in high levels of bioactivity. They play an important part in membrane-dependent 
processes1*41 and are found extensively in lipoproteins1*42, hormones1*43, lung surfactant
11
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Figure 1.7. Representative amphipathic a-helix and 3io-helix wheel diagrams. N 
represents non-polar, hydrophobic residues. P represents polar, cationic residues. 
Empty circles represent non-occupied positions on the helical wheel cross-section.
proteins1'44, cytotoxic immunodefense proteins1'45 and antimicrobial agents.1'46 By 
generating sequence permutation isomers of several peptides, we have attempted to 
selectively induce a- or 3io-helices, based purely on amphipathic sequence design. 
Incorporation of the ionizable C“,Ca-disubstituted amino acid, 4-aminopiperidine-4- 
carboxylic acid (Api) (see chapter 2) along with other common Ca,Ca-disubstituted 
amino acids such as 2-aminoisobutyric acid (Aib) and l-aminocyclohexane-l- 
carboxylic acid (Ac6c) allows for the production of short, amphipathic peptides with up 
to 80% Ca,Ca-disubstituted amino acids which are highly water soluble, but retain 
helical character in organic and aqueous/organic media (Table 1.2). Each peptide is 
designed to have maximum amphipathic character either as an a-helix or a 3to-helix, 
and were found to preferentially adopt their respectively designed structures (see 
Chapter 3).
12
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Table 1.2. List of prepared de novo peptides designed for study of structural influences 
of amphipathic design and antimicrobial activity against Brucella abortus.
Peptide Sequence Design
Pi-10 H-Aib-Aib-Api-Iys-Aib-Aib-Api-Lys-Aib-Aib-NH2 a
Ipi-10 H-Api-Aib-Aib-Zys-Aib-Aib-Lys-Aib-Aib-Api-bftfc 3io
Ach-lOa H-Ac6 c-Aib-Lys-Api-Aib-Ac6 c-Api'£ys-Ac6 c-Aib-NH2 a
Ach-10 H-Api-Aib-Ac6c-Lys-Ac6c-Aib-Iys-Aib-Ac6c-Api-NH2 3io
Cyh-10 H-Ac6c-Ac6c-Api-Iyj-Ac6c-Ac6c-Api-Zy.s-Ac6c-Ac6c-NH2 a
Ich-10 H-Api-Ac6c-Ac6c-Iys-Ac6c-Ac6c-Lyy-Ac6c-Ac6c-Api-NH2 3io
Amphipathic peptide structures are gaining considerable recent attention due to 
growing interest in utilizing these compounds as antimicrobial agents.1*36*37 Antibiotic 
resistance is a growing problem, which is developing in a number of pathogenic 
bacteria. To combat this problem, new sources of antibiotic therapy are required. Some 
of the most promising candidates for this purpose are antimicrobial peptides. Naturally 
occurring antimicrobial peptides are generally linear, amphipathic a-helices, and are 
relatively short in length (<40 residues). Although this number is relatively small in the 
realm of protein science, it is far too large to allow these compounds to be used 
effectively in a therapeutic fashion. However, sequences o f this length are generally 
required to produce significant helical character in proteinogenic helices. The
13
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incorporation o f high levels o f Ca,C°-disubstituted amino acids into the peptide 
structure allows for the production of relatively short sequences (~10 amino acids) 
which display high levels of helicity in amphipathic environments. Besides showing 
moderate to high levels of antimicrobial activity against representative Gram-positive 
and Gram-negative bacteria, the designed peptides show a significant selectivity 
towards the destruction of macrophages infected with intracellular pathogens (see 
chapter 4). An added benefit of using aaAAs in the design of therapeutic peptides is 
their resistance towards enzymatic degradation and increased thermal stability.
1.6. INTRACELLULAR PATHOGENS
Infection with intracellular pathogens, such as Brucella abortus (Ba) and 
Mycobacterium tuberculosis (Mtb), are very difficult to treat by classical antibiotics due 
to the lack of any significant extracellular component to the infection.138 The bacteria 
reside within the white blood cells of the host, where no significant concentrations of 
antibiotic accumulate. Current recommended treatments for Mtb infection include the 
administration of four first-line antibiotics over periods of six to eight months.139 In 
vitro studies of the cytolytic activity of our designed peptides show that infected 
macrophages are killed selectively over non-infected macrophages with high 
selectivity.1,40 In addition, in vivo studies of the peptide Pi-10 have shown that 
administration of oxytetracycline together with peptide in BALB/c mice infected with 
Ba results in a dramatic reduction of intracellular infection over 24 hours.1,40 This 
promising result prompted us to investigate the selective cytolytic activity of the rest of 
the peptides in the Pi-10 family (Table 12). These results are presented in chapter 4 of 
this manuscript
14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The mechanism by which antibiotic peptides function is still under considerable 
debate. It is generally accepted, however, that the peptides induce cell membrane 
disruption by one of several proposed mechanisms (see chapter 4). In contrast to 
classical antibiotics, the interaction is not enzyme or receptor mediated, which lowers 
the possibility of resistance development towards this kind of therapy. Peptide 
selectivity towards bacterial cells in mammalian environments is due to cellular 
membrane composition differences between eukaryotic and prokaryotic cells.1-37 
Bacterial cell walls are unique in that they contain lipopolysaccharides (Gram-negative) 
or teichoic and teichuronic acids (Gram-positive), giving their cell wall a predominantly 
negative charge, which attracts the positive charge of cationic peptides. Mammalian 
cells are composed predominantly of zwitterionic sphingomyelin phospholipids, which 
have been shown to show low affinity for natural antimicrobial peptides.1-37 This theory 
is further supported by the significantly lower activity of linear amphipathic peptides 
which are anionic in character, suggesting a coulombic interaction between peptide and 
target cell. Subsequent incorporation of the peptide into the cellular membrane of the 
target causes membrane disruption and cell death.
A question that remains unanswered is why these peptides are selective towards 
macrophages that are infected with intracellular pathogens. Since it has been 
established that coulombic attraction is the prime method of peptide incorporation into 
pathogenic membranes, is there a change of potential in the infected macrophage which 
promotes incorporation of the peptide, or are peptides evenly distributed between 
healthy macrophages and infected ones? hi the latter case, are the infected 
macrophages more susceptible towards membrane disruption than the healthy ones?
15
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These questions are addressed further in chapter 4. The first step towards answering 
these questions is addressed by a study in which macrophages are activated by PMA 
and show the same susceptibility towards Pi-10 as macrophages infected with 
intracellular pathogens. In turn, inhibition of PKC production in the cell results in 
reduced sensitivity, rendering Pi-10 inactive. This suggests that intracellular pathways 
“signal” the presence o f an infection to the exterior cellular matrix (chapter 4).
1.7. CONCLUSIONS
Clearly there is more to be discovered within this field of peptide chemistry. 
New amino acids, new solid-phase coupling techniques, and new methods for the 
determination of peptide structure will provide the tools with which we can accomplish 
these goals. The ultimate goal is, of course, to deduce protein function directly from 
primary sequence. A greater understanding of peptide structure-function relationships 
will allow us to apply synthetic peptides more effectively as therapeutic agents. Future 
studies stemming from the material presented in this dissertation are summarized in 
chapter 6. These future studies include fluorescently labeling peptides so as to more 
carefully monitor the mechanism by which macrophages infected with intracellular 
pathogens are destroyed, and designing new, highly active peptides with shorter length. 
Increased awareness of the cellular response to these types of infections is crucial for 
the ongoing war against disease.
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CHAPTER 2 
SYNTHESIS OF A SERIES OF IONIZABLE 
C“,Ca-DISUBSTITUTED AMINO ACIDS
2.1. INTRODUCTION
The use of Ca,Ca-disubstituted amino acids (aaAAs, Figure 2.1) in the design 
of novel peptides has taken a sharp rise within the past few years. There are several 
reasons why these derivatives are desirable in the synthesis of de novo peptides with 
bioactive applications. 1) It has been shown that peptides containing high levels of 
Ca,C“-disubstituted amino acids are resistant to enzymatic degradation under 
physiological conditions.2,1,61 2) The presence of the common Ca,Ca-disubstituted 
amino acid Aib (2-aminoisobutyric acid) in naturally occurring, membrane active 
peptides.2,2,3 3) The high secondary structure promoting ability of Ca,Ca-disubstituted 
amino acids by peptide torsion angle restriction.2'4' 13
Hi
.N.
Q .
H3C C H 3
h 2n  c o 2h  h 2n '  " c o 2h  h 2n '  " c o 2h
Alb Acte Api
Figure 2.1. Ca,Ca-Disubstituted amino acids aminoisobutyric acid (Aib), 1- 
aminocyclohexyl-1 -carboxylic acid (Ac«c), and 1 -aminopiperidine-1 -carboxylic acid 
(Api).
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2-Axninoisobutyric acid (Aib) is the most commonly used Ca,Ca-disubstituted 
amino acid and is found extensively in nature. The antibiotic alamethicin,2'14*15 and 
related antimicrobial peptides suzukacillin,216 emmerimidns,2'17 and antiamoebins218 
all contain high levels of this amino acid. Most of the pioneering work on the structural 
influences of Aib in short, synthetic peptides is accredited to Balaram, 2‘8'10’11’19’20 and 
more recently by Toniolo, Benedetti and coworkers.2'2'12,21 'n  Aib, and other aaAAs 
like it, promote secondary structure formation by severely restricting possible rotation 
about the N-C° (<j>) and C°-C' (\y) bonds.2'8 Theoretical calculations have deduced that 
allowable torsion angles of these bonds in aaAA-rich peptides fall in a very narrow 
region near -57°, -47°, and +57°, +47°, respectively.2-23 In Ramachandran space, this 
corresponds to the formation of a right or left handed a-helix or 3to-helix (see chapter 
3). Since symmetrical aaAAs do not have a chiral center, they may give rise to either 
right or left handed screw sense, if no other chiral amino acids are present in the peptide 
to induce enantiomeric preference. In contrast to Aib, C°,C°-di-n-ethylglycine and 
Ca,Ca-di-n-propylglycine have been shown to induce extended conformations of 
resulting peptides (Figure 2.2).2*10
o  y
h 2n  c o 2h  h 2n  c o 2h  h 2n  c o 2h
Dpg Deg Acsc Ac7c
Figure 2.2. Other common Ca,C°-disubstituted amino acids: Ca,Ca-Dipropylglycine 
(Dpg), Ca,Ca-Diethylglycine (Deg), 1 -amino-1 -cyclopentanoic acid (Acsc), and 1- 
amino-l-cycloheptanoic acid (Ac7c).
21
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The effect of alicyclic Ca,Ca-disubstituted amino acids on secondary structure 
has been extensively researched. 2 ' 1 0 ,1 2 ,2 4 ’2 5  While longer chain Ca,Ca-di-n-alkyl amino 
acids promote extended conformations, 2 ,1 0  alicyclic C^C^-disubstituted amino acids, in 
which the Ca carbon forms a cyclic bridge with itself, such as 1 -aminocyclopentane-1 - 
carboxylic acid (Acsc) and 1-aminocyclohexane-l-carboxylic acid (Acgc), have helix 
forming characteristics similar to those of Aib. 2 ,1 0 ,2 4  This theory was recently extended 
to include the seven membered ring variant, 1 -amino-cycloheptane- 1 -carboxylic acid 
(AC7C) (Figure 2.2).124
Due to the presence of symmetry at the exposition, achiral aaAAs due not 
induce selective screw sense and are equally prone towards the formation of right and 
left handed helices. Synthetic peptides, incorporating high levels of Ca,C“-disubstituted 
amino acids, often include proteinogenic amino acids to induce preferred helical sense. 
It has been shown that synthetic peptides increase their helical character by substituting 
Aib residues with chiral aaAAs such as C“-methyl valine or Ca-ethyl alanine. 2 '2 6 ,2 7  
Some chiral Ca-alkylated phenylglycines have also recently found use as selective 
antagonists of metabotropic glutamate receptor. 2 -2 8 ,2 9  Chiral aaAAs are generally 
synthesized by the enandoselective alkylation of chiral enolates. 2"3 0 "3 2  However, these 
reaction conditions are limited due to multiple reaction steps and difficult separations of 
racemic products.
Since most Ca,Ca-disubstituted amino acids are hydrophobic in nature, peptides 
rich in aaAAs are generally restricted to study in organic solvents due to their low 
solubility in aqueous media. There have been very few examples of side-chain 
functionalized aaAAs that would allow for the synthesis of highly water soluble
22
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peptide rich in Ca,C“-disubstituted amino acid content6'62 This is primarily due to 
difficulty of synthesis. Since side-chain functionalized aaAAs have the ability to 
induce branching and side-reaction at their side-chain functionality, they must be 
orthogonally protected to allow for incorporation into solid-phase peptide synthesis. 
The harsh conditions, under which standard methods of C“,Ca-disubstituted amino acid 
synthesis are performed, make this a difficult task (Figure 2.3).
©
A 9  NH3  | H HCN ^  H2N ,CN H3Q+ ^  H3 N CO2 H
R R’ R R’ R R' heat r^ r-
B 9  (NH4 )2 C03^ h n T X 0  60M u O V  H2 ^ ° ?
R R' KCN R R' heat, pressure R R'
Figure 2 J .  The Strecker Method A, and the Bucherer-Berg Method B, for the synthesis 
of C“,Ca-disubstituted amino acids.
Two traditional methods exist for the synthesis of aaAAs. The Strecker method 
is characterized by the addition of cyanide to an imine synthesized from the 
corresponding symmetrical ketone, followed by acid catalyzed hydrolysis of the 
resulting a-aminonitrile (Figure 2.3).2J3 This method is experimentally simple, but 
limited to the use of simple ketones as starting materials as the hydrolysis requires 
strongly acidic conditions, high temperatures and pressure. Recently, Ma and 
coworkers presented an asymmetrical Strecker synthesis to generate chiral aaAAs from 
a-aryl ketones.234 The Bucherer-Berg method of hydantoin formation by the reaction
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of ketones with sodium cyanide and ammonium carbonate is still the most prevalent 
method to generate aaAAs in good yields.2'35,36 However, hydantoins also suffer from 
the limitation of requiring harsh conditions for hydrolysis, thus minimizing the ability to 
generate side-chain functionalized amino acids (Figure 2.3). This problem was partially 
overcome by Rebek and coworkers, whom discovered that N,N'-Bis-(/- 
butyloxycarbonyl) hydantoins can be hydrolyzed under much milder conditions.2,37 The 
ease of hydrolysis of the functionalized hydantoin is presumably due to a number of 
reasons: 1) Induced ring strain in the hydantoin moiety, 2) greater electrophilicity of the 
hydantoin carbonyls, making it more susceptible towards nucleophilic attack by 
hydroxide and, 3) The nitrogen of the hydantoin becomes a better leaving group as a 
carbamate. The progress made in Ca,Ca-disubstituted amino acid synthesis by 
hydantoin hydrolysis allowed us to develop the synthesis of the orthogonally protected 
C°\Ca-disubstituted amino acid Fmoc-Api(Boc)-OH 2.1 (Figure 2.4).2J8 This alicyclic 
Ca,C°-disubstituted amino acid analog of lysine allows for the preparation of peptides 
rich in aaAAs, while retaining water-solubility.2,6 As with other alicyclic aaAAs, Api 
has been found to strongly favor helical conformations of resulting peptides.
Figure 2.4. Orthogonally protected C°,Ca-disubstituted amino acid 9-1 -tert- 
butyloxycarbonyl-4-((9-fluorenylmethyloxycarbonyl)amino)-piperidine-4-carboxylic 
acid (Fmoc-Api(Boc)-OH).
2.1
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Nitroacetic esters are common starting materials for a number of synthetic 
transformations.239 The high reactivity of the a-methylene group of these compounds 
allows for unique carbon-carbon bond forming ability. Alkylations of these activated 
starting materials has been useful in the synthesis of 2-nitroalkanoic acids, nitro 
alcohols, nitro amines, halonitro compounds, nitroacrylates, oxazolidines, oxazoles and 
carbohydrates.239 Although there have been reports o f the use of benzyl- and r-butyl- 
nitroacetate,2*40'43 most of the work on nitroacetates have been restricted to the use of 
the methyl and ethyl esters2'44"47 due to the difficulty of synthesizing other derivatives. 
The ability to efficiently alkylate nitroacetic esters has lead to the successful synthesis 
of amino acids and amino acid esters.2'48’53 These reactions are usually 
monoalkylations with an appropriate electrophile using weakly basic conditions, 
followed by reduction of the nitro group to the corresponding amine. Alkylations have 
been performed by the use of sodium or potassium hydroxide, benzyltrimethyl 
ammonium hydroxide, trimethylanilinium benzenesulfonate and diethylamine as 
bases.239 In addition, metal catalysis by copper (II) acetate and palladium catalysts has 
been employed for a number of Michael additions.2*4534 Electrochemically generated 
anions have been used on a small scale to perform mono- and di-alkylations of 
nitroacetic esters.2*47 However, since monoalkylation of nitro acetates is non- 
stereospecific, these reactions result exclusively in racemic mixtures of a-nitro esters, 
which have limited application for peptide synthesis.
Dialkylation of nitroacetic esters yields symmetrical dialkylated nitroacetates 
which are suitable precursors for the synthesis of Ca,Ca-disubstituted amino acids 
(Figure 2.5). The high acidity of the a-methylene protons of ethyl nitro acetate allow
25
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o2n^ 0.
o BASE
Figure 2.5. Base catalyzed alkylation of ethyl nitroacetate. BASE= potassium 
hydroxide, sodium hydroxide, sodium ethoxide, trialkylamine. Rg= alkyl halide, 
Michael acceptor.
for alkylations under very mild conditions. This, in turn, allows for the incorporation of 
chemically labile groups, which would be too unstable to incorporate via the Strecker, 
Bucherer-Bergs, malonic ester alkylation or glycine template alkylation methods. A 
synthetic scheme was envisioned for the preparation of three orthogonally protected 
tetrafunctional Ca,Ca-disubstituted amino acid analogs of glutamic acid, aspartic acid 
and lysine / omathine using ethyl nitroacetate as a synthetic precursor: N“-(9- 
fluorenylmethyloxycarbonyl)-2,2-bis(ter/-butylcarboxyethyl) glycine (Fmoc-Bglu(r- 
Bu)2-OH, 2.2), Na-(9-fluorenylmethyloxycarbonyl)-2,2-bis(terf-butylcarboxymethyl) 
glycine (Fmoc-Basp(/-Bu)2-OH, 2.3) and Na-(9-fluorenyImethyloxycarbonyl)-2,2- 
bisCN^-tert-butyloxycarbonyl-S-aminopropyl) glycine (Fmoc-Bap(Boc)2-OH, 2.4) 
(Figure 2.6). These targets were chosen for three reasons: 1) There does not, as of date, 
exist any recorded results on the synthesis of orthogonally protected tetrafunctional 
amino acids capable of incorporation into peptides by solid-phase peptide synthesis (see 
chapter 6). 2) The use of a polyfunctional amino acid may allow for the synthesis of 
peptides that retain high levels of amphipathicity with very short length (see chapter 3).
3) Polyanionic and polycationic amino acids have interesting possibilities for 
application as salt bridge inducers towards stabilization of peptide secondary structure.
26
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OH
■ NH NH I
OH
tBuO, ■OtBu
2.2 23 2.4
Figure 2.6. Fmoc-Bglu(r-Bu)2 -OH 2.2, Fmoc-Basp(/Bu)2-OH 23  and Fmoc- 
Bap(Boc)2 -OH 2.4.
23 . RESULTS AND DISCUSSION
Synthesis of l-ter/-butyloxycarbonyl-4-((9-fluorenylmethyloxycarbonyl) 
amino)-piperidine-4-carboxylic acid (Fmoc-Api(Boc)-OH) 2.1 was realized according 
to the synthetic scheme in Figure 2.7. The reaction of 4-piperidone hydrate 2.1a with 
potassium cyanide and ammonium carbonate in ethanol/water gives the resulting 
hydantoin 2.1b in good yields. The piperidone hydantoin is then tri-Boced using excess 
l-butyldicarbonate in DME with triethylamine and a catalytic amount of DMAP as 
deduced by Wysong et. al.2-55 Attempts to tri-Boc the piperidone hydantoin without the 
use of DMAP or triethylamine results in incomplete reaction. Hydrolysis of the 
resulting triBoc piperidine hydantoin 2.1c under alkaline conditions results in the 
formation of the amino acid 2.1d in good yield. This hydrolysis was initially achieved 
by aqueous NaOH. However, isolation of the resulting zwitterion 2.1d is difficult, as 
the product is highly contaminated with the hydrolysis side-product, bis(f- 
butyl) carbamate. Isolation of this side product verifies that the mechanism of 
hydrolysis occurs by one of two pathways as shown in Figure 2.8. In the first
27
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Figure 2.7. Synthesis of Fmoc-Api(Boc)-OH 2.1. 
mechanism, A, nucleophilic attack of hydroxide on the amide carbonyl of the hydantoin 
ring substitutes the carbamate-type moiety. Intramolecular f-butyloxy carbonyl transfer, 
followed by base catalyzed hydrolysis and subsequent decarboxylation of the resulting 
carbamic acid give the observed products. The other hydrolysis mechanism, B, is 
initiated by nucleophilic hydroxide attack on the urea-carbonyl of the hydantoin. 
Decarboxylation of the carbamic acid and intramolecular /-butyloxycarbonyl transfer 
yields the free amine. Base hydrolysis of the resulting amide releases bis-(f-butyl)- 
carbamate and results in the free carboxylate (Figure 2.8).
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Although both mechanisms are theoretically feasible, mechanism A is more 
likely to occur for two reasons: 1) The greater electrophilicity of the amide-type
carbonyl versus the urea-type carbonyl promotes initial nucleophilic attack according to 
mechanism A. 2) Intramolecular f-butyloxycarbonyl transfer in mechanism A involves 
an amide leaving group, mechanism B requires that a deprotonated amine act as 
a leaving group. The greater kinetic activity of the amide-type leaving group would 
promote mechanism A. It was attempted to probe the mechanism of the hydrolysis by 
13C-NMR. However, the results were inconclusive.
Although the hydrolysis of the tri-Boc hydantoin give the desired amino acid in 
high yield, the reaction has difficulties associated with bis-(/-butyl)-carbamate 
contamination of the isolated amino acid. Bis-(/-butyl)-carbamate has a pKa and 
solubility similar to that of the Api(Boc) zwitterion making separation difficult even by 
chromatographic means. Presence of this contamination causes difficulty in isolation 
and residual bis-(/-butyI)-carbamate results in severe side reaction if  present in the 
preparation of Fmoc-Api(Boc)-OH.
Contamination with bis-(f-butyl)-carbamate is avoided by performing the 
hydrolysis of 2.1c in a biphasic mixture of THF and 2.0M KOH. Under basic 
conditions, bis-(/-butyl)-carbamate has a higher solubility in THF, while the 
deprotonated zwitterion stays in the aqueous solution. Under high ionic contents THF 
and water are not miscible and are easily separated in a separatory funnel (Figure 2.9). 
Evaporation of the separated THF yields a nearly quantitative recovery of bis-(r-butyl)- 
carbamate. Neutralization of the aqueous layer yields the precipitated zwitterion 2.1d in 
very good yield. To introduce the Fmoc group for N*- protection, Fmoc-Cl is used, as
30
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Figure 2.9. Biphasic hydrolysis of triBoc Api hydantoin. 
reported by Bolin.2-63 The N8-f-butyloxycarbonyl group was found to be stable under 
these conditions and the reaction yields the orthogonally protected amino acid 2.1 in 
good overall yield. Unfortunately, the tri-Boc-hydantoin route can not be extended to 
non-cyclic multi-functional amino acid derivatives. The required a-, P-, or y- 
difunctionalized ketones do not form hydantoins to an appreciable extent (Figure 2.10). 
Thus, the tri-Boc-hydantoin route was not utilized for the synthesis of Fmoc-Bglu(f- 
Bu)2-OH and Fmoc-Bap(Boc)2-OH.
< • ~ 0% Hydantoin : COjMa
/  i \  .
BocHN' v  NHBOC o
Figure 2.10. Failed attempts at difunctionalized hydantoin synthesis.
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The scheme devised for the synthesis of Fmoc-Bglu(f-Bu)2-OH and Fmoc- 
Bap(Boc)2-OH is shown in Figure 2.11 and 2.12. Based on evidence that the ethyl 
nitroacetate anion is a more potent nucleophile when the counter ion is a highly 
dissociated quaternary ammonium salt, initial dealkylation was achieved using N,N'- 
diisopropyl ethylamine.2*47 The reactivity of the anion is increased when a catalytic 
amount of tetraethylammonium bromide is added to the reaction to act as an activated 
counter ion. Michael addition was performed with a number of electrophilic acceptors. 
Reaction of the nucleophile with acrolein is facile but gives a diastereomeric mixture of 
products due to the very rapid intramolecular Aldol cyclization of the resulting enolate 
(Figure 2.13). Michael addition with terf-butyl acrylate and acrylonitrile, respectively, 
gave the Ca-disubstituted ethyl nitroesters in excellent yields. Interestingly, alkylation 
with benzyl acrylate gave only a small portion of dialkylated product after 24 hours at 
room temperature. Most of the recovered product was monoalkylated. The ethyl ester 
of the dialkylated nitroacetate cannot be hydrolyzed without risking carbon dioxide 
elimination. Thus, the next logical step in the synthesis of an amino acid derivative is to 
reduce the a-nitro group to the corresponding amine. However, reduction of the nitro 
group did not prove trivial. Nitro compounds are known to be reduced by a variety of 
methods, the most prevalent being catalytic hydrogenation over Pd2-49'50 or Raney 
Ni.2-48,52’53 There are, however, several other techniques, such as Zn/acetic acid 
reduction and tin catalyzed hydrochloric acid reduction. Ammonium formate has 
recently found application as a suitable catalytic hydrogen transfer agent for the 
reduction of nitro compounds.2'56’58 To our surprise, only catalytic hydrogenation at 50 
psi over T-l Raney Nickel in ethanol resulted in the desired amine: ethyl-2,2-bis(/-
32
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Figure 2.11. Synthetic soheme of the synthesis of Fmoc-Bglu(tBu>2-OH 2.2.
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Figure 2.12. Synthetic scheme of the synthesis of Fmoc-Bap(Boc)2-OH 2.4.
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Figure 2.13. Addition of acrolein to ethyl nitroacetate, followed by base catalyzed 
intramolecular Aldol cyclization to yield diastereomeric mixture.
butylcarboxyethyl)glycine 2.2b. Hydrogenation over Pd/C (5 or 10%) at 50 psi in 
ethanol or with ammonium formate results in almost quantitative conversion to the 
corresponding hydroxylamine, which was apparent by NMR and MS analysis (Figure 
2.14-16). While suitable for the reduction of ethyl-2,2-bis(/-butylcarboxyethyl)-2- 
nitroacetate 2.2a, catalytic hydrogenation can not be utilized in the reduction of the 
corresponding nitro group of ethyl-2,2~bis(3-cyanoethyl)-2-mtroacetate 2.4a, as nitriles 
are readily reduced under these conditions.
Acid catalyzed hydrolysis of the ethyl ester of 2.2b results in immediate /-butyl 
deprotection and saponification using KOH, NaOH, or LiOH in various aqueous and/or 
aqueous/organic mixtures failed to selectively hydrolyze the ethyl ester. Recovered 
material from several hydrolyses showed evidence that the /-butyl groups of the 8- 
carboxylates were also lost to an appreciative extent. Selective hydrolysis of ethyl 
versus /-butyl esters has been well documented. 2J9' 60 However, hydrolysis of this 
ethyl / /-butyl ester compound is very difficult. Difficulty in isolation of the complex 
mixtures of partially hydrolyzed derivatives makes definitive evidence impossible, but a
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Figure 2.14. 'H-NMR analysis of Pd catalyzed reduction of nitro group to yield 
hydroxylamine (top) versus Raney nickel catalysis to yield amine 2.2b (bottom).
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Figure 2.15. I3C-NMR analysis of Pd catalyzed reduction of nitro group to yield 
hydroxylamine (top) versus Raney nickel catalysis to yield amine 2.2b (bottom).
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Figure 2.16. MALDI-MS analysis of Pd catalyzed reduction of nitro group to yield 
hydroxylamine (top) versus Raney nickel catalysis to yield amine 2.2b (bottom).
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theoretical lack of selectivity in hydrolysis arises from the presence of a tertiary carbon 
center a  to the ester carboxylate. This ester, thus, becomes essentially neopentyl in 
character and is highly sterically inaccessible. The lowered kinetics of the ethyl ester 
hydrolysis may compete with the already very low rates of t-butyl ester hydrolysis and 
result in lower selectivity. In turn, side-chain a-deprotonation and/or intramolecular 
cyclization by Dieckmann-type reactions may be a prominent factor. In addition to acid 
and base catalyzed ester hydrolysis, nucleophilic dealkylations of the ethyl ester with 
NaCN, Nal, NaSePh and KOSi(Me) 3  were attempted with no success. 2 -6 0 The best 
hydrolysis results were realized by the use of 1.4 equivalents tetramethyl ammonium 
hydroxide in a 1 : 2  water and methanol mixture which was cooled to zero degrees and 
slowly allowed to rise to room temperature over 24 hours. Evaporation of the solvent 
and acidic precipitation of the zwitterion from a saturated sodium chloride solution 
gives the amino acid in 20-30% yield. Isolation of side-products from this hydrolysis 
showed that ester-hydrolysis selectivity was not the primary cause of the problems 
associated with the synthesis. Selective ethyl ester hydrolysis occurs slowly under 
weakly basic conditions. However, the a-amino carboxylate that results rapidly 
cyclizes with the 8 -f-butyl ester to form a racemic mixture of 3-carboxy-3-(r- 
butylcarboxyethyl)-2-pyrrolidinone (Figure 2.17). The structure of this intermediate, 
which was isolated in -70% yield, was verified by X-ray crystallography and NMR 
(Figure 2.18). The N°-Alloc protected ethyl amino ester was also prepared (see 
experimental 2.3.15) to attempt to avoid cyclization. However, hydrolysis of this 
compound resulted in a complex mixture of side-products, most likely arising from 
incomplete hydrolysis, over-hydrolysis of the t-butyl esters, and/or cyclization.
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To overcome the problem of intermediate cyclization during ethyl ester 
hydrolysis, ethyl-2-nitroacetate was alkylated with l-butyl-2-bromoacetate in DMF and 
tetrabutyl ammonium iodide at SO °C. The shorter chain length of this alkylating agent
OH OH
tBu tBu tBu
2 .2 c 2 .2 d °"tBu
Figure 2.17. Base catalyzed intramolecular cyclization of 2,2-Bis(f-butylcarboxyethyl) 
glycine to yield racemic mixture of 3-carboxy-3-(f-butylcarboxyethyl)-2-pyrrolidinone 
2 .2 d.
Figure 2.18. ORTEP of 3-carboxy-3-(/-butylcarboxyethyl)-2-pyrrolidinone.
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assures that base catalyzed cyclization does not occur. Subsequent catalytic 
hydrogenation over Raney nickel in EtOH/AcOH at 60 psi yields the desired ethyl-2,2- 
bis(f-butylcarboxymethyl)glycine in quantitative yield (Figure 2.19). Lithium 
hydroxide induced hydrolysis yields the desired zwitterion of 2 ,2 -bis(/-butyl 
carboxymethyl)glycine in high yield. The zwitterion of this derivative can now be N°- 
protected to allow for SPPS incorporation (Figure 2.20).
0 4
C3
C2
02
C40 30 5 C6C9 0 8
C12
C11 C160 6C10 C7
0 7
C13
C15C14
Figure 2.19. ORTEP of 2,2-Bis(/-butylcarboxymethyl)-2-nitroacetate.
A selectivity problem is encountered when attempting selective reduction of the 
nitro versus nitrile groups in the synthesis of Fmoc-Bap(Boc)2-OH. Catalytic 
hydrogenation over Raney nickel shows complete reduction of all three functional 
groups. However, isolation of the triamine derivative has been found to be difficult and 
selective Fmoc/Boc protection of the resulting triamine resulted in low yields and
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complex mixtures. Borane is known to selectively reduce nitriles in the presence of 
nitro groups. Reduction with this reagent, however, yielded primarily starting material. 
Additional attempts at selective reduction of the nitro or nitriles have been unsuccessful. 
Thus, further attempts at the synthesis of Fmoc-Bap(Boc)2-OH from this starting 
material were abandoned. Alternative routes, which may lead to the successful 
synthesis of this fascinating amino acid, are presented in chapter 6  of this dissertation. 
23 . EXPERIMENTAL
23.1. Piperidine-4-spiro-5'-hydantoin (2.1b)
A 1000 mL round-bottom flask was fitted with a stirbar and charged with 4- 
piperidone monohydrate hydrochloride 2.1a (30.0 g, 195 mmol), ammonium carbonate 
(4139 g, 420 mmol), methanol (250 mL) and deionized water (150 mL). The mixture 
was allowed to stir at room temperature until all solids were dissolved and potassium 
cyanide (26.71 g, 410 mmol) dissolved in deionized water (100 mL) was added 
drop wise to the reaction mixture over a period of 10 minutes. The reaction was sealed 
with a rubber stopper and allowed to stir at room temperature for 48 hours. The 
resulting suspension was concentrated to a volume of 300 mL using rotary evaporation 
at 40 °C and the solution was cooled to 10 °C. The precipitated white solid was 
collected in a Buchner funnel using suction filtration. Additional concentration of the 
filtrate to a volume o f200 mL gave some additional product that was filtered and added
H
(NH4 )2C03
KCN
MeOH / H20  HN
O'
2.1a 2 .1 b
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to the first crop. The combined light yellow solid was washed with portions of 
deionized water (4 x 25 mL) until pure white. The product was allowed to air dry for 2 
hours and then dried in a vacuum oven (85 °C, 0.5 torr) overnight to yield 28.10 g (85% 
yield) of pure hydantoin 2.1b. 1H NMR (200 MHz, ck-DMSO) 5 10.75 (bs, 1H), 8.35 
(s, 1H), 2.84 (dt, 2H), 2.66 (td, 2H), 1.67 (td, 2H), 1.38-1.24 (m 2H). ,3C NMR (50 
MHz, d6 -DMSO) 177.46,156.30,61.09,41.14,37.79.
23.2. l-terf-butyloxycarbonylpiperidine-^-spiro-S’-O ’^ ’-bisff-butyloxy carbonyl)) 
hydantoin (2 .1 c)
TEA/DMAP
2 .1 b 2 .1 c
Hydantoin 2.1b, (26.0 g, 154 mmol), was suspended in 1000 mL of dry 12- 
dimethoxyethane in a 2000 mL three-necked round bottom flask, which was equipped 
with an argon inlet valve, an oil bubbler, and an overhead mechanical stirrer. To this 
suspension, triethylamine (15.7 g, 154 mmol) was added in one portion and the 
suspension was allowed to stir for 30 minutes. While stirring, di-/ert-butyl dicarbonate 
(168.0 g, 770 mmol) was transferred by pipette into the reaction mixture, followed by 4* 
dimethylaminopyridine (DMAP) (0.19 g, 1.54 mmol). A catalytic amount (020 g) of 
DMAP was added every 12 hours during the course of the reaction. The reaction vessel 
was flushed briefly with argon and allowed to stir vigorously for 72 hours. The solvent 
was removed by rotary evaporation and the crude product was dissolved in chloroform 
(500 mL). The solution was washed with 1.0 N HQ (3 x 200 mL) and the combined
44
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acid washes were backwashed with chloroform (100 mL). The organic layer was 
washed with saturated NaHCC) 3  (100 mL) and brine (100 mL). The organic layer was 
dried over MgSC>4 and the solvent removed by rotary evaporation. The resulting crude 
product was dried under vacuum at 0.01 torr for 24 hrs. The resulting light yellow solid 
was triturated by suspending the finely ground product in diethyl ether (400 mL), 
stirring for two hours, and vacuum filtering the solid in a Buchner funnel followed by 
washings with portions of diethyl ether (4 x 50 mL). The product was dried under 
vacuum (85 °C, 0.5 torr) for 24 hours to give 57.9 g (80% yield) of 2.1c. lH NMR (200 
MHz, CDClj) 5 4.29-4.01 (m, 2H), 3.42-3.57 (app dt, 2H), 2.67 (dt, 2H), 1.76 (m, 2H),
1.58 (s, 9H), 1.54 (s, 9H), 1.47 (s, 9H). 13C NMR (50 MHz, CDClj) 169.98, 154.71, 
14824,147.50,145.35,87.51,8536,80.13,62.53,39.96,29.87,28.62,2821,27.91. 
2 3 3 . l-/eif-butyIoxycarbonylpiperidine-4-amino-4-carboxylic add  (2.1d)
Boci, Boc
O  rS-  1) 2.0M KOH/THF I I
B o c - n ' T ^ 0  2\ oH 7 0 ®N r  2) pH 7.0 h3N C02
O 'Boc 
2 .1 c 2 .1 d
l-rerf-butyloxycarbonylpiperidine-4-spiro-5’-(r ,3 ’-bis(/errt>utyIoxycarbonyl)) 
hydantoin 2.1c (40.0 g, 0.083 mole), was suspended in THF (340 mL) in a 2000 mL 
Erlenmeyer flask. While stirring vigorously with a stirbar, 2.0 M aqueous potassium 
hydroxide solution (340 mL) was added in one portion. The flask was stoppered and 
the mixture was allowed to stir for 4 hours. The clear solutions were poured into a 
separatory funnel and the bottom layer was drained into a 1000 mL round bottom flask. 
Residual dissolved THF was removed by rotary evaporation and the aqueous solution
45
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was chilled in an ice bath. While stirring at 4 °C, the pH of the aqueous solution was 
adjusted to 7.0 by slow addition of a 2.0 N HC1 solution. The resulting white 
precipitate is filtered and dried in vacuo (85 °C, 0.5 torr) to yield 19.7 g (95% yield) of 
the amino acid. *H NMR (200 MHz, tk-DMSO) 8  3.61-3.35 (m, 4H), 1.95-1.79 (in, 
4H), 1.39 (s, 9H).
2.3.4. l-terf-butyloxycarbonyl-4-(9-fluorenylinethyloxycarbonylamino)-piperidine 
4-carboxylic acid (2.1) 4
Boc
Boc
0 e
h2n c o 2
2 .1 d 2 . 1
Finely ground tri-Boc hydantoin 2.1d (17.0 g, 69.6 mmol) was placed, together 
with a stirring bar, in a 1000 mL three-necked round bottom flask, which was stoppered 
and evacuated for three hours prior to use. While flushing with argon, the flask was 
equipped with an argon inlet/outlet valve, a septum, and a bubbler submerged into a 6 . 0  
M KOH bath. Anhydrous DCM (500 mL) was cannulated into the reaction vessel and 
DIEA (22.5 g, 174 mmol, 30.3 mL) was added via syringe. The reaction was stirred for 
thirty minutes and chlorotrimethylsilane (17.6 mL, 15.1 g, 140 mmol) was added 
dropwise while stirring. The reaction was allowed to stir for an additional thirty 
minutes and the septum was replaced with a reflux condenser. The solution was 
refluxed for three hours during which the reaction became homogeneous. At thirty- 
minute intervals, the reaction vessel was flushed for thirty seconds with argon to 
remove HC1 formed in the reaction. The solution was cooled to -10 °C and 9-
DIEA / TMS-CI
Fmoc-CI / DCM
Q COjH
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fluorenylmethyl chloroformate (Fmoc-Cl) (18.0 g, 70.0 mmol) was added in one 
portion. The solution was allowed to stir for 3 hours, under a constant slow stream of 
argon. The solvent was removed by rotary evaporation and the product distributed 
between diethyl ether (200 mL) and aqueous 2.5% Na2C0 3  (1000 mL). The aqueous 
layer was separated and washed with additional portions of diethyl ether (2 x 100 mL). 
The aqueous layer was placed on a rotary evaporator at room temperature to remove 
any dissolved ether and acidified to pH 2.0 in an ice bath using 2.0 N HC1. The 
precipitated free acid was extracted with ethyl acetate (300 mL) and additional portions 
of ethyl acetate (2 x 150 mL). The ethyl acetate extracts were combined, dried over 
MgS0 4 , filtered, and the solvent was removed by rotary evaporation to yield 29.56 g 
(91 % yield) of pure product 2.1e. lH NMR (200 MHz, CDC13) 5 8.30 (bs, 1H), 7.70 (d, 
2H), 7.53 (d, 2H), 7.30 (t, 2H), 7.25 (t, 2H), 4.37 (m, 3H), 3.76 (m, 2H), 3.04 (m, 2H), 
1.96 (m, 2H), 1.51 (m, 2H), 1.44 (s, 9H). l3C NMR (50 MHz, d^-DMSO) 175.01, 
155.41, 153.89, 143.81, 140.76, 127.63, 127.06, 125.28, 120.07, 78.71, 65.39, 59.74,
56.69.46.78.31.28.28.05.
2.3.5. Ethyl-2,2-Bis(f-butylcarboxyethyl)-2-nitroacetate (2.2a)
DIEA, TEAB 
CH3CN tBu
Ethyl nitroacetate (8.0 g, 60.1 mmol) was dissolved in acetonitrile (100 mL) in a 
250 mL roundbottom flask together with a magnetic stirrer. N,N'- 
diisopropylethylamine (15.54 g, 120.0 mmol) was slowly added to the solution while
47
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stirring at 0 °C. A catalytic amount of tetraethylammonium bromide (TGAB) (0.63g, 
0.3 mmol) was added, the reaction was sealed with a rubber septum and allowed to stir 
at 0 °C for 10 minutes. f-Butylacrylate (15.41g, 17.6 mL, 120.0 mmol) was added 
dropwise over a period of 15 minutes. The reaction was allowed to slowly rise to room 
temperature and stirred for 48 hours. The reaction was monitored by TLC (100% 
dichloromethane) until all starting material was consumed. The acetonitrile was 
removed in vacuo and the resulting crude was dissolved in diethyl ether (100 mL). The 
organic layer was washed with IN HCl (2 x 100 mL) and saturated sodium carbonate 
solution (2 x 100 mL). The organic layer was separated and filtered over a thin pad of 
silica in a Buchner funnel. The silica was washed with diethyl ether (2 x 30 mL) and all 
organic fractions combined. The ether was dried over anhydrous sodium sulfate and 
removed by rotary evaporation. The desired dialkylated a-nitro ester 2.2a was obtained 
in good purity with no further need for purification (21.95 g, 94.1%). ‘H NMR (250 
MHz, ck-DMSO) 8  4.24 (q, 2H), 2.38 (m, 4H), 2.24 (m, 4H), 1.40 (s, 18H), 1.21 (t, 
3H). 13C NMR (60 MHz, de-DMSO) 170.39, 165.81, 94.58, 80.33, 62.94, 29.04, 
28.33, 27.63, 13.53. HRFAB-MS m/z 3902119 (M+H)\ EA: Ci8H3 iN08. calc: 
55.51% C, 8.02% H, 3.60% N, found: 55.31%C, 7.83% H, 3.87% N.
23.6. Ethyl-2,2-bis(f-butylcarboxyethyl) glycine (2.2b)
h2n
H2 (50psi)
Raney Ni
O
Nitroester 2.2a (8.0 g, 24.63 mmol) was dissolved in absolute ethanol (30 mL) 
and 3.0 g o f a 50% (w/w) slurry of Raney Nickel in water was added. The reaction was
48
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hydrogenated over hydrogen gas (60 psi) for 72 hours. The reaction was monitored by 
TLC (100% DCM). The reaction was filtered carefully over Celite and the Celite cake 
washed with DCM (100 mL). Organic solvents were removed in vacuo to yield 2.2b in 
excellent purity (7.4 g, 93%). ‘H NMR (250 MHz, dg-DMSO) 8  4.09 (q, 2H), 2.34- 
1.64 (m, 8 H), 1.81 (s, 2H), 1.39 (s, 18H), 1.84 (t, 3H). I3C NMR (60 MHz, d<s-DMSO)
17524,172.03,79.51,60.40,59.22,34.20,29.83,27.69,14.05.
23.1. Ethyl-2,2-bis(f-butylcarboxyethyl)-2-hydroxylaminoacetate
Nitro ester 2.2a (1.0 g, 2.57 mmol) was dissolved in absolute ethanol (20 mL) 
and 10% (w/w) palladium on carbon (O.lg) was added carefully to the solution. The 
dark black suspension was placed in a hydrogenation flask and hydrogenated at 50 psi 
for 24 hours. The reaction was monitored by TLC (100% DCM) and continued until all 
starting material was consumed. The Pd / C was removed by vacuum filtration through 
a Celite cake which was washed with several portions of ethyl acetate. Additional 
filtrations through Celite may be required to remove all traces of catalyst The organic 
filtrate was dried over anhydrous sodium sulfate and the crude isolated by rotary 
evaporation. Drying under high vacuum overnight yields the hydroxylamine in 
quantitative yield (0.97 g, 100%). lH NMR (250 MHz, ds-DMSO) 5 723 (s, 1H), 5.69
n OH O
H2  (50psi)
2 2 a
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(s, 1H), 4.06 (q, 2H), 2.15 (m, 4H), 1.72 (m, 4H), 137 (s, 18H), 1.17 (t, 3H ).). I3C
NMR (60 MHz, dfi-DMSO) 173.65, 172.03, 79.54, 66.60, 29.12, 27.71, 26.31, 14.07. 
FAB-MS m/z 376.77 (M+H)+.
23.8. 2,2-bis(f-butyIcarboxyethyl) glycine (Bglu(/Bu)2-OH, 2.2c)
O O
> r °
1 o r
1.4 eg. Me4NOH^
H20  / MeOH > r °
1 o
o.ro o
2 .2 b 2.2c
Amino ethyl ester 2.2b (3.0 g, 8.34 mmol) was dissolved in methanol (20 mL) in 
a 100 mL round-bottom flask and 10 mL water was added to the solution. The solution 
was cooled to 0 °C and MejNOH solution (4.26 g, 25% w/w in methanol) was added 
dropwise through a pressure equalizing addition funnel. The flask was sealed with a 
rubber septum and was slowly allowed to rise to room temperature and stirred for 24 
hours. The reaction is monitored by TLC (100% EtOAc) until complete. After the 
reaction was determined to be complete, it was diluted with saturated NaCl (50 mL) 
solution and the pH adjusted to 5.0 with 1.0 N HC1. The methanol was removed in 
vacuo by rotary evaporation and the resulting suspension cooled in the refrigerator at 6  
°C for 24 hours until of the zwitterion precipitated from solution. The precipitated 
zwitterion was removed by suction filtration and dried overnight under high vaccum to 
yield the pure product 2.2c (0.72 g, 26%). lH NMR (250 MHz, d«-DMSO) 8  4.92 (s, 
3H), 2.42-1.91 (m, 8 H), 1.43 (s, 18H) I3C NMR (60 MHz, cfc-DMSO) 18022, 173.78, 
81.87,66.60,34.44,31.41,2831.
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23.9. 3-Carboxy-3-(f-butylcarboxyethyl)-2-pyrrolidinone (2.2d)
O Oo.» n  II^ Nv / ^ 0 H
Me4N0H
a H20/M e0H .0tBu'' tBu
0 0 tBu
2 .2 b 2 .2 d
Amino ethyl ester 2.2b (3.0 g, 8.34 mmol) was dissolved in methanol (20 mL) in 
a 100 mL round-bottom flask and water (10 mL) added to the solution. The solution 
was cooled to 0 °C and Me^NOH solution (4.26 g, 25% w/w in methanol) was added 
dropwise through a pressure equalizing addition funnel. The flask was sealed with a 
rubber septum and slowly allowed to rise to room temperature while stirring for 24 
hours. The reaction was monitored by TLC (100% EtOAc) until complete. After the 
reaction was determined to be complete, it was diluted with saturated NaCl (50 mL) 
solution and the pH adjusted to 5.0 with 1.0 N HC1. The methanol was removed in 
vacuo by rotary evaporation and the resulting suspension cooled in the refrigerator at 6  
°C for 24 hours until the zwitterion precipitated from solution. The precipitated 
zwitterion was removed by suction filtration and the aqueous filtrate further acidified to 
pH 2.0 with 1.0N HQ. The precipitated product was extracted with diethyl ether (2 x 
50 mL) and recrystallized from hot carbon tetrachloride to yield pyrrolidinone 2.2d in 
good yield (2.07 g, 78%) ‘H NMR (250 MHz, d^-DMSO) 8  8.10 (s, 1H), 2.46-1.63 (m, 
8 H), 139 (s, 9H).
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23.10. Ethyl-2,2-bis(f-butyIcarboxymethyI)-2-nitroacetate (23a)
DIEA, TBAI, DMF
O' bromo f-butyl acetate
23a
Ethyl nitroacetate (S.O g, 37.5 mmol) was dissolved in 20 mL DMF in a 250 mL 
round-bottom flask and 2-bromo-/-butylacetate (15.4 g, 78.9 mmol) was added. While 
stirring, tetrabutylammonium bromide (1.39 g, 3.75 mmol) was added in one portion 
and the solution allowed to stir for 15 minutes. In a pressure equalizing addition funnel, 
DIEA (10.7 g, 82,6 mmol) was added dropwise. The rate of addition was controlled to 
keep the temperature of the reaction at under 50 °C. After addition, the reaction was 
sealed tightly and kept at 50 °C for an additional 24 hours while stirring. The 
consumption of 2 -bromo-f-butylacetate can be monitored by gas chromatography. 
After 24 hours, the reaction was allowed to cool to room temperature, diluted with 
diethyl ether (500 mL) and washed successively with IN HC1 (2 x 100 mL), saturated 
aqueous sodium carbonate solution (2 x 100 mL), water (4 x 100 mL) and brine (100 
mL). The organic phase was dried over anhydrous sodium sulfate and the solvent 
removed in vacuo by rotary evaporation. Residual DMF was removed under high 
vacuum over 24 hours. The resulting dark red crude was recrystallized from boiling 
hexane to yield 9.8 g (79%) of analytically pure ethyl-2 ,2 -bis(f-butylcarboxymethyl)-2 - 
nitroacetate (23a) as pale yellow crystals. lH NMR (250 MHz, CDC13) 8  435 (q, 2H), 
335 (dd, 4H), 1.42 (s, 18H), 137 (t, 3H). l3C NMR (60 MHz, CDC13) 167.43,165.07,
90.09,82.64,63.58,39.90,28.15, 13.91. FAB-MS m/z 362.40 (M+H)+
52
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2J.11. Ethyl-2 J-bis(r-butylcarboxymethyI) glycine (23b)
H2 /60P S I _
Raney Ni. EtOH, AcOH ^
23b23a
Ethyl-2 J-bis(r-butylcarboxymethyl)-2-nitroacetate 23a (1.3 g, 3.92 mmol) was 
dissolved in absolute ethanol (10 mL) together with glacial acetic acid (1 mL). A 50% 
(w/w) slurry of Raney nickel in water (1.0 g) was added. The reaction was 
hydrogenated over hydrogen gas (60 psi) for 24 hours. The reaction was monitored by 
TLC (silica gel, 100% DCM). The resulting solution was filtered carefully over Celite 
and the Celite cake washed with EtOH (30 mL). Volatile solvents were removed in 
vacuo and the resulting crude dissolved in diethyl ether (30 mL). The ether was washed 
with saturated sodium carbonate (30 mL) and brine (SO mL). The organic fraction was 
separated, dried over anhydrous sodium sulfate and rotary evaporated to yield 2 J b  in 
excellent yield (1.1 g, 92%) and purity ‘H NMR (250 MHz, CDCI3 ) 8  4.12 (q, 2H),
2.58 (dd, 4H), 2.26 (s, 2H), 1.37 (s, 18H), 120 (t, 3H). l3C NMR (60 MHz, CDCI3 ) 
174.98,169.74,81.50,61.53,57.79,45.05,28.19,1428. FAB-MS m/z 331.8 (M+H)+ 
23.12.2J-bls(/-butylcarboxymethyl) glycine (Basp(fBu)rOH, 23c)
h2n .
LiOH
EtOH, H20
OtBu
23b 23c
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Ethyl-22-bis(/-butylcarboxymethyl) glycine (2.0g, 6.03 mmol) was dissolved in 
absolute ethanol (20 mL). LiOH (0.4g, 18.1 mmol) in water (10 mL) was added and 
the reaction stirred at SO °C until all starting material was consumed by thin layer 
chromatography (silica gel, 100% ethyl acetate, ca. 3 hours). The resulting solution was 
cooled to room temperature, diluted with brine (40 mL) and the ethanol removed in 
vacuo. The aqueous solution was neutralized with IN HC1 to pH 6.0 and the resulting 
precipitate was filtered. The white powder was allowed to dry under vacuum for 24 
hours to yield the analytically pure zwitterion 23c in quatitative yield (1.81.g, 100%). 
lH NMR (250 MHz, cfe-DMSO) 8  2.69 (dd, 4H), 1.40 (s, 18H). l3C NMR (60 MHz, 
dfi-DMSO) 171.80, 171.23,82.40,71.23,59.59,29.51.
23.13. N'-(9-fluorenylmethyloxycarbonyl)-2,2-bis(r-butylcarboxymethyI) glycine 
(Fmoc-Basp(fBu)2-OH, 23)
Fmoc—NDMF. HaO 
DIEA Fmoc-CI
OH
tBuO'
2323c
23c (0.25 g, 0.81 mmol) was dissolved in wet DMF (10 mL) along with DIEA 
(0.22 g, 1.61 mmol). Enough water was added to allow for the amino acid to go into 
solution, and Fmoc-CI (0.20 g, 0.78g) was added in one portion. The reaction was kept 
at 50 °C for 24 hours. IN HQ (30 mL) was added and the reaction extracted with 
diethyl ether (30 mL). The ether was washed with IN HQ (3 x 20 mL) and the organic 
layer dried over Na2 S04. Rotary evaporation gives the crude Fmoc-Basp(/Bu)2-OH in 
fair yield (0.30g, 71%). lH NMR (400 MHz, CDQ3) 8  7.68-7.19 (m, 8 H), 622 (t, 1H), 
426 (d, 2H), 336-2.61 (dd, 4H), 131 (s, 18H).
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23.14. Ethyl-2,2-Bis(2-cyanoethyl)-2-nitroacetate (2.4a)
O
o
acryionitrile
AcCN
DIEA/TEAB
NC' CN
2.4a
Ethyl nitroacetate (8.0 g, 60.1 mmol) was dissolved in acetonitrile (100 mL) in a 
250 mL roundbottom flask together with a magnetic stirrer. N,N’- 
diisopropylethylamine (15.54 g, 120.0 mmol) was slowly added to the solution while 
stirring at 0 °C. A catalytic amount tetraethylammonium bromide (TEAB) (0.63g, 0.3 
mmol) was added, the reaction was sealed with a rubber septum and allowed to stir at 0  
°C for 10 min. Acryionitrile (6.37 g, 120.0 mmol) was added dropwise over a period of 
15 min. The reaction was allowed to slowly rise to room temperature and stirred for 48 
h. The reaction was monitored by TLC (100% dichloromethane) until all starting 
material was consumed. The acetonitrile was then removed in vacuo and dissolved in 
diethyl ether (100 mL). The organic layer was washed with IN HC1 (2 x 100 mL) and 
saturated sodium carbonate solution (2 x 100 mL). The organic layer was separated and 
filtered over a thin pad of silica in a Buchner funnel. The silica was washed with 
diethyl ether (2 x 30 mL) and all organic fractions combined. The ether was dried over 
anhydrous sodium sulfate and removed by rotary evaporation. The desired dialkylated 
a-nitro ester was obtained in good purity with no further need for purification (16.47 g,
84.1%). ‘H NMR (250 MHz, de-DMSO) 5 437 (q, 2H), 2.63 (m, 8 H), 134 (t, 3H) l3C 
NMR (60 MHz, (fe-DMSO) 164.71,118.99,9337,63.58,28.55,13.44,11.79 HRFAB-
55
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MS m/z 262.0809 (M+H)+, EA: CioHl3N30 4 , calc: 5020% C, 5.48% H, 17.56% N, 
found: 50.07% C, 5.36% H, 17.61% N.
22.15. 0-Ethyl-N“-Allyloxycarbonyl-2,2-Bis(f-butylcarbo:xyethyl) glycine
Alloc—NAllooCI
DIEA/DCM
tBu' tButBu tBu
2 .2 b
The a-amino ethyl ester 2.2b (4.0g, 11.1 mmol) was dissolved in anhydrous 
DCM (40 mL) in a round-bottom flask. DIEA (1.72g, 13.4 mmol, 2.33 mL) was added 
in one portion and the reaction cooled to 0 °C in an ice-bath. Allyl chloroformate 
(1.48g, 1224 mmol, 1.30 mL) was added dropwise through an addition tunnel and the 
reaction was allowed to rise to room temperature over 20 h. The reaction was then 
diluted with DCM (50 mL) and washed with 1.0 N HC1 (2 x 100 mL). The organic 
layer was dried over anhydrous sodium sulfate and all volatiles removed in vacuo to 
yield the crude Alloc-Bglu(/Bu)2-OEt as a pale yellow oil (4.82 g, 97%), which was 
used without further purification. lH NMR (250 MHz, (k-DMSO) 6  7.53 (s, 1H), 5.73 
(m, 1H), 527 (dd, 1H), 5.15 (dd, 1H), 4.42 (d, 2H), 4.03 (q, 2H), 2.13-1.81 (m, 8 H),
1.37 (s, 18H), 1.13 (t, 3H). I3C NMR (60 MHz, d«-DMSO) 172.18, 171.57, 154.40, 
133.71,116.74,79.69,6423,60.45,32.30,29.16,28.32,27.66,13.93.
2.4. CONCLUSIONS
Ca,C°-disubstituted amino acids (cmxAAs) are highly useful tools for inducing 
desired secondary structure in short peptide segments. The synthesis of highly water- 
soluble amphipathic peptides with high levels of ococAAs is hindered by the intrinsically
56
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low solubilities of these residues. The synthesis of a series of polyfuctional aaAAs 
have been presented to overcome these difficulties. The incorporation of the Ca,Ca- 
disubstituted lysine analog, Api, into short peptides has been shown to successfully 
induce helical secondary structures while retaining high water solubility. Api has been 
synthesized through the application of the Bucherer-Berg hydantoin hydrolysis to yield 
an orthogonally protected derivative suitable for solid-phase peptide synthesis. 
Problems associated with contamination by bis(/-butyl)carbamate can be overcome by 
utilizing a selective aqueous / organic hydrolysis mixture composed of 2.0 M KOH and 
THF.
The successful application of Bglu/Basp and Bap, will allow for new peptides 
with interesting salt-bridging possibilities and increased amphipathic character in short 
sequences. These derivatives are synthesized by the rapid dialkylation of ethyl 
nitroacetate under weakly basic conditions. Tetraethyiammonium bromide (TEAB) 
facilitates Michael-type alkylations by acting as a highly dissociated counterion. Sn2 
alkylation with r-butylbromoacetate was achieved with DMF/TBAI. The use of a 
tetraalkylammonium iodide in the reaction of alkyl bromides was found necessary to 
result in satisfactory yields. Catalytic hydrogenation of the bis(/-butylcarboxylate) 
derivatives yields the corresponding ethyl amino esters in excellent yield. 
Saponification of the ethyl ester of the Bglu derivative results in rapid intramoecular 
cyclization to yield a racemic mixture of lactams. This was not observed in the 
corresponding 2 ,2 -bis(f-butylcarboxymethyl) derivative, as the cyclization would result 
in a four-membered ring. Na-Fmoc protection yields the orthogonally protected amino 
acid.
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The use of these synthetic pathways allows for the preparation of synthetically
sensitive side-chain protecting groups to be incorporated into polyfunctional amino acid
derivatives. Application of these derivatives in peptide synthesis will give new insight
into sequence induced secondary structure formation and structure-function studies.
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CHAPTER 3
AMPHIPATHIC CONTROL OF PEPTIDE STRUCTURE
3.1. INTRODUCTION
The ability to design desired secondary peptide structure is a major goal in 
peptide studies. How proteins function, as a result of peptide structure, is the central 
dogma of many areas of pharmacology, immunology, cell biology and medicinal 
chemistry. Like learning a new written language, the process of understanding how a 
protein works, is dependant upon one's ability to first have a thorough concept of the 
letters (or amino acids) which make up the alphabet of protein science. Once this is 
achieved, and the basis of the language is established, one moves on to piece the letters 
together to form words, which would represent structural domains within the protein. 
Next, the words are connected to make sentences, paragraphs, chapters and so on, until 
the entire quaternary structure of the protein is realized. However, to understand the 
meaning of what is in the text, one must be able to decipher the code of the words. 
What effect does rearranging the words in a sentence have on the overall expression of 
the sentence? In turn, what effect does rearranging the amino acid sequence of a 
peptide ultimately have on peptide structure and function? To answer this question, one 
must strive towards the ability to determine peptide structure and function a priori from 
specific amino acid sequence.
Protein structure is composed of four levels o f complexity: 1) Primary structure: 
the description of which amino acids are present in the peptide and in what sequence 
they are found. 2) Secondary structure: the local folding pattern that arises, as a direct 
result of hydrogen bonding in the primary sequence. These patterns include primarily 
sheet-type folding or helix-type folding. 3) Tertiary structure: long-distance
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interactions between residues (hydrogen bonding or covalent (disulfide bridging)), 
which induce a globular three-dimensional shape to the protein. 4) Quaternary 
structure: two or more proteins may converge to form a macromolecular cluster, which 
in turn encompass the functional protein.
The determination of peptide secondary structure depends on the intrinsic ability 
of covalent bonds within the peptide backbone to adopt preferred torsion angles. The 
torsion angle about the N-Ca bond of a peptide is denoted by <|>; the torsion angle about 
the Ca-C  bond is denoted by y; and the torsion angle about the amide C’-N bond by to, 
as is shown in Figure 3.1. In the cis configuration, these angles are all given the value 
of 0. Rotation from this point about the bonds, so that the atoms viewed behind the 
bond move clockwise are given positive values up to 180*. Rotation in the 
counterclockwise direction gives a negative torsion angle, to the extent of -180*.3,1 
The torsion angles of conformations such as (3-sheets, a-helices and 3to-helices are well 
established (Table 3.1).
Table 3.1. Parameters for peptide secondary structure. 3 ' 1
Conformation Bond Angle (degrees)
<|> \|f CD
Residues
/turn
Translation 
/residue (A)
Antiparallel [3-sheet -139 +135 -178 2 . 0 3.4
Parallel [3-sheet -119 +113 180 2 . 0 3.2
a-helix -57 -47 180 3.6 1.5
3 io-helix -49 -26 180 3.0 2 . 0
x-helix -57 -70 180 4.4 1.15
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Figure 3.1. Perspective drawing of polypeptide backbone showing two peptide units. 
The peptide is shown in the fully extended trans conformation where <jFtp=ca=180*.
More than any other secondary structure, the helix motif is found throughout 
nature in proteins. Helices are often found in, or near, active sites and constitute a large 
portion of the functional aspect of proteins. Of these helical motifs, the a-helix is by far 
the most prevalent, constituting nearly 80% of all protein structure. The a-helix has 3.6 
residues per turn and a translation per residue of 1.5A, or 5.41A per turn. The torsional 
angles for the a-helix are very favorable for most amino acids. The structure is 
characterized by the rth carbonyl oxygen of each residue hydrogen bonding to the 
backbone amide N-H bond of the r+4th residue along the chain. These hydrogen bonds 
are nearly parallel to the helix axis (Figure 3.2). This allows most proteinogenic amino 
acids to adopt the conformation without side chain interaction. Only proline is not 
found in the a-helical motif. 3 ' 1
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Figure 3.2. Hydrogen bonding pattern of the right handed a-helix.
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Figure 3 J . Hydrogen bonding pattern of the right handed 3io-helix.
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Although similar in structure, the a-helix is much more stable and occurs more 
frequently than it's relatively unexplored cousin, the 3io-helix; which comprises <1 0 % 
of all helix structure and is often found at the ends of a-helices (Figure 3.3). While the 
factors favoring a-helical (i«—i+4) structures have been well documented, the secrets of 
the 310-helical conformation (/<— i + 3 hydrogen bonding) have only recently begun to 
be understood. This helix is, however, gaining interest, as it is believed to be a folding 
intermediate to the a-helical configuration. 3 -2 ' 7  In addition, short stretches of 3io-helix 
frequently occur in globular proteins and protein recognition steps may involve facile 
transitions between the a-helix and 3io-helix. 3 -2 ' 10 Thus, the ability to understand and 
control the delicate equilibrium between these two closely related structures is desirable 
in the development o f peptide design research.
Most studies exploring the equilibrium between the a- and 3io-helix have been 
concentrated on short, hydrophobic peptides containing several Ca,Ca-disubstituted 
amino acids (aaAA’s) . 3 -1 1 ' 14 Natural a-helical sequences commonly require more than 
20-30 amino acid residues to obtain a significant helical character at room 
temperature. 3 -15 ' 17 However, the incorporation of high levels of C“,Ca-disubstituted 
amino acids (e.g. aminoisobutyric acid) into the sequence allows for the preparation of 
much shorter peptides with significant helical character (Figure 3.4) . 3-12’ 14,18 ' 2 2  These 
peptides, however, exhibit higher hydrophobic character than their proteinogenic 
counterparts. As a result, spectroscopic studies of these peptides have often been 
limited to organic solvents such as dimethylsulfoxide (DMSO), methanol, 
trifluoroethanol (TFE) and acetonitrile. Structures of these peptides have also been 
obtained by X-ray analysis of crystals grown from organic solvents. 3 -1 9 ,2 3 ,2 4 Recently,
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Toniolo and co-workers have reported spectroscopic studies of a peptide exhibiting 310- 
helical structure in water by the incorporation of the novel, aza-crown amino acid 
ATANP.3-25,26 Due to the interest of these helical configurations as they relate to 
physiological conditions and membrane interactions, it is important to study the helix 
equilibrium in aqueous/organic environments.
The first characterization of the amphipathic helix was performed by Kendrew 
and Perutz on the heme proteins.3-27 These structures are defined by the presence of a 
hydrophilic face and a hydrophobic face along the axis of the peptide. The tendency of 
these types of structures to self-associate and interact with bi-lipid membranes results in 
high levels of bioactivity and they play an important part in membrane-dependent 
processes3-28 as well as lipoproteins3-29, hormones3-30, lung surfactant proteins331, 
cytotoxic immunodefense proteins3-32 and antimicrobial agents.3-33
The use of Ca,Ca-disubstituted amino acids in synthetic helix design has been 
shown to induce high levels of helicity into short peptide sequences by introducing 
steric constraints on the peptide backbone. This has been exhaustively investigated 
with the use of a-aminoisobutyric acid, Aib (1, Figure 3.4)3-11'14, but also with the use 
of alicyclic amino acids, such 1 -cyclohexane-1 -carboxylic acid, Ac$c (2, Figure
3.4).3-12-34 Recently, the availability of the ionizable Ca,C°-disubstituted amino acid 4- 
aminopiperidine-4-carboxylic acid, Api (3, Figure 3.4) allows us to investigate the 
helix-forming ability of highly polar cyclic residues towards peptide secondary 
structure.3-35 In addition to introducing high levels of helicity to the peptide, aaAAs 
stabilize the peptide towards enzymatic degradation in vivo, which is important in the 
development of bioactive agents.
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HHalk CH3 0  Q
h2n c o 2h h2n c o 2h h2n c o 2h
1 2 3
Figure 3.4. Ca,Ca-Disubstituted amino acids aminoisobutyric acid (Aib) 1, 1- 
aminocyclohexyl-1 -carboxylic acid (Ac6c) 2 and 1 -aminopiperidine-1 -carboxylic acid 
(Api) 3.
Amphipathicity is a characteristic found in most naturally occurring 
antimicrobial peptides such as magainins, cercropins and dermaseptin.3'36 Due to the 
high levels of bioactivity of amphipathic peptides, it is not surprising that 50% of all ot- 
helices in soluble globular proteins are amphipathic.3*37 The amphipathic character of 
these peptides is thought to play a dominant role in the peptide-membrane interactions, 
which are responsible for antimicrobial activity. These amphipathic membrane 
interactions prompted us to investigate peptide helicity in micellar and aqueous/organic 
environments. Researchers have demonstrated that amphipathicity and hydrophobic 
interactions have a large influence on helix stability in aqueous solution.3*37 By 
generating sequence permutation isomers of several peptides, we have attempted to 
selectively induce a - or 3t0-helices, based purely on primary sequence design. 
Incorporation of ionizable and alicyclic Ca,Ca-disubstituted amino acids allow for the 
production of short, amphipathic peptides with up to 80% Ca,Ca-disubstituted amino 
acids which are highly water soluble, but retain helical character in organic and 
aqueous/organic media (Table 3.2). Each peptide is designed to have maximum 
amphipathic character either as an a-helix or a 3io-helix.
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Table 3.2. List of prepared de novo peptides. The incorporation of 20% L-lysine (Lys) 
allows for CD spectroscopic determination of peptide secondary structure by inducing 
right-handed helix formation. Pi-10, ACh-lOa and Cyh-10 were designed to be 
perfectly amphipathic as an a-helix while Ipi-10, ACh-10 and Ich-10 were designed to 
be perfectly amphipathic as a 3io-helix.
Peptide Sequence Design
Pi-10 H-Aib-Aib-Api-Lys-Aib-Aib-Api-Lys-Aib-Aib-NH2 a
Ipi-10 H-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2 3io
Ach-lOa H-Ac6c-Aib-Lys-Api-Aib-Ac6c-Api-Iys-Ac6c-Aib-NH2 a
Ach-10 H-Api-Aib-Ac6c-Lys-Ac6c-Aib-Iys-Aib-Ac6c-Api-NH2 3io
Cyh-10 H-Ac6c-Ac6c-Api-Lys-Ac6c-Ac6c-Api-Lys-Ac6c-Ac6c-NH2 a
Ich-10 H-Api-Ac6c-Ac6c-Lys-Ac6c-Ac6c-Lys-Ac6c-Ac6c-Api-NH2 3io
The ability of the peptides to selectively adopt their preferred helical motifs can 
be illustrated by studying the helical wheel conformations of the peptides in their a- and 
their 3io-helical configurations. Amphipathicity is maximized when the peptides have a 
continuous hydrophobic and a continuous hydrophilic face. Otherwise hydrophilic 
residues are distributed throughout the cross-section of the helix. The work presented in 
this chapter tests this premise as a design principle. The general sequence of our a- 
helical peptides is: H-N-N-P-P-N-N-P-P-N-N-NH2; (N=non-polar residues; P=polar 
residues) and our 3to-helical peptides have the sequence: H-P-N-N-P-N-N-P-N-N-P- 
NH2. Peptides designed to adopt the a-helical amphipathic conformation are less 
amphipathic in the 3io-helical form and vice versa, (Figure 3.5-11).
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a-helical wheel
©
Preferred Conformation Non-preferred Conformation
Figure 3S . Helical wheel cross-sections of empirical peptide sequences in their 
preferred conformation and non-preferred conformations. P designates ionizable polar 
amino acid residues (Lys or Api); N designates non-polar residues (Aib or Acec). 
Empty circles represent non-occupied locations in the alpha helical wheel.
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a-helix
(preferred)
3io-helix
(non-preferred)
® Lv*
Figure 3.6. Helical wheel motifs showing a-helical and 3io-helical conformations of 
Pi-10 (designed to be a-helical).
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©oc-helix
(non-preferred)
Api
Mb
Mb
Mb
X
©
Figure 3.7. Helical wheel motifs showing a-helical and 3io-helical conformations of 
Ipi-10 (designed to be 3io-helical).
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a-helix
(preferred)
l»»X ^
Api
cyti
Aib
Api
Cyh
L** Y Aib
3io-heUx
(non-preferred) Apt
Api
Cyh
Alb
AbCyh
Uy*Cyh
Figure 3.8. Helical wheel motifs showing a-helical and 3io-helical conformations of 
ACh-lOa (designed to be a-helical; Cyh=Ac6c).
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3 io-helix
(preferred)
/ubX **•
Cyh
a-helix
(non-preferred)
Cyh
Ly*
V
Figure 3.9. Helical wheel motifs showing a-helical and 3io-helical conformations of 
ACh-10 (designed to be 3io-helical; CyhFAcec).
75
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
a-helix
(preferred)
Cyh
Cyh
Cyh
Api
Cyh
Y Cyh
Cyh
Api
3io-helix
(non-preferred) ®( Ly«
Cyh
Api
Cyh
Cyh
Cyh
Cyh
Figure 3.10. Helical wheel motifs showing a-helical and 3 io-helical conformations of 
Cyh-10 (designed to be a-helical; Cyh=Ac6c).
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3to-belix
(preferred)
@( Ly«
( = $ #
©
Cyh
Lyta-helix
(non-preferred'
Cyh
Cyh
^  Y Apt
Figure 3.11. Helical wheel motifs showing a-helical and 3io-helical conformations of 
Ich-10 (designed to be 3io-heIical; Cyh=Ac6c).
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In order to study the relative formation of 3io- and a-helices in the 
aforementioned peptides, one needs to distinguish between the two. For this purpose, 
electronic circular dichroism (ECD) spectroscopy has been established as a powerful 
tool, hi ECD spectroscopy, helical peptides are characterized by two minima. The 
n—mc* transition is centered around 222 nm and one of the two the 7t—>7t* transitions is 
centered near 207 nm. Since both the 3io- and a-helices exhibit these minima, the 
relative intensities of the minima are used to distinguish between a-helical and 310- 
helical structures. The ratio, R, where R = [0]n-nc*/[6]n-««, has been proposed as the 
factor to distinguish a 3io-helix from an a-helix. In 3io-helices R < 0.4, while for a- 
helices R = l.3'38 An additional distinguishing feature is the positive CD band near 195 
nm. This band is much weaker in the 3io-helix than in the a-helix. Other techniques 
such as electron spin resonance and NMR are complicated by peptide dynamics and 
have met with mixed results, especially with peptides containing aaAA’s.3'39'41
As stated previously, a sufficient database of 3to-helix structures does not yet 
exist. As a result, exact estimation of % 3to-helicity in a specific peptide is very 
difficult. It has been suggested that the CD bands of a 3io-helix will be highly 
dependent on the <|>- and nt-torsion angles in the peptide backbone. 3io-HelicaI peptides 
comprised of aaAA’s have different <(>- and y-angles than 3io-helical peptides 
comprised only of natural amino acids. Toniolo and co-workers synthesized Ac- 
(cxMeVal)g-OtBu which exhibited significant 3io-helical structure, and recently reported 
a short peptide exhibiting significant 3io-helical structure in water.3*38,42 The peptide 
contains the novel azacrown functionalized amino acid, 2-amino-3 - [ 1 -(1,4,7- 
triazacyclononane)] propanoic acid.3,26
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3.2. RESULTS AND DISCUSSION
It was hypothesized that the peptides would adopt the helical structure that 
allowed them to be most amphipathic. As expected, Pi-10 (Figure 3.12), ACh-lOa 
(Figure 3.14) and Cyh-10 (Figure 3.16) shows CD spectra characteristic of an a-helix in 
all solvent systems. Ipi-10 (Figure 3.13) and ACh-10 (Figure 3.15) display a transition 
from an a-helix to a 3io-helix as the solvent system increases in organic content. The 
most prominent 3io-helical character for both Ipi-10 and ACh-10 was observed in SDS 
micelles, which indicates that an amphipathic environment strongly favors the 
amphipathic structure in the peptide. It was expected that Ich-10 would display this 
same transition; however, this does not occur. Ich-10 displays an nearly perfect a- 
helical CD-spectrum in all of the solvent systems tested (Figure 3.17). This effect may 
be due to steric interactions between adjacent cyctohexano moieties in the tightly 
wound 3io-helix (see modeling in figure 3.11). A transition to an a-helix would relieve 
this stress by increasing the diameter of the helix, as well as staggering adjacent 
alicyclic groups to avoid interference. It is interesting to note the prominent minimum 
present at 185 nm for both of these 3io-helices in SDS micelles. These minima are not 
found in any of the a-helical peptides, nor are they apparent in the constitutional 
isomers of Ipi-10 and Ach-10. Thus, one must assume that this transition is structure 
based and not an effect of solvent or residue absorption. This minimum has seldom 
been studied due to solvent interferences in the <190 nm region. It may, however, be an 
important factor in the interpretation of 3io- vs. a-helical segments. Further 
investigation into the significance of these minima in 3io-helical peptides is currently 
underway.
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Figure 3.12. CD spectrum of Pi-10 in various solvent systems.
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Figure 3.13. CD Spectrum of Ipi-10 in various solvent systems.
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The percent a-helix was estimated according to the following: percent a-helix 
= -lOOCfBjn-Hf + 3000)/33000, where the minimum for the [0]n-wi* transition is 
observed in the range 222-225 nm. Little work has been done to quantify the percent 
3[o-character in a helix; therefore, we have used the CD spectrum of H-(Leu-Arg-Leu)g- 
OH in diphosphatidyl-choline liposomes as the model 3io-helix.3'42 In this peptide, 
= -21,500 deg cm2 dmol'1 is defined as 100% 3io-helix. Using this model, the 
above equation is modified to estimate percent 3io-helicity: percent 3to-helix = - 
1 OO([0]ff_«./-21500). It should, however, be noted that the issue of determining relative 
amounts of 3io-helical character is still under review and a widely accepted 
determination of % 3io-helicity is still not available. The results of CD-spectra 3.12-17 
are summarized in Tables 3.3,4 and 5. The peptides showed minimal structure in water 
or pH 7.1-7.4, 2.5 mM phosphate buffer. This is not surprising since solvation of the 
ionizable residues, which account for 40% of the peptide composition would inhibit 
intramolecular hydrogen bonding patterns necessary for secondary structure formation. 
Interestingly, Pi-10, ACh-lOa and Cyh-10 all exhibit an isodichroic point near 201,203 
and 205 nm, respectively. This suggests a cooperative helix/coil transition. An 
additional observation is the reduction of helicity as organic solvent composition 
declines. The increase in helicity as the solvent system becomes rich in organic 
composition has been observed in other monomeric a-helices.337 Others have predicted 
that peptides with high percentages of aaAA’s 50%), such as Pi-10 and Cyh-10, 
would be 3 io-helical.319,43 In addition, theoretical calculations suggest these peptides 
would exhibit a shift to a 3io-helix as organic content increases.33 This is not observed 
in our studies, suggesting that amphipathy is a significant factor in determining helix
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Table 3 3 . CD data and calculated structural information for Pi-10 and Ipi-10.a Peptide 
concentration was 200 pM. b Units for [0] are deg cm2 dmol'1. c The minimum for the 
[0]jc-*x* band is taken in the range from 205-209 nm. d The minimum for the [9]n-»x* 
band is taken in the range from 222-225 nm. e In this solvent, Ipi-10 is probably 
mixtures of coil structures. The % a-helix is estimated to be -20% and the % 3io-helix 
is estimated to be -30%.
Peptide* Solvent ieix^ R % Helicity Helix
Pi-10 25 mM SDS -8748 -7933 0.90 33 a
9:1 CHjCN-TFE -10709 -7930 0.74 33 a
9:1 CH3CN-H20 -6184 -4287 0.71 22 a
1:1 CHjCN-HjO -3181 -2128 0.66 15 a
Ipi-10 25 mM SDS -5516 -1750 0.32 25 3io
9:1 CHjCN-TFE -9916 -3145 0.33 33 3 to
9:1 CHjCN-HiO -6740 -3605 0.54 e e
1:1 CHjCN-H20 -4204 -3118 0.74 19 a
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Table 3.4. CD data and calculated structural information for ACh-lOa and ACh-10.a 
Peptide concentration was 200 pM. b Units for [0] are deg cm2 dmol'1. 6 The minimum 
for the [0]*-*. band is taken in the range from 205-209 nm. d The minimum for the 
[0]n-Mc* band is taken in the range from 222-225 nm. e In this solvent, ACh-10 is 
probably mixtures of coil structures. The % a-helix is estimated to be ~20% and the % 
3io-helix is estimated to be ~30%.
Peptide* Solvent I 9 U V [01b-«*M R % Helicity Helix
ACh-lOa 25 mM SDS -9542 -7218 0.76 31 a
9:1 CHjCN-TFE -10580 -6714 0.63 29 a
9:1 CH3CN-H20 -4334 -3358 0.77 19 a
1:1 CH3CN-H20 -2943 -1886 0.64 15 a
ACh-10 25 mM SDS -3288 -893 027 15 3 io
9:1 CHjCN-TFE -7480 -4622 0.62 e e
9:1 CH3CN-H20 -6898 -5785 0.84 27 a
1:1 CH3CN-H20 -6869 -6494 0.95 29 a
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Table 3.5. CD data and calculated structural information for Cyh-10 and Ich-10. * 
Peptide concentration was 200 pM. b Units for [0] are deg cm2 dmol'1. c The minimum 
for the [0]x-»k« band is taken in the range from 205-209 nm. d The minimum for the 
[0]n-«* band is taken in the range from 222-225 nm.
Peptide* Solvent [el*-**6* [ e i n ^ R % Helicity Helix
Cyh-10 25 mM SDS -10874 -9978 0.92 39 a
9:1 CHjCN-TFE -10285 -9014 0.88 37 a
9:1 CH3CN-H20 -9339 -8185 0.88 34 a
1:1 CHjCN-HjO -7846 -7027 0.88 30 a
Ich-10 25 mM SDS -4792 -5461 1.14 26 a
9:1 CHjCN-TFE -10959 -8063 0.73 33 a
9:1 CHjCN-HjO -6974 -6094 0.87 28 a
1:1 CH3CN-H20 -6766 -6579 0.97 29 a
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structure. The transition of Ipi-10 from an a-helix to a 3io-helix and the lower R-value 
fen* Ich-10 in 100% organic solvent agrees with predictions of solvent effects on the 3io- 
/a-helix equilibrium. It has been shown that peptides rich in Aib favor a 3io-helix in 
less polar media and an a-helix in water.3*3 The increased stability of the 3io-helix in 
non-polar solvents is attributed to the extra hydrogen bond formed relative to the a- 
helix. a-Helices are favored in water because the “extra” carbonyl and amide are able 
to interact with the solvent For Pi-10, Ich-10, Cyh-10 and Ach-lOa, a maximum 
number of 7 hydrogen bonds are possible in the a-helix conformation. For Ipi-10 and 
ACh-10, in 3io-helical structure, 8 hydrogen bonds are possible. Helix end effects and 
incomplete micelle binding tend to reduce the absolute helicity of peptides. In the case 
of Pi-10, ACh-lOa, Cyh-10 and Ich-10, three N-terminal amides and the two C- 
terminal carbonyls do not have any internal hydrogen bonding partners. For Ipi-10 
and ACh-10, the two N-terminal amides and the two C-terminal carbonyls are without 
internal hydrogen bonding partners. As a result, the peptides may adopt non-ideal 
structures at the ends to interact with solvent.
Temperature studies of a number of the peptides show a surprisingly high 
stability towards helix melting in the range 5-50 °C. This further confirms the theory 
that a,a-disubstituted amino acids stabilize helix stability towards temperature 
denaturation, as well as enzymatic hydrolysis.313 Representative CD spectra of ACh-10 
in SDS micelles and Cyh-10 in 9:1 acetonitrile/TFE are shown in Figure 3.18 and 3.19. 
This relatively small deviation in peptide helicity as a result of increasing temperature 
in the range between 5-50 °C was, however, observed in all of the peptides. Helicity 
was not determined at 0°C due to the insolubility of SDS micelles at that temperature.
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Figure 3.18. Helix stability temperature studies of ACh-10 in 25mM SDS micelles. 
Note the strong minimum at 186 nm.
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Figure 3.19. Helix stability temperature studies of Cyh-10 in 9:1 CH3CN-TFE.
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33. EXPERIMENTAL
33.1. Peptide synthesis
Peptides were synthesized using standard Fmoc-amino acid fluoride coupling 
conditions. The first 3 or 4 residues were manually coupled onto PAL-PEG-PS solid 
support by gently stirring 8  equivalents of the Fmoc-acid fluoride, 3 equivalents of 
DIEA and the resin in methylene chloride, until an acceptable yield was determined by 
quantitative Fmoc test. Sometimes gentle reflux was required to obtain successful 
coupling. After the first residues were coupled to the resin, the remainder of the peptide 
was synthesized using a Milligen 9050 peptide synthesizer on the PAL-PEG-PS solid 
support using 8  equivalents of preformed Fmoc-amino acid fluorides, 3 equivalents of 
DIEA and a 1.5 h recycling time. Residues were double coupled when they are third in 
a series of Ca,Ca-disubstituted amino acids and the coupling times were extended to 2.5 
hrs. A solution of 20% piperidine / 2% l,8-diazabicyclo[4.5.0]undec-7-ene (DBU) in 
DMF was used for Fmoc removal. The peptides were simultaneously cleaved from the 
resin and side-chain deprotected using reagent B (8 . 8  : 0.2 : 0.5 : 0.5, trifluoroacetic 
acid (TFA) : triisopropylsilane : water : phenol). The resulting acidic solution was 
diluted with cold 30% acetic acid, washed with diethyl ether (4 x 50 mL), and 
lyophilized.
33.2. Peptide Purification
The crude peptides were purified by preparative reverse-phase HPLC on a 
Waters 15 pM Deltapak C4  column using a water (0.05% TFA) and acetonitrile (0.05% 
TFA) gradient system. The gradient was run from 10% to 50% organic and the 
absorption monitored at 222 nm. Purity of the peptides was then checked on a Vydac 5
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jiM Cis column using the same conditions. Matrix assisted laser desorption ionization 
(MALDI) mass spectrometry was used to verify the peptide masses. All peptides were 
analyzed in positive ion mode using a glycerol matrix. Pi-10,1037.1 (M+H)+; Ipi-10,
1037.1 (M+H)+; ACh-lOo, 1157.6 (M+H)+; ACh-10, 1157.6 (M+H)+; Cyh-10, 1277.8 
(M+H)+; Ich-10,1277.8 (M+H)+.
3 3 3 . Circular Dichroism
Circular dichroism measurements were taken on a (+)-camphor sulfonic acid 
calibrated Aviv 60DS spectrophotometer at 5°C. The measurements were recorded 
over 250-180 nm using a 0.1 cm path length quartz cell, 1 nm bandwidth, 10 nm/min 
scan speed and a 5 second time constant. Background spectra were acquired prior to 
each sample spectrum and the two subtracted. Three repetitive scans were recorded and 
averaged to improve signal to noise. The reported mean residue ellipticity [6] (deg cm2 
dmol'1) was derived from the observed ellipticity, [6]obs (millidegrees), using the 
formula [0] = [0]obs (MRW/10/c), where MRW is the mean residue molecular weight of 
the peptide (molecular weight of the peptide divided by the number of peptide bonds), / 
is the pathlength (cm) and c is the peptide concentration (mg/mL). CD spectra of all 
peptides in this study were taken in solvent systems ranging from 100% organic to 1:1 
organic/water. Final peptide concentrations of 0.2 mM were used for all CD 
experiments. The peptides were dissolved in trifluoroethanol for spectra taken in 9:1 
CH3CN:TFE, pH 7.1-7.4, 2.5 mM phosphate buffer for spectra taken in SDS, and 
doubly distilled water for the aqueous/organic spectra. For representative 
aqueous/organic experiments, pH 7.1, 2.5 mM buffer was also used as the aqueous 
component and resulting spectra were nearly identical to the pure H2O/CH3CN spectra!'
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3.4. CONCLUSIONS
Ca,Ca-Disubstituted amino acids have long been recognized as powerful tools 
for inducing helicity into relatively short peptide sequences. With this work, we have 
shown that amphipathicity, too, is a significant driving force in the secondary structure 
adopted by short peptides rich in Ca,Ca-disubstituted amino acids. Increasing helicity, 
and a transition from a-helix to 3to-helices as a result of increasing organic 
environments may suggest that there is a cooperative aggregation by the hydrophilic 
side of the amphipathic helices in organic solvents. In addition, it is shown that 
mi cellar environments, similar to those found under physiological conditions, have a 
significant effect upon the ability of peptides to adopt an amphipathic configuration. It 
is interesting to hypothesize as to the nature of Ich-10 and why it does not, in fact, adopt 
the 3 10-helical formation. Previous studies have supported the fact that cyclic aaAAs 
form stable 3i0-helices. This does not, however, occur in the case of Ich-10. It is 
possible that steric repulsion, due to the eclipsed i and t+3rd residues in 3io-helical 
segments, is a determining factor.
The study of the bioactivity of these types of peptides may lead to the 
development of new therapeutic agents that act by selective interactions with cellular 
membranes of macrophages that are infected with pathogenic bacteria such as Brucella 
abortus and Afycobacterium tuberculosis. The bioactivity assays and selectivity of the 
peptides included in this study are described in chapter 4 of this manuscript.
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CHAPTER 4
SELECTIVE BIOACTIVITY OF SYNTHETIC AMPHIPATHIC 
PEPTIDES AGAINST AN INTRACELLULAR PATHOGEN
4.1. INTRODUCTION
Brucella abortus (Ba) and Mycobacterium tuberculosis (Mtb) are intracellular 
pathogens that live and replicate within the macrophages of their hosts.4'1 Ba are rod­
shaped gram-negative bacteria which are the primary cause of brucellosis, or undulant 
fever in humans.4'2 The fever is characterized by fever, anorexia, muscular weakness, 
arthritis and dementia, as well as cardiac and neurological disorders, and may be fatal if 
untreated.4,3 In animals, Ba localizes in the reproductive organs, resulting in abortion 
and infertility.4'4,5 Human infection often results from exposure to infected animals or 
infected animal products, thus brucellosis is a prominent occupational hazard for 
humans whom are involved with animal handling.46 Since the bacteria live and 
replicate within the white blood cells of the host, treatment is difficult. The multiple 
membrane barrier which seperates the pathogen from the extracellular environment 
reduces the antibiotic concentration within the macrophage and reduces the 
effectiveness of the antibiotic.4'7,8 In addition, the mechanism by which these organisms 
survive and replicate within host macrophages is poorly understood.4'15,16
Mycobacterium species are intracellular pathogens that cause diseases with 
etiologies similar to Brucella. Afycobacterntm tuberculosis {Mtb), the causative agent 
of tuberculosis, and is one of the more worrisome elements of the developing antibiotic- 
resistance problem since Mtb patients that fail treatment have a high risk of death. The 
pathogen infects about a third of the world’s population and kills more people, about 
two million each year, than any other infectious agent besides HIV/AIDS.4'9*12 Unlike
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many lethal pathogens, Mtb has been found on all continents and is especially prevalent 
in countries of the former Soviet Union.4'13
Mtb is a rod-shaped, acid-fast Gram-positive bacterium that localizes mainly in the 
respiratory system. The symptoms of tuberculosis include low-grade fever, night 
sweats, fatigue, weight loss and persistent cough. Like Ba, Mtb can live and replicate 
within a host’s macrophages, making it difficult to treat Current treatment consists of 
short-course chemotherapy based on a regiment of four first-line drugs taken for 6-8 
months.4,9,10,12 In addition, there are currently no vaccines to prevent Ba or Mtb in 
humans.4,14 Many strains of Mycobacterium now resist antibiotics, making the 
development of alternative treatments critical.
Due to exponential growth in the use of classical antibiotic therapy, bacterial 
resistance towards antibiotics is becoming an ever growing problem. This problem is 
exacerbated in the case of intracellular pathogens since they reside within the cellular 
environment of the very immune system which is used to target it and infection is not 
associated with a significant extracellular component of the pathogen. Because of this 
resistance problem, several new approaches towards antimicrobial defense have been 
explored within the past twenty years. One of the most promising routes toward 
developing a new weapon to battle bacterial agents have been the growing interest in 
linear amphipathic peptides as antimicrobial agents. Amphipathic peptides are highly 
ubiquitous in nature and make up an important part of the natural defenses of several 
species of invertebrates,4,17*22,36,37 fish,4-23"26 amphibians,4'27'30'39,40 and mammals.4"31,32,42 
The peptides are characterized by the presence of a definable cationic amphipathic 
helical structure and are usually relatively short (<40 residues), thus suggesting that
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considerable biological activity can be exhibited by relatively short sequences.433 
These peptides have been found to be active against a wide array of pathogens, 
including gram-positive and gram-negative bacteria, protozoa, and fungi.434 Although 
currently not prevalent as therapeutic agents, some peptides are currently under review 
for use as drugs. Recently, Hancock reviewed two antimicrobial peptides that are 
currently being clinically studied as topical treatments for oral mucositis and the 
sterilisation of central venous catheters.435 Some examples of naturally occuring, linear 
antimicrobial peptides are listed in Table 4.1.
Table 4.1. Naturally occurring antimicrobial peptides.
Peptide Source Ref.
Andropin Fruit Fly (Drosophila melangaster) 4.36
Bombolitin Bumblebee (Megabombus pennsylvcmicus) 4 J7
Cercropin A Silk Moth (,Hyalophora cercropia) 4.18
Clavanin A Tunicate (Styela clava) 4 J*
Dermaseptin 1 Arboreal frog (Phyllomedusa sauvageii) 4 J9
Magainin 1 South African clawed frog (Xenopus laevis) 4.40
Melittin Honeybee {Apis mellifera) 4.41
Pleuroddin Winter flounder {Pleuronectes americanus) 423
Seminalplasmin Ox {Bos taurus) 4.42
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There has been overwhelming evidence to suggest that these peptides function 
by a non-receptor mediated response, thus making them less susceptible towards the 
development of resistance.4’43"47 This has been established by the fact that most 
antimicrobial peptides are equally active in their D- and L-isoforms. Peptides are, 
apparently, initially attracted to cellular membranes by coulombic interactions. The 
charge on the polar face of the peptide cross-section is almost exclusively positive, 
which accounts for the peptides’ selectivity and bioactivity towards bacterial cells. 
Bacterial cell membranes are unique in that they contain lipopolysaccharides (gram- 
negative) or teichoic and teichuronic acids (gram-positive), giving their cell membrane 
a predominantly negative charge, which attracts the positive charge of the peptides.434 
Mammalian cells are composed predominantly of zwitterionic sphingomyelin 
phospholipids, which have been shown to show low affinity for natural antimicrobial 
peptides.433,34 Although there have been several theories on the mode of action of 
antimicrobial peptides, it is generally accepted that they function by cellular membrane 
permeation after a threshold concentration has been established on the cell surface. 
Most antimicrobial peptides are non-helical in solution, which makes pre-surface 
aggregation to form rod-like pores, that insert into the membrane, an unlikely scenario. 
Hydrophobic partitioning of the surface peptides into the amphipathic environment of 
the cellular membrane induces helix formation and disrupts the membrane integrity by 
one of two proposed mechanisms: the “carpet model”4'48 or the “barrel-stave
model”.4*49 Each of these models involves the aggregation of peptides on the cell 
surface and disruption of the cellular membrane. However, the process by which the 
membrane is permeabilized varies between the two mechanisms. The carpet
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mechanism is characterized by massive peptide aggregation on the cell surface with the 
non-polar face of the peptides incorporated into the hydrophobic interior of the lipid bi­
layer and the polar face facing the exterior of the cell (A). This aggregation is most 
likely electrostatically driven between the negative phospholipid headgroups and the 
positive charge of the amphipathic peptide. When a threshold concentration of peptide 
has been reached, the membrane can fold in on itself (B), exocytizing a portion of the 
membrane as a solubilized micelle (Q , resulting in membrane disruption. (Figure 4.1).
barrel-atave" mechanismcarpet" mechanism
mum
nmaffimmr
Figure 4.1. "Carpet" vs. "Barrel-Stave" mechanism of amphipathic peptide-cell 
membrane insertion (reproduced from: Oren, Z., Shai, Y. Biopolymers, Pept. Set 1999, 
451-463).
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The “barrel-stave” model follows a different pathway. It assumes that peptides 
aggregate into a pore-like superstructure on the surface prior to membrane interaction 
(A). The pre-formation of a peptide-aggregate pore allows a relatively small number of 
peptides to acquire great potency as membrane disruptors. After the intial pore 
formation, the pore inserts itself into the membrane causing cell lysis (B). This model 
holds less credence for explaining the activity of shorter peptides (<20 residues), which 
in theory do not have the physical size to transverse the cell membrane bilayer (—35 
A).434 Because the peptide-host interaction is not receptor mediated, the issue of 
selectivity has always been a key factor to consider in anti-microbial peptide design. 
This question of selectivity may be overcome by the presence of hyper-susceptibility of 
target cells towards the attacking peptide.
Due to the promising outlook of amphipathic peptides as potential antimicrobial 
agents, six helical amphipathic peptides were designed to act as natural antimicrobial 
peptide analogs. Incorporation of high levels of Ca,Ca-disubstituted amino acids 
allowed for the preparation of amphipathic helices which were helical in amphipathic 
environments despite very short sequences (10 residues, see chapter 3). In addition, the 
presence of Ca,Ca-disubstituted amino acids prevents enzymatic degradation of the 
peptides in vitro and in vivo. The designed peptides are shown in Table 4.2.
These peptides were designed to be either 3io- or a-helical based on amphipathic 
distribution of the residues (see chapter 3). Although preliminary testing of the direct 
bacteriacidal activity of these peptides showed low to moderate direct effect towards 
bacteria, the selectivity o f Pi-10 towards killing macrophages infected with intracellular 
pathogens such as Ba and Mtb430 prompted us to further investigate the selectivity of
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the rest of this family of peptides. Studies on the effect of these peptides on 
intracellular pathogens, such as Ba, may provide insight in to the development of 
therapeutics to battle infections o f higher current interest, such as Mtb.
Table 4.2. List of prepared de novo peptides. The incorporation of 20% L-lysine (JLys) 
allows for CD spectroscopic determination of peptide secondary structure by inducing 
right-handed helix formation. Pi-10, Ach-lOa and Cyh-10 were designed to be 
perfectly amphipathic as an a-helix while Ipi-10, Ach-10 and Ich-10 were designed to 
be perfectly amphipathic as a 3io-heIix.
Peptide Sequence Helix Design
Pi-10 H-Aib-Aib-Api-Iys-Aib-Aib-Api-Z.ys-Aib-Aib-NH2 a
Ipi-10 H-Api-Aib-Aib-£y -^Aib-Aib-Z!yj-Aib-Aib-Api-NH2 3jo
Ach-lOa H-Ac6C-Aib-£ys-Api-Aib-Ac6C-Api-Z,ys-Ac6C-Aib-NH2 a
Ach-10 H-Api-Aib-Ac6c-Lys-Ac6c-Aib-Ly.y-Aib-Ac6c-Api-NH2 3io
Cyh-10 H-Ac6c-Ac6c-Api-Lyj-Ac6c-Ac6c-Api-Iy5-Ac6c-Ac6c-NH2 a
Ich-10 H-Api-Ac6C-Ac6C-Z,_V5-AcsC-Ac«c-£._ys-Ac6C-Ac6C-Api-NH2 3io
To test the hypothesis, that the selective cytocidal character of the peptides are 
dependent on the activation of the macrophage membrane, in vitro activation of protein 
kinase C (PKQ was performed with the application of PMA.4-53,54 PMA (Phorbol 12- 
myristiol 13-acetate) is a polycyclic alcohol derived from croton oil, and is persistent in 
physiological conditions as it is not readily degraded. PMA is a known activator of
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PKC when applied in a short-term manner, and mediates the response to a number of 
hormones and growth factors, which stimulate phospholipid hydrolysis (via 
phospholipase C, D, and A2).4'ss The activation includes the translocation of PKC to 
cellular membranes as a result of increased levels of n-1,2-diacy Iglycerol (DAG) of 
fatty acids.4,56 12 PKC isoforms are described: conventional PKC (cPKC) a , pi, pH 
and y; novel PKC (nPKQ as 8, e, o, p., T |, and 0; and atypical PKC (aPKC) £, X, l 4,57 
The different types of PKC show different activation patterns: cPKC isoforms are 
activated by calcium and DAG fatty acids in presence of phosphatidyl serine. nPKC 
isoforms are activated by PMA and DAG, but are insensitive to Ca. aPKC £ and 
members of nPKC class can be activated by the phospholipid phosphatidylinositol- 
3,4,5-trisphosphate, produced in response to growth factors and G protein linked 
receptors. The unique activation of PKC 8 and PKC ^ link the PKC system to actions 
of growth factors which stimulate tyrosine kinase activity. Long term incubation (>12 
h) depleted PKC, probably through proteolytic degradation of the activated enzyme 4,58 
A number of PKC inhibitors have been described. A novel PKC inhibitor 
GF109203X is a bisindolylmaleimide (Bis). Bis is highly specific as it inhibits only 
PKC as a competetive inhibitor of ATP.4,59 In contrast to other PKC inhibitors, Bis is 
very specific for PKC without interaction with protein kinase A. Several studies were 
performed incorporating the administration of PMA, PKC inhibitor and peptide to 
determine whether peptide activity is dependent on cellular membrane activation and 
subsequent increased PKC activity. Observations clearly indicate that cellular 
membrane pathways are involved in the increased susceptibility of infected 
macrophages towards cell lysis by selective peptides.
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To test the hypothesis that these peptides selectively destroy infected 
macrophages over non-infected macrophages, in vitro studies were performed using a 
strain of Ba containing a green fluorescent protein (GFP). Ba is too small to be seen at 
the magnification levels used to visualize the macrophages; therefore, the strain 
expressing the GFP allows the infected macrophages to be identified. Post-infection, 
the infected macrophages are plated out together with the non-infected macrophages 
and the infected cells can clearly be visualized by fluorescence photography (See Figure 
4.2)
Figure 4.2. Visible photomicrograph o f untreated macrophages infected with Ba- GFP 
(top). Fluorescence photomicrograph of untreated macrophages infected with Ba- 
GFP (bottom).
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4.2. RESULTS AND DISCUSSION
It is not known why synthetic peptide of this family selectively destroy 
macrophages infected with intracellular pathogens, since macrophages, like most 
mammalian cells are known to be relatively resistant to amphipathic peptides o f this 
length. Linear a-helical antimicrobial peptides containing high levels of hydrophobic 
residues with lengths over 20 residues are known to retain high levels of 
cytotoxicity.4-51,52 Lowering the length to 10 amino acid residues reduces direct 
bacterial and mammalian cytotoxicity; however, the peptides still retain high levels of 
bioactivity against macrophages infected with intracellular pathogens. There are two 
plausible explanations for the phenomenon: 1) Infection of the macrophage causes a 
cellular membrane alteration, making the peptide more "attracted” towards its 
membrane, or, 2) peptide distribution is equal in infected and healthy macrophages and 
the infected cells display an increased sensitivity towards membrane disruption.
In order to establish direct antibacterial activity, minimum inhibitory 
concentration (MIC) studies were performed to determine relative cytolytic activity 
against representative Gram-positive (S. aureus) and Gram-negative (£. coli) bacteria. 
The MIC data of naturally occurring antimicrobial peptides mellitin, cercropin B amide 
and magainin 2 amide are included as reference. Table 4.3 summarizes the results. The 
synthesized peptides showed moderate to high levels of activity for both representative 
bacterial groups. Oddly, Pi-10 and Ipi-10 showed little to no effect on S. aureus. Direct 
cytolytic activity against Ba was also tested to verify that no significant cytotoxity was 
observed under conditions similar to those of the studies of selective macrophage 
destruction. 20 pL of a 1.4 x 109 suspension of Brucella abortus 2308/gfp was added to
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Table 43 . Peptide antimicrobial activity as determined by minimum
Peptide MIC (pM) vs. E. coU MIC (pM) vs. S. aureus
Pi-10 8 123
Ipi-10 4 Not active
Ach-lOa 8 4
Ach-10 4 4
Cyh-10 6 6
Ich-10 13 3
Melittin 3 3
Cecropin B amide 1 12
Magainin 2 amide 10 19
200 |iL of media in individual wells. Each well contained media with 200 pM of one of 
the peptides in Table 4.2. At 30 minutes post addition of bacterial cells, the wells were 
serially diluted and plated on blood agar. They were left to incubate for 72 hours and 
counted. The inoculation suspension was also serially diluted and plated to ascertain the 
precise number of bacteria added. A standard two-sample T-test and confidence interval 
was run to compare the final counts with the inoculation suspension count, and no 
significant differences were noted. There was no significant killing with any of the
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peptides as was apparent by comparing post-treatment colony forming units as 
compared with the inoculation dose. This was not surprising since it has been 
thoroughly documented that Ba is considerably more resistant to bactericidal cationic 
peptides than most gram-negative bacteria (See Table 4.4).460’62
Table 4.4. Direct toxicity of peptides against Brucella abortus 2308/gfp.
Peptide Treatment (200 uM) CFU/ml Significance
Ipi-10 1.2X10* None
Ach-10 1.3 X 109 None
Pi-10 1.5 X 109 None
Ach-lOa 1.4 XIO9 None
Ich-10 1.4 X109 None
Cyh-10 1.3 X 109 None
Control (no peptide) 1.4 XIO9
Table 4.5 summarizes the direct cytotoxic effect of the presented peptides 
against non-infected murine peritoneal macrophages. Peptides were dilutes in warm 
0.9% Saline + Fetal Calf Serum (10%) and added to cells. Cells were allowed to 
incubate 1.5 hours and then stained for viability with Trypan Blue. As expected, the 
more hydrophobic Cyh-10 and Ich-10, incorporating four AC6C residues, had the highest 
direct cytolytic activity against non-infected macrophages. ACh-lOa andACh-10
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Table 4.5. Normal macrophage survival versus peptide concentration.
Peptide %  Macrophage Survival
200 uM lOOuM 50uM 10uM 8iiM 6iiM 3uM luM
Pi-10 >95 % 75% 100% 100% 100% 100% 100% 100%
Ipi-10 >95 % >95 % 100% 100% 100% 100% 100% 100%
Ach-lOa 20% 30% 100% 100% 100% 100% 100% 100%
Ach-10 <5% 70% 90% 100% 100% 100% 100% 100%
Cyh-10 0% 0% <5% <5% 25% 50% 90% 100%
Ich-10 0% 0% <5% 85% >95 % >95 % 100% 100%
show slightly higher cytotoxic character due to the incorporation of two residues of 
A^c; Pi-10 and Ipi-10 had the lowest cytotoxicity levels and are the least hydrophobic 
of this family of peptides. Cyh-10 and Ich-10 are highly active, but may be too toxic to 
pursue as selective agents for the destruction of infected macrophages. In contrast, the 
high activity and relatively low cytotoxicity of ACh-lOa and ACh-10 make them 
promising candidates.
In vitro studies confirming the selective killing of infected vs. non-infected 
macrophages by the designed peptides were performed using a strain of Ba containing a 
green fluorescent protein (GFP). Ba is too small to be seen at the magnification levels 
used to visualize the macrophages; therefore, the strain expressing the GFP allows the 
infected macrophages to be identified. Trypan blue occlusion was used to visualize 
dead macrophages. The results of the peptide selectivity studies are illustrated in 
Figures 43-4.5. Cyh-10 was, by far, the most bioactive peptide, showing an optimum
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Figure 43 . Selective bioactivity of Pi-10 (top) and Ipi-10 (bottom) towards healthy 
macrophages and macrophages infected with Brucella abortus-GF?,
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Ach-10a Activity
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Figure 4.4. Selective bioactivity of Ach-lOa (top) and Ach-10 (bottom) towards 
healthy macrophages and macrophages infected with Brucella abortus- 
GFP.
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Cyh-10 Activity
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Figure 4.5. Selective bioactivity of Cyh-10 (top) and Ich-10 (bottom) towards healthy 
macrophages and macrophages infected with Brucella abortus-GFP.
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concentration dose at 3 (iM. Although the in vitro bioactivity and selectivity of this 
peptide is very high, in vivo toxicity studies may reveal this peptide to be too cytotoxic 
to be used effectively in therapeutic studies. Ich-10 also showed high activity at low 
dosage concentrations. However, cytolytic activity was much lower, as was selectivity 
at all concentrations. In general, all peptides designed with the 3io-helix permutations 
showed significantly lower bioactivity and selectivity than their a-helical counterparts 
Table 4.6). The optimum concentration for each peptide was established as the dosage 
at which maximum differentiation between infected macrophage killing and non- 
infected macrophage killing was observed.
Table 4.6. Activity summary of designed peptides. a Optimum concentrations for each 
peptide were established at the dose which gave highest selectivity between infected 
macrophage killing and non-infected macrophage killing. b Activity = (% Infected 
killed - % Non-infected killed) at optimum concentration. 0 Efficacy = Activity / 
optimum concentration.
Peptide Optimum Concentration QiM)' Activity" Efficacy0
Pi-10 100 90 0.9
Ipi-10 >200 25 0.13
Ach-lOa 100 75 0.75
Ach-10 100 60 0.60
Cyh-10 3 95 31.67
Ich-10 20 40 2.0
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Optimum concentrations decreased as the peptides increased in hydrophobia ty, 
with the a-helical permutation isomer retaining higher activity than the 3io-helical 
isomer. This may suggest that the a-helical conformation is a more active membrane- 
disruption agent than a 3io-helical peptide of the same hydrophobicity. As expected, Pi- 
10 and Ipi-10 showed the lowest direct activity, as a result of their lower 
hydrophobicity. Ipi-10 showed significantly lower activity than Pi-10. Overall efficacy 
of the tested peptides was established by peptide activity (% difference in infected vs. 
non-infected killing at the optimum concentration) divided by the optimum 
concentration dosage. As can be seen in Table 4.6., Cyh-10 and Ich-10 showed the 
highest efficacy. However, as previously stated, these peptides may be too cytotoxic to 
be utilized effectively in in vivo studies. Ach-lOa and Pi-10 are the most interesting 
candidates for further study, as they retain high activity and relatively low cytotoxicity.
It is not known what mechanism is responsible for peptide selectivity towards 
infected macrophages. However, it is hypothesized that cellular membrane activation is 
responsible for increased sensitivity towards the administered peptides. Studies were 
performed incorporating the administration of PMA, PKC inhibitor and peptide to 
determine whether peptide activity is dependent on cellular membrane activation and 
subsequent increased PKC production. Infected and non-infected macrophages in 
DMEM with 5% Fetal bovine serum (FBS) were treated with either 1.0 pM, 100 nM, or 
SO nM concentrations of Phorbol-12-myristalate-13 -acetate (PMA) at 1 hour prior to 
treatment with S pM Bisindoly maleimide 1 (PKC inhibitor). Separate groups of both 
infected and non-infected macrophages were treated with 5 pM PKC inhibitor 1 hour 
prior to treatment with the various concentrations o f PMA. Following each treatment,
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the macrophages were incubated for 1 hour at 37 °C with 5.0 % CO2 . 100 uM Pi-10 
was added to PMA, PMA/PKC inhibitor, or PKC inhibitor/PMA treated infected and 
non-infected macrophages and allowed to incubate at 37 °C with 5.0 m% C02. Infected 
and uninfected macrophages, which had not been exposed to PMA or PKC inhibitor, 
were also treated with 100 pM Pi-10 for comparison. Macrophages were then washed 3 
times with warm Phosphate buffered saline (PBS) with 5% FBS (PBS/FBS) after which 
warm PBS/FCS was added back and cells were examined microscopically. Trypan 
Blue exclusion was used to determine viability of cells (Table. 4.7).
Table 4.7. PMA / PKC inhibitor studies showing differential bioactivity of Pi-10 
towards PMA infected macrophages. “ PMA concentration: H=1.00pM, M=100nM, 
L=50nM. b PKC inhibitor concentration: H = l.OOpM , L = 50.0nM. c Peptide 
treatment: Pi-10 concentrations = 100pM. * Denotes significant killing of macrophages 
due to PMA activation.
Experiment # PMA* PKc Inhibitor1* Peptide6 %  Survival
1 - - - 94.4
2 H, M, L - - 93.6
3 - H, L - 95.8
4 - - 1 hr 97.1
5 H, M, L H, L - 96.7
6 H, M, L - 1 hr 40.8 (p<0.005)*
7 L H 1 hr 96.8
8 M L 1 hr 95.3
9 H L 1 hr 49.8 (p<0.005)*
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Observations clearly indicate that cellular membrane pathways are involved in 
the increased susceptibility of infected macrophages towards cell lysis by selective 
peptides. Control populations of macrophages only (experiment 1), PMA and 
macrophages (experiment 2), PKC inhibitor and macrophages (experiment 3), Pi-10 and 
macrophages (experiment 4) and PMA with PKC inhibitor (experiment S) all showed 
insignificant variation in viable macrophage populations. Macrophage activation with 
PMA at varying concentrations combined with Pi-10 treatment showed significant 
killing of infected macrophage populations (experiment 6 ). Incubation times for PMA 
activation over 2-24 hours showed no significant difference in activation levels of 
macrophages. PKC inhibitor was successful in inhibiting low to medium levels of PMA 
activation in the presence of peptide to show no significant levels of infected 
macrophage killing (experiment 7,8). However, high levels of PMA with low levels of 
PKC inhibitor still showed significant cytolytic activity of Pi-10. This suggests that 
there is a quenching of the PKC inhibitor by excess PMA and PKC production is not 
successfully repressed. Thus, cell membrane activation is still significant enough to 
induce cell lysis.
43. EXPERIMENTAL 
43.1. Peptide Synthesis
Peptides were synthesized using standard Fmoc-amino acid fluoride coupling 
conditions. The first 3 or 4 residues were manually coupled onto PAL-PEG-PS solid 
support by gently stirring 8  equivalents of the Fmoc-acid fluoride, 3 equivalents of 
D1EA and resin in methylene chloride, until an acceptable yield was determined by 
quantitative Fmoc test. Sometimes gentle reflux was required to obtain successful
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coupling. After the first residues were coupled to the resin, the remainder of the peptide 
was synthesized using a Milligen 9050 peptide synthesizer on the PAL-PEG-PS solid 
support using 8  equivalents of preformed Fmoc-amino acid fluorides, 3 equivalents of 
DIE A and a 1.5 h recycling time. Residues were double coupled when they are third in 
a series of Ca,Ca-disubstituted amino acids and the coupling times were extended to 2.5 
hrs. A solution of 20% piperidine / 2% l,8-diazabicyclo[4.5.0]undec-7-ene (DBU) in 
DMF was used for Fmoc removal. The peptides were simultaneously cleaved from the 
resin and side-chain deprotected using reagent B (8 . 8  : 0.2 : 0.5 : 0.5, trifluoroacetic 
acid (TFA) : triisopropylsilane : water : phenol). The resulting solution was diluted 
with cold 30% acetic acid, washed with diethyl ether (4 x 50 mL), and lyophilized.
4.3.2. Peptide Purification
The crude peptides were purified by preparative reverse-phase HPLC on a 
Waters 15 pM Deltapak C4  column using a water (0.05% TFA) and acetonitrile (0.05% 
TFA) gradient system. The gradient was run from 10% to 50% organic and the 
absorption monitored at 222 nm. P urity  of the peptides was then checked on a Vydac 5 
pM Cig column using the same conditions.
4 3 3 . Peptide Analysis (MALDI-MS, AAA, CD)
Matrix assisted laser desorption ionization (MALDI) mass spectrometry was 
used to verify the peptide masses. Pi-10, 1037.1 (M+H)+; Ipi-10, 1037.1 (M+H)+; ACh- 
10a, 1157.6 (M+H)+; ACh-10,1157.6 (M+H)+; Cyh-10,1277.8 (M+H)+; Ich-10,1277.8 
(M+H)+.
Amino acid analyses were performed according to reference 2.21 using a 
Beckman 6300 Amino Acid Analyzer. In short, the peptides were hydrolyzed in 6N
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HC1 and 0.01% phenol for 24 h at 110°C. The samples were analyzed on a cation 
exchange column at 65°C with post-column ninhydrin derivitization at 130°C.
Circular dichroism measurements were taken on a (+)-camphor sulfonic acid 
calibrated Aviv 60DS spectrophotometer at S°C. See chapter 3 for experimental details.
43.4. MIC Experiments
E. coli American type culture collection (ATCC) 25922 and S. aureus ATCC 
25922 were used as representative Gram-positive and Gram-negative bacteria in 
minimum inhibitory concentration assays. The bacterial cultures were grown in nutrient 
broth to midlog phase and standardized using McFarland standard before dilution. A 
512 pg/mL peptide stock solution was prepared and 1:2 serial dilutions were prepared 
and added to the culture media to give final peptide concentrations o f256 pg/mL.
50 pL of cells (5 X 104) and 50 pL of the peptide solution were added to a 
sterile well and the MIC was determined by the lowest concentration that inhibited cell 
growth. The inhibition of cell growth was indicated by the absence of turbidity after 
four hours. Turbidity in the wells was monitored visually. The MIC values are 
reported as the median value for at least three experiments.
4 3 3 . Peptide Cytotoxicity Assays Against Brucella abortus
A suspension of 20 pL of a 1.4xl09 of Brucella abortus 2308/GFP (green 
fluorescent protein) was added to 200 pi of media in individual wells. Each well 
contained media with 200 pM of a particular peptide. At 30 minutes post addition of 
bacterial cells, the wells were serially diluted and plated on blood agar. They were left 
to incubate for 72 hours and counted. The inoculation suspension was also serially 
diluted and plated to ascertain the precise number of bacteria added. A standard two-
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sample T-test and confidence interval was nm to compare the final counts with the 
inoculation suspension count, and no significant differences were noted 
4.3.6. Direct Peptide Toxicity Against Murine Peritoneal Macrophages
Briefly, harvested peritoneal macrophages were harvested from Balb/C mice, 
and 2xl07 cells were laid down in wells of a 96 well plate. Cells were allowed to 
adhere for 2 1/2 hours at 37 °C, 5.0% CO2 . Peptides were dilutes in warm 0.9 % Saline 
+ Fetal Calf Serum (10 %) and added to the cells. Cells were allowed to incubate 1.5 
hours and then stained for viability with Trypan Blue. The cells were then examined 
microscopically after viable staining with Trypan Blue for morphological changes and 
viability. Reported macrophage viability is determined by the total %-ratio of dead vs. 
healthy cells in three separate fields of three experimentally identical wells. The results 
are reported in the Table 4.5.
43.7. GFP-Ua Studies
Following euthanasia, cells were harvested by lavage from the peritoneal cavity 
of ten-week old BALB/c mice using 8 mL of DMEM (Dulbecco’s Modified Eagle 
Medium) + 5% fetal calf serum (FCS). The cells were cultured in 96 well plates at a 
concentration of 1.5xl05 per well in 200 pL of DMEM + 5% FCS at 37°C in 5% CO2 . 
Cell cultures were enriched for macrophages by washing away non-adherent cells after 
overnight incubation with PBS + 5% FCS and 200 pL of fresh media was added to the 
cultures. Normal macrophage cultures were treated with 0 to 200 pM of the test 
peptide. The peptides were incubated with the cells for 1 hour at 37°C in 5% CO2 . The 
cells were washed 3 times with PBS + 5% FCS to remove any residual peptide. Peptide 
treated cells were stained with 0.04% trypan blue in DMEM + 5% FCS. One to two
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hundred cells per well were counted using an inverted microscope and the number of 
stained cells was recorded. Three wells were examined per peptide concentration. 
Percent survival was calculated by subtracting the number of blue (dead) cells from the 
total cells and normalized. B. abortus-GFP opsonized with a sub-agglutinating dilution 
(1:2000) of hyperimmune BALB/c mouse sera in DMEM + 5% FCS was added to the 
macrophages at a ratio of approximately 100 bacteria per macrophage. Phagocytosis 
proceeded for 2 h at 37°C. Extracellular organisms were removed by washing 3 times 
with PBS + 5% FCS and fresh DMEM. Peptides were added to infected and non- 
infected cell cultures for 1 hour at 37°C, 5% C 02. The cells were washed 3 times with 
PBS + 5% FCS to remove any residual peptide. Percent viability was determined as 
described above.
43.8. PMA Activation / PKC Inhibition of Macrophages.
Infected and non-infected macrophages in DMEM with 5% Fetal bovine serum 
(FBS) were treated with either 1.0 pM, 100 nM, or 50 nM concentrations of Phorbal 12- 
myristalate 13-acetate (PMA) at 1 hour prior to treatment with 5 uM Bisindoly 
maleimide 1 (PKC inhibitor). Separate groups of both infected and non-infected 
macrophages were treated with 5 pM PKC inhibitor 1 hour prior to treatment with the 
various concentrations of PMA. Following each treatment, the macrophages were 
incubated for 1 hour at 37 °C with 5.0 % CO2 . 100 uM Pi-10 was added to PMA, 
PMA/PKC inhibitor, or PKC inhibitor/PMA treated infected and non-infected 
macrophages and allowed to incubate at 37 °C with 5.0m% C 02. Infected and 
uninfected macrophages that had not been exposed to PMA or PKC inhibitor were also 
treated with 100 pM Pi-10 for comparison. Macrophages were then washed 3 times
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with warm Phosphate buffered saline (PBS) with 5% FBS (PBS/FBS) after which warm 
PBS/FCS was added back and cells were examined microscopically. Trypan Blue 
exclusion was used to determine viability of cells (Table 4.7).
4.3.9. Pi-10 Peptide Treatment of PMA Activated Macrophages
100 uM Pi-10 was added to PMA, PMA/PKC inhibitor, or PKC inhibitor/PMA 
treated infected and non-infected macrophages and allowed to incubate at 37 °C with 
S.0m% COj. Infected and uninfected macrophages which had not been exposed to PMA 
or PKC inhibitor were also treated with 100 pM Pi-10 for comparison. Macrophages 
were then washed 3 times with warm Phosphate buffered saline (PBS) with 5% FBS 
(PBS/FBS) after which warm PBS/FCS was added back and cells were examined 
microscopically. Trypan Blue exclusion was used to determine viability of cells.
43.10. Biological Containment and Animal Use
All procedures involving live Brucellae and Mycobacteria were performed in a 
Biological Level 3 (BL-3) containment facility at the LSU-SVM following Centers for 
Disease Control/National Institutes of Health guidelines.4'63 In conducting research 
using animals, the investigators adhered to the “Guide for the Care and Use of 
Laboratory Animals” prepared by the Committee on Care and Use of Laboratory 
Animals of the Institute of Laboratory Animal Resources, National Research 
Council.4'64
4.4. CONCLUSIONS
A series o f novel linear amphipathic peptides with high levels o f Ca,Ca- 
disubstituted amino acids to promote helical conformations have been prepared. The 
biological activity of these peptides has been determined. Although no direct
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bioactivity was observed towards Brucella abortus, MIC studies against representative 
Gram-positive and Gram-negative bacteria support the theory that increased 
hydrophobicity in peptide . composition increases cytolytic activity. This 
hydrophobicity-dependent cytolytic character is also observed in mammalian non- 
infected peritoneal macrophages from BALB/c mice.
Studies of selective bioactivity in vitro against peritoneal macrophages infected 
with an intracellular pathogen, Brucella abortus-GFP, clearly show that the peptides 
show a selective cytolytic activity towards infected macrophages at concentrations that 
are non-lethal to healthy macrophages. In vitro activation of harvested macrophages 
with PMA induces peptide-promoted cell killing in a similar fashion to Ba infected 
macrophages. In contrast, PKC inhibition of PMA-induced cellular activation 
suppresses peptide activity completely. This suggests a cellular membrane-mediated 
response by infected macrophages towards the presence of a pathogen. This response 
may increase susceptibility of the infected cells towards peptide activity or promote 
peptide aggregation at the cellular membrane. Further studies to promote the 
understanding of cellular response towards intracellular pathogenic infections are 
required to fully understand the mechanism by which these peptides function. In 
addition, peptide activity at the cellular membrane and peptide affinity for infected 
versus non-infected macrophages must be determined.
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CHAPTERS
ANHYDROUS SYNTHESIS AND SPECTROSCOPIC 
CHARACTERISTICS OF o-NITROBENZENE SULFONYL- 
Ca,C°-DISUBSTITUTED AMINO ACID ADDUCTS
5.1 INTRODUCTION
Since the first pioneering publication by Merrifield in 1953,51 solid-phase 
peptide synthesis (SPPS) has become the primary route by which to obtain many 
synthetic peptides,5'2 and peptidomimetics.5'3'7 The technique has since been adapted to 
a number of other biomolecules, such as nucleic acids5*8,9 and oligosaccharides.5'10 
More recently, the use of solid-phase synthesis has been at the center of a chemical 
revolution with the development of combinatorial methods5'11 and high throughput 
synthesis and screening, causing an enormous impact on several aspects of chemistry 
and molecular biology, especially drug-discovery. In the wake of the first solid-phase 
applications, several new techniques have been developed which further this exciting 
new aspect of synthetic chemistry. This chapter introduces new insights with which to 
enhance productivity and efficacy of a recently introduced coupling-protection scheme 
of solid phase peptide synthesis (SPPS). This scheme is intended to overcome problems 
associated with difficult couplings in synthetic peptides incorporating high levels of 
Ca,C°-disubstituted amino acids. The material covers the synthesis of oNBS-C“,Ca- 
disubstituted amino acid adducts and the UV spectroscopic characterization of the 
oNBS-cleavage product
The process of solid phase synthesis of any compound or peptide is 
characterized by the covalent anchoring of a starting material, or first residue of an 
oligomeric material, to an insoluble polymer resin, or solid support Common resins
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include divinylbenzene cross-linked polystyrene (PS),5'12 polyamides,5*13 polyethylene 
glycol grafted covalently onto divinylbenzene cross linked polystyrene (PEG-PS),5*14 
and in some cases, natural polymers such as cellulose.5'15 An efficient polymeric 
support for solid-phase synthesis must have the following characteristics:5*16 1) 
Physical stability and of the right dimensions to allow for manipulation and filtration 
from liquids. 2) Chemical inertness to all reagents involved in the synthesis and 
manipulation. 3) An ability to swell to an appreciative extent while under reaction 
conditions to allow permeation of solvents and reagents to the reactive sites within the 
resin. 4) Derivatization with functional groups to allow for the covalent attachment of 
an appropriate linker or first monomeric unit. In most cases, this linker unit must be 
cleavable under conditions which allows for the isolation of the desired product after 
synthesis is complete.
Solid supports for SPPS are functionalized with chemically active linkers, which 
are stable to the reaction conditions of the coupling process, but are labile under 
conditions which allow for isolation of the final product Common linker- 
functionalized resins include chloromethyl polystyrene (Merrifield resin)5*12, p~ 
(carbamoylmethyl) benzyl ester (PAM resin)5*17, 4-(2',4'-dimethoxyphenyl- 
aminomethyl)-phenoxymethyl) (Rink amide resin), tris(alkoxy)-benzylamide (PAL 
resin), 4-alkoxybenzyl alcohol (Wang resin) and 2-chlorotrityl resin.5*15 Excess 
reagents and solvent can be removed by filtration from the insoluble support and 
subsequent reagents or residues are added in an iterative fashion. After the desired 
monomer units have been attached to the linker the product is chemically cleaved from 
the resin and isolated by filtration. Cleavage conditions are dictated by which linker is
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used. The advantage of solid phase synthesis lies in the ease of separation of the 
product from access reagents, which minimizes loss of material during intermediate 
product purification.
The key to successful solid phase synthesis lies in the protection scheme that is 
used to assure reaction only at the desired position(s). Any monomeric unit (X) that is 
utilized in solid-phase synthesis can be expressed with the empirical formula n-X-e, 
where n is the nucleophilic portion of the residue and e is the electrophilic portion. The 
first monomeric unit is coupled to the resin at either the nucleophilic or the electrophilic 
site. However, the portion of the molecule that is not covalently bound to the resin must 
be protected to avoid subsequent polymerization of excess monomers in solution. Thus, 
if the electrophilic portion of the first residue is coupled to the resin, the nucleophilic 
portion must be protected, and vice versa. The protecting group must be stable to the 
reaction conditions under which the couplings are executed. After coupling is 
performed, the protecting group is removed to expose a new reactive site and synthesis 
continues.
If several nucleophilic and/or electrophilic groups are present in a monomeric 
unit, they must be orthogonally protected with groups that vary in reactivity. This 
allows for deprotection of the portion of the molecule to which further reaction is 
desired to take place in subsequent couplings, while preventing reaction at side-chain 
functional groups. SPPS is almost exclusively performed in the C—>N direction, with 
the amino group being the nucleophilic portion and the C-terminus the electrophilic 
portion (Figure 5.1). Common protecting groups and the conditions under which they 
are cleaved are listed in Table 5.1.
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Figure 5.1. General scheme for solid-phase peptide synthesis.S2
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Table 5.1. Common linkers used in SPPS.
Protecting Gronp Structure Cleavage
Method
Reference
N“-Protecting
Groups
Fluorenylmethoxy- 
carbonyl (Fmoc) a iV S — o r V
Base-catalyzed 
(20% Piperidine 
in DMF)
5.19
Allyloxycarbonyl 
(Alloc)
0 Hydrogenolysis 
(Pd/C; ethanol)
520
2-(4-
nitrophenylsulfonyl)
ethoxycarbonyl
(Nsc)
o^ Q - I ch^ oK
Base catalyzed 
(2 0 % piperidine 
in DMF
5.21
BenzothiazoIe-2- 
sulfonyl (Bts)
c o t *
Zn-Acetic Acid
Al-Hg/THF/H20
Na2 S2 0 4
5.22
5-Methyl-l,3,4- 
thiadiazole-2 - 
sulfonyl (Ths) x y hH3C s  0
Zn-Acetic Acid 
Al-Hg/THF/H20
5.22
Side-Chain 
Protecting Groups
Benzyloxycarbonyl
(Z)
/-Butyl
Dimethoxytrityl
(Dmt)
C p A
CH3  
H3 C—j—I
CH3___ __
0083
Catalytic
Hydrogenation
Acidolysis
Acidolysis (TFA)
Acidolysis (Weak 
Acid)
5.18
5.2425
526
/-Butyloxycarbonyl 
(Boc)
c h 3  0 Acidolysis
(TFA/DCM)
5.127
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One of the difficulties associated with solid-phase peptide chemistry is 
prevention of reaction on fimctionalized side chains o f amino acids such as lysine, 
glutamic acid and cysteine. In order to prevent these reactions from taking place, side- 
chain protecting groups must be applied. These groups must be stable to the coupling 
conditions, stable under conditions that cleave the active terminus for continued growth, 
but labile under conditions which cleave the product from the resin, allowing for 
isolation of the fully deprotected product. Thus, the ^-terminal and side-chain 
protecting groups must be orthogonal to each other in a solid-phase coupling scheme. 
Several coupling schemes have been developed which match linker, ^/-terminal 
protection and side-chain protection in an orthogonal manner. Some of the most 
commonly used include the Boc-benzyl strategy51,28 (Figure 5.2), the Fmoc-Boc 
strategy519,29 (Figure 5.3).
One aspect of solid phase synthesis that has seen tremendous development is in 
the field of coupling reagents. Traditionally, peptide coupling under solid phase 
conditions can be realized in two ways: 1) A reactive electrophilic derivative of the 
amino acid , such as an acid halide5-30"36 or an N-carboxyanhydride (NCA)5-37 can be 
synthesized, isolated and then allowed to react with the nucleophilic portion of the 
resin-bound residue. These active species are easy to synthesize and relatively stable, 
allowing for characterization. In addition, the simplicity o f by-products released from 
such couplings, such as a carbon dioxide, chloride or fluoride ion, allow for simple 
purification after coupling has occurred. Alternately, a coupling reagent may be added 
to the reaction mixture, to generate a reactive electrophilic derivative in situ. These 
coupling reagents include carbodiimides5-38'40 such as DCC, DEC, and DIPCDI, triazole
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Table 5.2. Common coupling reagents used in SPPS.
Coupling Reagent Structure Reference
DCC
WJV-Dicyclohexyl-
carbodiimide
N=C=N— 5.38-40
DEC
W -D iethyl-
carbodiimide
H3CH2C-N=C=N-CH 2CH3 5.38-40
DIPCDI
Af^iV-Diisopropyl-
carbodiimide
h3c. ch3
/ — N=C=N—<
h3c  ch3
5.38-40
HOBt
1 -Hydroxybenzotriazole o >
OH
5.41
HOAt
7-Aza-1 -hydroxybenzo­
triazole
0 3
OH
5.42-44
HBTU
N- [(1 -tf-Benzotriazol-1 -y 1)- 
(dimethylamino)rnethylene]- 
Ar-methylmethanaminium 
hexafluorophosphate N- 
oxide
(H3C)2N®.N(CH 3)2
a >
° ©
5.45
HATU
N-[( 1 -//-7-Azabenzotriazol- 
1 -yl)-(dimethylamino)- 
methylene]-Af- 
methylmethanaminium 
hexafluorophosphate
(H3C)2N®.N(CH 3)2
0 3
° ©
5.43,46
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derivatives, such as HOBt5'41 and HOAt5 42-44 and tertiary ammonium salts of triazole N- 
oxides, such as HBTU5 45 and HATU5-43,46 (Table 5.2), in addition to several others.5-39 
The advantage of these types of coupling is the relative ease of handling of non­
activated species which are introduced into the reaction along with the coupling reagent. 
In addition, in situ activation allows for the preparation of highly activated species that 
are often not isolable.
Ca,Ca-Disubstituted amino acids, such as Aib (2-aminoisobutyric acid), Ac6c (1- 
amino-l-cyclohexylcarboxylic acid), and Api (4-aminopiperidine-4-carboxylic acid) 
(Figure 5.4), are becoming recognized tools for the selective control of peptide 
secondary structure5 4731 and for accentuating physiological properties of resulting 
peptides (refer to chapters 2,3 and 4). Recently, these derivatives have been shown to 
generate highly helical segments with peptides as short as 10 residues in length.152 In 
particular, close proximity of these residues cause dramatic increases in the helical 
propensity of resulting peptides, and stabilization of the peptides towards enzymatic 
degradation under physiological conditions.543 C^C^-Disubstituted amino acids 
(aotAAs) are of current interest in the development of novel amphipathic peptides with 
high levels of helicity for study as in vivo selective weapons against macrophages 
infected with intracellular pathogens (See Chapter 4).553
As with iV-alkylated amino acids, Ca,Ca-disubstituted amino acids offer a 
significant challenge in their ability to couple under solid phase peptide synthesis 
conditions. Their inherent difficulty in coupling stems primarily from the steric 
repulsion that arises between the residue which is being coupled and the residue which 
is already on the resin.
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Figure 5.4. Examples of C^C^disubstituted amino adds: 2-aminoisobutyric add 
(Aib), 1-amino-l-cyclohexanecarboxylic add (Ac6c), and 4-amino-4-piperidine- 
carboxylic add (Api).
A number of methods for the solid phase coupling of Ca,Ca-disubstituted amino 
adds have been presented over the years, the most effident and cost effective being the 
Fmoc-protected amino add fluorides, developed during the early 1990s by Carpino and 
coworkers.3JiJU4 For the purposes of proteinogenic amino adds and some less hindered 
Ca,Ca-disubstituted amino adds, this technique provides a fast, cheap and effident 
method towards peptide synthesis. However, we have found that on-resin couplings 
involving multiple Ca,Ca-disubstituted amino adds, in high proximity, result in low 
yields and require reaction times on the order of several days. These difficulties are 
particularly accentuated with the continuous coupling of several residues of very bulky 
amino adds, such as Ac6c and Api. These couplings require large molar excesses of 
amino add and high temperature conditions to achieve acceptable coupling yields. 
Thus, difficult couplings of this nature become very time-consuming and expensive, 
consuming large quantities of excess reagent and solvents.
Aib Ac6c Api
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Iii an attempt to develop a new, faster method for couplings of these difficult 
amino acids, our attention has turned to the higher reactivity of amino acid chlorides, 
which have been shown to have very high reaction rates in solution phase 
couplings.**'32'11 In addition to being of higher reactivity, amino acid chlorides are 
considerably less expensive to synthesize in comparison to their corresponding acid 
fluorides and can be prepared by a number of simple reagents such as thionyl chloride, 
oxalyl chloride and phosphorous trichloride. Recently, Falb and coworkers described 
the effective in situ generation of proteinogenic Fmoc amino acid chlorides using 
bis(trichloromethyl)-carbonate.5J0 However, pre-formed C^.C^-disubstituted amino acid 
chlorides generally do not perform as well in solid phase peptide synthesis. Oxazalone 
formation, by intramolecular cyclization of the acid chloride functionality with N- 
urethanyl-type moieties like the Fmoc protecting group (Figure 5.5), compete with 
coupling.*12
Figure 5.5. Base promoted oxazalone formation of N^fluorenylmethoxycarbonylated 
C^C^-di substituted amino acid halides.
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CaCa-Disubstituted amino acid fluorides have been found to react faster than 
corresponding amino acid chlorides under solid phase conditions due to their lower rate 
of oxazalone formation.*3* To take advantage of the increased reactivity of the amino 
acid chlorides, we face the task of incorporating a different protecting group incapable 
of intramolecular cyclization. The protecting group must have chemical properties that 
allow it to be orthogonal to the Boc side-chain protection scheme used in Api and lysine 
residues. In addition, it must have a quantifiable cleavage chromophore, which allows 
for the monitoring of coupling rates and yields by resin tests. The fluorenyl-piperidine 
adduct produced as a result of base promoted Fmoc deprotection has a characteristic 
UV absorbance at 300 nm and a molar absorbtivity (e^)  of 7800 M lcm ‘, which allows 
for quantitative monitoring of the couplings by sample resin testing. Other SPPS 
monitoring procedures include on-resin ninhydrin testing,5*4 and on-resin infra-red 
spectroscopy.***** Because of the difficult, and highly varied, coupling conditions 
associated with Ca,Ca-disubstituted amino acids, couplings can take anywhere from a 
few minutes to several days. It is thus imperative that a coupling strategy includes 
facile, quantitative monitoring of coupling efficiency.
Arylsulfonyl-groups were introduced as protecting groups for solution phase 
peptide synthesis as early as the 1950s.**9 Specific use of the o- and p- 
nitrobenzenesulfonyl (oNBS) derivatives was first described by Fukuyama in 1994 for 
the purposes of N-alkylation.**0'61 The p-nitrobenzenesulfonyl group has also been 
described by Sabirov and coworkers as a suitable side chain protecting group for the 
indole moiety of tryptophan.** However, Miller first incorporated this group into solid 
phase synthesis context, albeit for use in site specific N-alkylation.*63* Recently, 
Reichwein and Liskamp reported successful tf-alkylation of amino acid esters or resin
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bound amino acids, in which the Fmoc protecting group had been removed and replaced 
by the oNBS group while on resin.165 In addition to being orthogonal to both acid and 
base labile groups, oNBS-groups introduce high levels of crystallinity to the amino acid 
residues. This has allowed for easy isolation and purification of synthesized adducts, as 
well as crystallographic description.566 Other arylsulfonyl protecting groups include the 
benzothiazole-2-sulfonyl group (Bts) and the 5-methyl-l,3,4-thiadiazole-2-sulfonyl 
group (Ths).5ja
The sulfonyl oxygens of the oNBS group are less nucleophilic than the carbonyl 
group of a urethanyl type protecting group, such as Fmoc, Alloc or Boc. Thus, 
intramolecular cyclization is not of concern in the preparation and application of oNBS- 
amino add chlorides or other activated ester functional groups, such as those of HATU 
and/or DIC. This phenomenon may in turn result in lower racemization of oNBS 
protected proteinogenic amino adds, since oxazalone formation is the key intermediate 
in facilitating this side reaction. The protecting group differs from the recently 
introduced and very popular 2-(4-nitrophenylsulfonyl)ethoxycarbonyl (Nsc) in that 
cleavage is performed by an i/uo-nucleophilic aromatic substitution. The Nsc group is 
cleaved by base-catalyzed elimination.567 This, and the fact that the Na-Nsc connection 
is achieved through a urethanyl bond, capable of oxazalone formation, make the Nsc 
group chemically related to the Fmoc group. Other arylsulfonyl protecting groups, such 
as Bts and Ths are generally removed by Zn-acetic add hydrolysis. Thus, they are 
generally considered to be chemically unrelated to the oNBS group. The oNBS group 
is stable to addic and basic conditions (when N-alkylated). Thus, a feasible solid-phase 
protection scheme, with oNBS orthogonal to Boc and Z groups, can be visualized 
(Figure 5.6).
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This chapter discusses the development of a spectroscopic standard by which the 
oNBS group can be monitored during solid-phase synthesis. Anhydrous synthesis 
conditions of oNBS-amino acid adducts are described, as well as the UV activity of the 
oNBS-cleavage adduce This information will help develop the use of the oNBS group 
as a successful N“-protecting group for difficult couplings under solid-phase peptide 
conditions.
5.2 RESULTS AND DISCUSSION
Standard conditions to generate oNBS adducts of proteinogenic amino acids 
under aqueous conditions were reported by Milne and Peng in 1957.5"59 This process 
involves dissolving the free amino acids in aqueous base, such as sodium hydroxide, 
followed by treatment with the corresponding arylsulfonyl chlorides. However, this 
method is ineffective in generating oNBS-Ca,C“-disubstituted amino acid adducts due 
to the low solubility o f these compounds under aqueous conditions. This is especially 
true in the case of the very hydrophobic residue AC6C. A similar difficulty is faced 
when attempting to introduce the Fmoc-group to Ca,Ca-disubstituted amino acids via an 
aqueous approach using Fmoc-succinimide. This problem is overcome by the use of a 
non-aqueous procedure using Fmoc-Cl. This procedure seemed logical to extend 
towards the generation of oNBS-adducts as well. Thus, we present an effective way to 
generate oNBS adducts of C“,Ca-di substituted amino acids under anhydrous conditions 
based on the procedure set forth by Bolin.5'58 This technique has also been extended to 
proteinogenic amino acids, such as lysine(Z). Theoretically, it could be extended to a 
variety of amino acids. In the procedure, chlorotrimethylsilane is used to facilitate 
solubilization of the diisopropyl-ethylammonium salts of the Ca,Ca-disubstituted amino
140
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acids in DCM. This is followed by the slow addition of 2-nitrobenzenesulfonyl 
chloride. The silylated amino acids react very quickly and efficiently. Using this 
procedure, the amino acids are successfully protected in high yield and without need for 
further purification after crystallization (Figure 5.7). The high crystallinity of the oNBS 
adducts allows for easy purification and analysis.
u  p  p u ____________________________ ___  rt H3C CH3
3x J o h  i >D|g » '™ s g ' -  r y ^ _ N> Y 0H
X  2) oNBS-CI » H 0
N02
h2n
O
5.1
✓=\ oQH 1) DIEA, TMS-CI / = \  «
2) oNBS-CI \ ~ \  O H
0  N02
Boc 
1
,N
U  OH 1) DIEA, TMS-CI / = \ _ f
H2N X  2) oNBS-CI o  H
O 
NHZ NHZ
OH
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2) oNBS-CI
Q f r Y
N02 
5.4
Figure 5.7. Synthesis of oNBS adducts of Aib, Acsc, Api(Boc) and Lys(Z) to yield 
oNBS-amino acid adducts 5.1,5.2, 5 3  and 5.4.
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Several reagents have been proposed as suitable cleavage agents for the removal 
of the oNBS-group, such as mercaptoethanol / potassium ferr-butyloxide, thiophenol / 
potassium carbonate and n-propylamine in DCM. Cleavage of the oNBS group by all 
of these methods is reported as an ipso-attack of the mercaptoacetic acid sulfide 
followed by sulfur dioxide elimination and subsequent deprotection through a 
nucleophilic aromatic substitution mechanism (Figure 5.8).560-61 Cleavage with 
mercaptoacetic add offers the advantage of using a relatively non-noxious reagent, and 
the cleavage adduct which is generated (8) by this reagent has spectroscopic advantages 
which allow for in situ monitoring of the progress of the reaction. The cleavage 
product, 2-nitrophenylcarboxymethylthioether (5.5), can be readily synthesized by 
nucleophilic aromatic substitution using the DBU salt of mercaptoacetic add with o- 
chloronitrobenzene (Figure 5.9).
Figure 5.8. On-resin nucleophilic displacement of the oNBS-group by the 
mercaptoacetic add anion yielding the 2-(2-nitrothiophenyl)acetate anion (5.5) as a 
cleavage product
HSCH2C02H 
DBU, CH3CN
^ C 0 2
5.5
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NO2 mercaptoacetic add
0  DBU— H
5.5
Figure 5.9. Nucleophilic aromatic substitution of o-nitrochlorobenzene by the 
mercaptoacetic add anion to yield the cleavage adduct 5 .5.
One of the key advantages of traditional Fmoc procedures in solid phase peptide 
synthesis is the ability to actively monitor coupling rates and efficiency by 
spectrometric analysis. The piperidine-fulvene adduct which result from the 
deprotection of Fmoc groups can be analyzed by removing a small portion of resin from 
the reaction and cleaving the Fmoc-groups which are covalently linked to the solid 
support This cleavage adduct has a molar absorptivity of 7800 M‘,cm'1 at 300 nm in 
DMF/MeOH which can be quantitated on a very small scale (4-8mg resin; ~20pM) by 
UV-spectroscopy. By comparing the level of Fmoc-protected termini on the resin with 
the established substitution level of the resin used, one can determine the degree of 
coupling. Applying oNBS-amino add chlorides as successful activated reagents in 
SPPS requires the adaptation of such a procedure for the quantitative analysis of 
coupling effidency.
Repetitive scans from 700-200 nm of the deprotection adduct 5.5 at various 
concentrations shows a consistent absorption maximum at 390 nm (Figure 5.10). Thus, 
the cleavage product of oNBS-protected amino acids allows the couplings to be easily 
quantitated by spectrometric determination. To determine the exact spectroscopic 
nature of 5.5, a series of dilution studies under reaction conditions were performed to
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oNBS Cleavage Product Dilution Studies
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Figure 5.10. Scanning UV-Vis Spectrometry of 5.5 under reaction 
conditions showing consistent X ^  at 390 nm at various concentrations.
show a linear correlation between concentration and at 390nm in acetonitrile (Table 
53). For absorbances under 2.0, Beer’s Law correlation results in a molar absorptivity 
(e) of 2950 M'Icm't. At high concentrations, deviations from Beer’s Law are discarded. 
In-solution cleavage of the oNBS-amino acid adducts with 0.4M mercaptoacetic acid 
and 0.8M DBU in acetonitrile for 20 minutes yields quantitative detection of the 
cleavage product, with a maximum absorbance at 390nm. According to Beer's Law, the 
molar absorptivity of 8 can be determined by plotting the data in Table 53 and 
extrapolating the slope for absorbance values under 2.0 as shown in Figure 5.11.
Table 53 . Summary of dilution studies done on cleavage adduct 53 . ‘Absorptivities 
above 2.0 are discarded in averaging due to Beer’s Law deviations at high 
concentrations.
Concentration (fiM) K . A ^  (corrected) By*
10.0 391 0.030 3021
25.0 390 0.074 2942
50.0 390 0.149 2978
100.0 390 0391 2949
250.0 391 0.729 2947
500.0 390 1.457 2934
1000.0 390 2.427 2425*
Average 390 - 2950
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Figure 5.11. Graph showing the linear correlation of absorption versus concentration 
of the oNBS cleavage product 5.5 in 5:1 acetonitrile/water. (Slope= =2950). 
Deviation from Beer's Law linear correlation is clearly visible above A=2.0.
1.2
Thus, the progress of a potential coupling of oNBS-amino acid adducts on the solid 
phase can be monitored by a process similar to that of the Fmoc-piperidine assay. The 
sampled resin (5-10 mg) would be treated with l.OmL deprotection solution for 30 
minutes, washed with 6 x 1.0 mL acetonitrile and the washes combined. The cleavage 
sample would be analyzed for absorbance at 390 nm and percent substitution would be 
determined by:
%Substitution=[(AMOxl0sx0.007)/(EMoxW)J/L
, where A*, is the corrected absorbance at 390 nm, e*, is the molar absorbtivity at 390 
nm for the cleavage adduct (2950M'*cm I), W is the mg of resin tested and L is the 
substitution level of the resin used (mmol/g).
To test the ability of the deprotection reagent to effectively cleave the oNBS 
group in a consistent and quantitative way, cleavage studies were performed with four 
oNBS-amino acid adducts: oNBS-Aib-OH 5.1, oNBS-Acsc-OH 5.2, oNBS-Api(Boc)- 
OH S 3  and oNBS-Lys(Z)-OH 5.4. The pure adducts are weighed out in various 
amounts and treated with 1.00 mL deprotection solution for 30 minutes. The resulting 
solutions are then diluted with 5 x 1.00 mL acetonitrile and the resulting solution tested 
by UV-spectroscopy at 390 nm for observed absorbance. In all cases, deprotection is 
efficient, quantitative, and correlates well with the theoretical predictions based on the 
derived molar absorbtivity of the cleavage product (Table 5.4).
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Table 5.4. In-solution cleavage study of four oNBS-amino acid adducts.
Substrate MW mg M A^ ». A/A.(%)
oNBS-Aib-OH 288.23 1.20 5.95e-4 1.75 1.75 100%
oNBS-Api(Boc)-OH 429.42 1.71 535e-4 1.56 130 95%
oNBS-Ac6c-OH 32832 1.40 6.09e-4 1.79 1.76 973%
oNBS-Lys(Z)-OH 455.45 1.40 439e-4 1.29 1.32 102%
Coupling of the synthesized oNBS-amino acids onto PAL-PEG-PS was initially 
performed by the use of PyAOP/HOAt in DMF over several hours without success. 
The acid fluorides of the oNBS-adducts were then generated and allowed to couple in 
DCM / 2,4,6-collidine for 24 hours. The use of excess base in the coupling reactions of 
oNBS-protected amino acids was found to be detrimental to the reaction due to 
decomposition of oNBS protected primary amines, which was evident by (he 
development of S02 gas from the resin under these conditions. This occurs by catalytic 
deprotonation of the sulfonamide and an intramolecular rearrangement to eliminate S02 
via decomposition of the intermediate Mesenheimer Complex (Figure 5.12). The 
decomposition takes place even in the presence of excess weak, hindered bases such as 
2,4,6-collidine. Although the decomposition should not directly compete with the 
mechanism of coupling, the resulting o-nitrophenylated amine, 5.6, can not be 
deprotected and thus caps the peptide from further growth, in addition to preventing 
spectrometric analysis of coupling yield to be determined. Due to this composition, it is 
impossible to determine exact coupling yield. In addition, one cannot be sure as to (he 
efficiency of the deprotection step versus the coupling efficiency.
148
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Figure 5.12. Base catalyzed rearrangement of the oNBS-protected N-terminus of an 
amino acid by sulfonamide proton extraction and subsequent intramolecular sulfur 
dioxide elimination, to yield N-arylated amino acid 5.6.5 60,61
A number of methods were investigated for the chlorination of the oNBS- 
protected amino acids. For the chlorination of 5.1 it was found that oxalyl chloride is 
superior to all other chlorinating agents studied (phosgene, thionyl chloride, Bis- 
(trichloromethyl) carbonate (BTC)). The reaction of the free acid of oNBS-protected 
amino acids with BTC results in almost quantitative yield of the corresponding N- 
carboxyanhydride (NCA) derivative, 5.7, by intramolecular cyclization. Cyclization 
results from one of two routes involving either cyclization of the initial mixed 
anhydride of BTC (Scheme 1; Figure 5.13), or induced nucleophilic attack of the 
sulfonamide on BTC followed by secondary cyclization by the free carboxylate 
(Scheme 2; Figure 5.13). The resulting NCA derivative, 5.7, was verified by NMR and 
X-ray crystallography. Crystals were isolated in 75% yield from the corresponding 
oNBS-protected amino acid. (Figure 5.14) NCAs have been used extensively as 
coupling agents and have the advantages of being highly crystalline and very stable in 
dry conditions for extended periods of time. In addition, the coupling side product is
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Figure 5.14. ORTEP of dimethyl-N-o-nitrobenzenesulfonyl N-carboxyanhydride.
carbon dioxide, causing minimal contamination during purification. Preliminary 
investigations of the coupling ability of 5.7 showed poor activity under solid phase 
synthesis conditions. However, it has not been exhaustively studied. Different 
coupling conditions and applications of this derivative are under current investigation 
and may yield desired results as a successful activated derivative of <?NBS-Aib-OH. 
Further attempts to generate oNBS-amino acid chlorides with oxalyl chloride, S0C1,, 
PCI, and PCI, have met with mixed results. Most problems associated with the 
synthesis of this derivative are due to the presence of excess base in the reaction which 
acts as a proton sponge to keep the oc-amino group deprotonated. However, 
sulfonamide deprotonation may be causing severe side reactions. These synthetic 
problems are currently being addressed.
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S3. EXPERIMENTAL
5.3.1 oNBS-C^C^-Disubstituted Amino A dd Derivatives
5.3.1.1. Na-(2-nitrophenyIsulfoiiyI)-2-aininoisobutyric add (5.1)
O
1) DIEA. TMS-CI
2) oNBS-CI
N02
5.1
2-aminoisobutyric add (10.0 g, 95.8 mmol) was added to a 500 mL Schlienk 
flask and dissolved in DCM (200 mL). Diisopropylethylamine (27.55 g; 213.0 mmol) 
was added and the reaction stirred for ten minutes while being flushed with argon. 
Chlorotrimethylsilane (21.05 g; 210.0 mmol) was added via syringe slowly and the 
reaction refluxed for 3 hours until all solid was in solution. After allowing the reaction 
to cool to room temperature, o-nitrobenzenesufonyl chloride (21.47 g; 194.0 mmol), 
dissolved in 100 mL DCM, was added dropwise from an addition funnel to the reaction 
mixture and the reaction stirred for 15 hours at room temperature. The DCM was 
removed by rotary evaporation and the resulting residue was distributed between 2.5% 
sodium carbonate solution (100 mL) and 100 mL diethyl ether. The aqueous layer was 
separated and washed with portions of diethyl ether (2 x 100 m L). The aqueous layer 
was placed on a rotary evaporator to remove residual organic solvent for 10 minutes. 
The reaction was cooled in an ice bath and acidified to pH 2.0 with 1.0 N hydrochloric 
arid, then allowed to sit in a refrigerator for 1 hour. The resulting precipitate was 
extracted with ethyl acetate (3 x 200 mL), which was dried over Na2S0 4  and 
concentrated in vacuo to yield 24.7 g (89%) of the crude oNBS-amino arid adduct The
152
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product was recrystallized from dichloroethane to yield 20.7 g (75%) analytically pure 
5.1. lH NMR (250 MHz, tfc-DMSO) 8 12.83 (s, 1H), 8.34 (s, 1H), 8.09-7.81 (m, 4H), 
1.31 (s, 5H). l3C NMR (60MHz, de-DMSO) 174.95, 147.10, 135.47, 133.58, 132.39,
129.34, 124.18, 58.57, 25.55. FAB-MS (glycerol) m/z 2892 (M+H)+. (For 
crystallographic data see Appendix I).
5.3.1.2. Na-(2-nitrophenyIsulfonyI)-l-amino-l-cyclohexanecarboxylic add (5.2)
1-Aminocyclohexane-l-carboxylic add (3.0 g; 20.95 mmol) was weighed out 
into a 250 mL 3-necked round bottom flask. The flask was filled with anhydrous DCM 
(100 mL) while flushing with argon. Diisopropylethylamine (5.95 g; 45.09 mmol) was 
added in one portion and the reaction allowed to stir at room temperature for 10 minutes 
under argon. Chlorotrimethylsilane (5.3 mL; 4.55 g; 41.90 mmol) was added via 
syringe and the reaction was stirred for 4 hours under argon. 2-Nitrobenzenesulfonyl 
chloride (4.41 g; 20.0 mmol) dissolved in 30 mL anhydrous DCM, was added dropwise 
from an addition funnel to the reaction while stirring in an ice bath, while flushing 
under a slow stream of argon. The reaction was allowed to rise to room temperature 
and stirred for 3 hours. The DCM was removed in vacuo and the crude distributed 
between 2.5% sodium carbonate solution (100 mL) and diethyl ether (100 mL). The 
aqueous layer was washed with portions of diethyl ether (2 x 100 mL), separated and 
residual diethyl ether removed on a rotary evaporator. The water layer was cooled in an
O
1) DIEA, TMS-CI
2) oNBS-CI
NOz
5.2
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ice bath and acidified to pH 2.0 with 1.0 N hydrochloric acid and then allowed to sit in a 
refrigerator for 1 hour. The resulting precipitate was extracted with ethyl acetate (3 x 
100 mL), dried over Na2SC>4 and the solvent removed in vacuo to yield the crude 
product in 85% yield (5.5 g). The crude product was recrystallized from hot 100% 
ethanol to yield the analytically pure product as pale yellow crystals (4.9 g; 74%). lH 
NMR (250 MHz, dfi-DMSO) 8 12.55 (s, 1H), 8.21 (s, 1H), 8.08-7.81 (m, 4H), 1.91-1.05 
(m, 10H). l3C NMR (60MHz, dfi-DMSO) 175.08, 147.13, 135.04, 133.73, 132.30,
129.65, 124.18, 51.54, 32.47, 24.54, 20.88; FAB-MS (glycerol) m/z 329.2 (M+H)+. 
(For crystallographic data see Appendix I).
53.13 . Na-(2-nitrophenylsulfonyl)-4-amino-l-(tert-butyloxycarbonyl)piperidine- 
4-carboxyIic add (53)
Api(Boc)-OH (4.12g;17.0mmol) was weighed out into a 250 mL 3-necked 
round bottom flask. The flask was filled with anhydrous DCM (100 mL) while flushing 
with argon. Diisopropylethylamine (5.05 g; 39.1 mmol) was added in one portion and 
the reaction allowed to stir at room temperature for 10 minutes under argon. 
Chlorotrimethylsilane (4.0 mL; 3.42 g; 31.6 mmol) was added via syringe and the 
reaction was stirred for 4 hours under argon. 2-Nitrobenzenesulfonyl chloride (3.39 g, 
16.3mmol), dissolved in 30 mL anhydrous DCM, was added dropwise from an addition 
funnel to the reaction while stirring in an ice bath, while flushing under a slow stream of 
argon. The reaction was allowed to rise to room temperature and stirred for 3 hours.
Boc Boc
O
1) DIEA, TMS-CI
2) oNBS-CI
N02
53
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The DCM was removed in vacuo and the crude distributed between 2.5% sodium 
carbonate solution (100 mL) and diethyl ether (100 mL). The aqueous layer was 
washed with portions of diethyl ether (2 x 100 mL), separated and residual diethyl ether 
removed on a rotary evaporator. The water layer was cooled in an ice bath and 
acidified to pH 2.0 with 1.0 N hydrochloric acid and then allowed to sit in a refrigerator 
for 1 hour. The resulting precipitate was extracted with ethyl acetate (3 x 100 mL), 
dried over Na2S0 4  and the solvent removed in vacuo to yield the crude product in 95% 
yield (6.3 g). The crude product was recrystallized from hot 100% ethanol to yield the 
analytically pine 5 J  as pale yellow crystals (5.2 g; 79%).
*H NMR (250 MHz, dfi-DMSO) 8 12.91 (s, 1H), 8.53 (s, 1H), 8.09-7.84 (m, 4H), 3.45 
(m, 4H), 1.93 (m, 2H), 1.75 (m, 2H), 1.35 (s, 9H). ,3C NMR (60MHz, de-DMSO) 
174.08,153.55,147.07,134.53,134.04,132.49,129.55,124.35,78.87,59.95,31.70,
27.99. FAB-MS (glycerol) m/z 430.2 (M+H)+. (For crystallographic data see Appendix
I).
5.3.I.4. N°-(2-nitrophenylsulfonyl)-N*-(benzyIoxycarbonyl)-L-lysine (5.4)
1) DIEA. TMS-CI
2) oNBS-CI
OHS—NOH
O
5.4
NE-(benzyloxycarbonyl)-L-lysine (3.0g; 10.7mmol) was dried for 1 hour under 
vacuum and suspended in 100 mL anhydrous DCM in a 250 mL three-necked round-
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bottom flask fitted with an argon inlet valve, a septum and reflux condenser. 
Diisopropylethylamine (3.04g; 23.5mmol) was added and the reaction mixture was 
allowed to stir for 10 minutes at room temperature. While flushing with argon, the 
solution was cooled to 0 °C in an ice bath and chlorotrimethylsilane (2.33 g; 21.40 
mmol) was added via syringe slowly. Extensive HC1 gas production was observed. 
The reaction was refluxed under argon for 2 hours until the solution was homogenous. 
The solution was then re-cooled to 0 °C and 2-nitrobenzenesulfonyl chloride (2.26 g; 
10.17 mmol), dissolved in SO mL anhydrous DCM, was added dropwise from an 
addition funnel. The reaction was allowed to rise to room temperature and stirred for 2 
hours. The DCM was removed in vacuo by rotary evaporation and the crude residue 
distributed between 2.5% sodium carbonate (100 mL) and diethyl ether (100 mL). The 
aqueous layer was washed with diethyl ether (2 x 100 mL) and placed on a rotary 
evaporator to remove residual organic solvent. The resulting clear aqueous solution 
was cooled to 0 °C and acidified to pH 2.0 with 1.0 N HC1. The solution was allowed to 
sit in a refrigerator for 2 hours and the resulting lightly colored precipitate was extracted 
with ethyl acetate (3 x 100 mL). The organic solution was dried over Na2S0 4  and 
concentrated in vacuo, yielding the crude product in 62% yield (5.1 g). The crude was 
recrystallized from chloroform to yield 7 as analytically pure crystals (4.5 g; 47%). lH 
NMR (250 MHz, cfe-DMSO) 6 12.35 (s, 1H), 8.48 (d, 1H), 8.05-7.81 (m, 4H), 7.35 (m, 
5H), 721 (t, 1H), 5.01 (s, 2H), 3.81 (m, 1H), 2.90 (m, 2H), 1.54 (m, 2H), 1.23 (m, 4H). 
l3C NMR (60MHz, (fc-DMSO) 172.58, 155.071, 147.27, 137.30, 133.95, 133.34, 
132.42, 129.84, 128.37, 127.75, 124.09, 55.13, 55.74, 31.40, 28.59, 22.38; FAB-MS
(glycerol) m/z 455.2 (M+H)+. (For crystallographic data see Appendix I).
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5J.2 . 2-(2-nitrothiobenzene)-acetic add (5.5)
H S ^ . N02
DBU, CH3CN
s ^ Y 0H
o
2-ChIoronitrobenzene (1.0 g; 5.35mmol) was dissolved in 40 mL acetonitrile 
and mercaptoacetic acid (0.92 g; 9.50 mmol) was added. The reaction was cooled to 0 
°C and DBU (2.85 g; 19.05 mmol) was added slowly, dropwise while stirring. The 
reaction was allowed to rise to room temperature over 1 hour and monitored by thin 
layer chromatography (1:1 DCM; Hexane) on silica. After 15 minutes, no 2- 
chloronitrobenzene was visible in the reaction the acetonitrile was removed in vacuo by 
rotary evaporation. The resulting crude oil was dissolved in 50 mL ethyl acetate and the 
organic solution was washed with 1.0 N hydrochloric acid (3 x 50 mL). The organic 
layer was dried over anhydrous Na2S0 4 and the solvent removed by rotary evaporation 
to yield the crude product as bright yellow clumps, which has some impurity by TLC 
(99:1 ethyl acetate; acetic acid). Recrystallization from hot ethanol, followed by slow 
cooling and refrigeration yielded the analytically pure adduct 5.5 as small bright yellow 
crystals in good yield and with excellent purity (1.12 g; 83%). lH NMR (250 MHz, ck- 
DMSO) 8 13.04 (s, 1H), 8.24 (d, 1H), 7.73 (dd, 1H), 7.59 (d, 1H), 7.42 (dd, 1H), 4.03 
(s, 2H). l3C NMR (60MHz, (fe-DMSO) 8 170.04, 145.39, 135.90, 134.32, 127.30,
125.95,125.53,34.39. FAB-MS (glycerol) m/z 213.0 (M-H)‘. (For crystaUographic data 
see Appendix I).
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5 3 3 . A-(2-nitrobenzenesulfonyl)-2-aininoisobutyric acid-A'-carboxyanhydride 
(5.7)
1) 2,4,6-Collidine
2) BTC. DCM
5.7
2.57g Bis-(trichloromethyl)carbonate was dissolved in anhydrous DCM (20 mL) 
and stirred at 0 °C. A solution of e>NBS-Aib-OH (5.0 g, 17.35 mmol) and 2,4,6- 
collidine (4.2 g; 34.59 mmol), in 50 mL DCM, was slowly added and the reaction was 
allowed to go to room temperature. After stirring for 2 hours, 1.0 N hydrochloric acid 
(100 mL) was added and the reaction stirred for an additional five minutes. The organic 
layer was separated, washed with an additional 1.0 N hydrochloric acid (100 mL) and 
dried over Na2SC>4 . The solvent was removed by rotary evaporation and the crude 
product (5.03 g; 98%) was recrystallized from hot chloroform overnight to yield the 
NCA adduct as large white crystals (3.57 g; 73%). lH NMR (250 MHz, d2-DCM) 8
8.41 (d, 1H), 7.93-7.81 (m, 3H), 1.92 (s, 5H). I3C NMR (60MHz, d2 -DCM) 159.24, 
148.54, 14737, 135.99, 134.54, 132.54, 129.82, 124.97, 59.15, 24.38. FAB-MS
(glycerol) m/z 3153 (M+H)+. (For crystallographic data see Appendix I).
53.4. Deprotection Solution
The deprotection solution (0.4 M mercaptoacetic acid; 0.8 M DBU; in 
acetonitrile) was prepared by diluting mercaptoacetic acid (3.58 g, 40 mmol) to 50 mL
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in acetonitrile and DBU (12.18 g, 80 mmol) to SO mL with acetonitrile. Both solutions 
were sealed and cooled to 5 °C. The solutions can be stored this way for several 
months. The DBU solution is slowly added to the thiol solution dropwise while stirring 
and maintaining a low temperature. After addition, the solution is stirred to ensure 
complete mixing, and stored in the refrigerator. Kept at 5 °C, the deprotection solution 
can be stored for several weeks before discoloration appears, which may cause 
interference in spectrometric analysis. At room-temperature, the deprotection solution 
becomes discolored after 2-3 days.
5.3.5. UV-Absorbance vs. Concentration Studies
Serial dilutions were made to produce the desired concentrations of 2- 
nitrophenyl-mercaptoacetid acid under experimental conditions (CH3CN / Deprotection 
solution, 6:1). The cleavage adduct was dissolved and diluted in a 1:6 mixture of 
deprotection solution (0.4 M mercaptoacetic acid; 0.8 M DBU in acetonitrile) and 
acetonitrile. Serial dilutions were made to 1.0 mM, 500 pM, 250 pM, 125 pM, 100 
pM, 50 pM, 25 pM and 10 pM. The samples were scanned on an AVIV Instruments 
14DS UV-Vis-IR Scanning Spectrometer in quartz cells (path length=l cm) from 500- 
250 nm. The background spectra ( 1 : 6  deprotection solution : CH3CN), were subtracted 
from the sample spectra. Derivation of molar absorptivity is determined by 
extrapolation from Beer’s Law so 8 3 9 0  = A3 9 0  /be (where E3 9 0  is the molar absorptivity of 
the cleavage product at 390nm, A3 9 0  is the absorbance, b is the path length (lem) and c 
is the molar concentration o f the dissolved cleavage adduct) for all concentrations. The 
observed molar absorptivities are plotted according to A vs. c, and the graph slope 
extrapolated to yield the average molar absorbtivity o f2950 M'Lcm_1.
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53.6. Solution Phase Cleavage Studies
In-solution deprotection studies were performed on four oNBS-protected amino 
acids: oNBS-Aib-OH, 0 NBS-AC6 C-OH, oNBS-Api(Boc)-OH and oNBS-Lys(Z)-OH. 
All of the amino acids were weighed out and treated with 1.0 mL deprotection reagent 
(0.4 M mercaptoacetic acid; 0.8 M DBU in acetonitrile). The solution rapidly becomes 
bright yellow. The solution was agitated for 30 minutes at room temperature and then 
diluted with 6.0 mL acetonitrile to simulate resin cleavage conditions. The solutions are 
scanned from 500-300 nm using an AVTV Instruments 14DS UV-Vis-IR 
Spectrophotometer in a quartz cuvette with 1.0 cm path length and background 
corrected from a solution of 1.0 mL deprotection reagent in 6.0 mL acetonitrile in a 
matched quartz cuvette. The corrected absorbance at 390 nm is recorded and correlated 
to calculated theoretical absorbances for the corresponding concentrations.
53.7. Solid-Phase Cleavage Studies
Solid-phase coupling was performed with 4 equivalents of oNBS-Aib-OH and 4 
equivalents of HATU in the presence of 2,4,6-collidine or preformed amino add 
fluorides. The activated ester was preformed in CHjCN for thirty minutes, then added 
to a pre-swollen suspension of PAL-PEG-PS in CH3CN. The coupling was allowed to 
proceed for 24 hours with coupling tests performed every two hours. Coupling tests 
were performed by removing 5-10 mg of the resin, successive washing with CH3CN 
and MeOH and drying the resin under high vacuum for 1 h. An exact amount of the 
resin was weighed out and treated with I mL of the deprotection solution for 30 
minutes. The supernatant was then removed and the resin washed with CH3CN ( 6  x
1.00 mL) to give a total volume of 7.00 mL. A 1.0 mL sample of the combined washes
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was studied by scanning UV-spectroscopy from 500-300 nm and the background 
corrected absorbance value at 390 nm was noted. This value was entered into the 
substitution equation %Substitution=[(A3Mxl0‘x0.007)/(eJWxW)]/L. Couplings of 
several attempts never reached higher values than 32%. This may be due to poor 
coupling or poor compatibility of the highly polar deprotection solution with the 
relatively hydrophobic interior of the PEG-PS resin. Increased coupling efficiency may 
be reached with the use of more polar resins.
5.4. CONCLUSIONS
We have shown that the ort/jo-nitrobenzenesulfonyl group (oNBS) is a viable 
potential alternative to many common protecting groups, including the Fmoc-group. 
The oNBS group should allow for the use of highly activated C-terminus activating 
groups, such as acid chlorides and HATU adducts. The lowered nucleophilicity of the 
sulfonamide oxygen of oNBS-amino acid adducts are not prone to oxazalone formation 
and should greatly increase coupling yields and lower reaction times. In addition, the 
oNBS group is considerably less bulky than the Fmoc-group and should interfere less 
with solid-phase couplings of hindered amino acids. The deprotection of the oNBS 
group by mercaptoacetic acid in basic media is fast, effective and quantitative. In 
addition, the cleavage reaction yields a stable chromophore that can be detected by UV- 
spectroscopy for in situ reaction monitoring in real time. Solid-phase coupling attempts 
using preformed amino acid fluorides and activated esters (HATU) of the oNBS- 
adducts were inconclusive. Poor observed coupling yields may be due to poor activity 
of the activated amino acid derivative, or incompatibility of the deprotection solution 
with the PEG-PS resin. The use of different resins and varying solvents may aid in 
coupling efficiency. The application of this new coupling scheme could lead to the
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ability to generate longer, more difficult sequences in high yields, with lower costs and 
decreased reaction times.
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CHAPTER 6 
SUMMARY, FUTURE STUDIES AND INSIGHTS
6.1. DISCUSSION
There is still much to be learned about the synthesis, structure, and bioactivity of 
linear, helical, amphipathic peptides. This dissertation addresses some of the hurdles 
that must be overcome if the development of this field is to continue. The design and 
synthesis of short, amphipathic helical peptides incorporating high levels of Ca,Ca- 
disubstituted amino acids is a difficult task. Development of new methods with which 
to synthesize these difficult targets with greater efficiency and purity is crucial for the 
successful continued study of the bioactivity of these compounds. New amino acids 
need to be synthesized and their helix promoting ability and their ability as structure 
stabilizing elements need to be assessed. Foremost, the mechanism by which 
antimicrobial peptides function must be further studied. Insights into these and other 
areas of peptide synthesis, characterization and biological screening will allow linear, 
helical peptides to be at the forefront of biomedical studies in the next few years. As 
bacterial resistance becomes a growing problem, newer and "smarter" drugs are 
required to battle increasing pathogenic activity. Antimicrobial peptides are one of the 
best candidates to take on this task.
Chapter 2 of this dissertation presents the synthesis of orthogonally protected 
polyfunctional Ca,Ca-disubstituted amino acids (Fmoc-Api(Boc)-OH, Fmoc- 
Bglu(/Bu)2-OH, Fmoc-Basp(/Bu)2-OH and Fmoc-Bap(Boc)2-OH). Ca,Ca-Disubstituted 
amino adds have provided peptide chemists with powerful tools for secondary structure 
promotion. 6 1 ' 5  Api has found a niche as the preferred source of cationic Ca,C°- 
disubstituted amino adds for the synthesis of peptides of this family. 6 ' 6 ' 8  It allows high
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levels of ionizable residues to be incorporated into short peptides containing up to 80% 
Ca,Ca-disubstituted amino acids, yet still retain a preferred helical sense, allowing 
secondary structure studies to be performed. 6 ,9  Api complements the family of alicyclic 
Ca,Ca-disubstituted amino acids, all of which have been found to be strongly helix 
promoting. 6 1 0 ' 13 The synthesis of Api is characterized by the selective hydrolysis of a 
di-Boced hydantoin, which can be easily purified under aqueous/organic alkaline 
conditions to yield the ^-protected amino acid in good yield. N“-Fmoc-protection is 
then realized to give the orthogonally protected amino add . 6 ,1 4
Ethyl nitroacetate (ENA) is a common precursor to a number of organic 
targets. 6 ,1 5  It has provided us with an exciting starting material for the synthesis of 
orthogonally protected, polyfunctional Ca,Ca-disubstituted amino adds. The mild 
conditions under which ENA can be alkylated, allows for tremendous versatility in the 
choice of electrophilic alkylating agents. Mild base-catalyzed alkylation of ENA allows 
for the preparation of a number of tetrafunctional precursors, suitable for conversion 
towards orthogonally protected polyfunctionalized Ca,C°-disubstituted amino adds. 6 1 6
The synthesis of Fmoc-Bglu(rBu)2-OH, an orthogonally protected 
tetrafunctional Ca,Ca-disubstituted amino acid analog of glutamic add, and Fmoc- 
Bap(Boc)2-OH, an orthogonally protected tetrafunctional Ca,Ca-disubstituted amino 
add analog of lysine, are based on base catalyzed nucleophilic alkylation of the ethyl 
nitroacetate (ENA) anion. This electrophilic addition has been highly accelerated by 
utilizing a tetraalkyl ammonium halide to function as a highly dissodated counter-ion 
during alkylation. 6 ' 1 6  The nucleophilic addition o f the ethyl nitroacetate anion has been 
extended to several alkyl halide acceptors and Michael acceptors. As a result of the
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base-catalyzed cyclization of ethyl-2,2-bis(/-butylcarboxyethyI) glycine during the a- 
amino ester hydrolysis, the synthesis was refocused on the corresponding Bis-aspartic 
acid derivative Fmoc-Basp(/Bu)2 -OH. The shorter side-chain length allows for 
hydrolysis without competition from cyclization reactions. Subsequent ^-protection 
of this amino acid is currently underway.
Regioselective reduction of ethyl 2,2-bis(3-cyanoethyl)-2-nitro acetate towards 
the synthesis of Bap(Boc)2-OH has proven very difficult Thus, several alternative 
synthetic pathways have been envisioned for the successful synthesis of Bap-like 
analogs. These schemes are illustrated in Figure 6.1 and Figure 6.2. The synthetic 
scheme in Figure 6.1 takes advantage of the already optimized dialkylation of ethyl 
nitroacetate with /-butyl acrylate. Acid catalyzed /-butyl ester cleavage may allow for 
the preparation of a Boc-protected diamino derivative through a modified Curtius 
rearrangement. Subsequent nitro reduction and ethyl ester hydrolysis should allow for 
the preparation of Fmoc-Bae(Boc)2-OH (Bae=Bis(amino ethyl)).
o
°>«vA 0^  0jN> < " 'o ^
- / A y  hv V  „ / s
/ l o o '  0 0  Boc
P O
NHi
Boc
H2/N>
OC" | ^ <s ' OH ^TMS-CU DIEA ^ x N > 0  ^  ° H H2|J x J ^ O XV
HN NH HN NH E*°H A
Boc Boc Boc Boc ^
Boc Bo<?
Figure 6.1. Curtius rearrangement approach towards the synthesis of Fmoc-Bae(Boch- 
OH.
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The second synthetic scheme (Figure 6.2) is based on the ring opening ability of 
N-alkylated aziridines. The high nucleophilicity of the ethyl nitroacetate anion may 
allow for a one-step conversion to the side-chain protected a-nitro ester. Subsequent 
nitro reduction, hydrolysis and N“-protection may provide a very rapid and efficient 
route to Fmoc-Bae(Boc)2-OH. The development of these exciting new amino acids 
towards functional SPPS monomers will allow for the preparation of new peptides with 
which to further study amino acid induced secondary structure promotion.
4 .  A
AcCN HN NH
DIEA, TEAE
Boc Boc Boc
NHi
Boc
HN
Boc
Fmoc—N
tTM8-a, DIEA 
Fmoc-CI HN" NHi t
Boc Boc
0
OH
EtOH
Figure 6.2. Aziridine ring-opening approach towards the synthesis of Fmoc- 
Bae(Boc)2-OH.
Several key secondary structure questions can be addressed utilizing these new 
amino acids. It has recently been shown that helical secondary structures can be 
induced and stabilized by amphipathic control.6*9 Studies have also determined that 
higher bis(n-alkyl) Ca,Ca-disubstituted amino acids strongly favor extended 
conformations.6'3’4 Incorporation of bifunctional amino acids, such as Bap or Bae into a
169
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
short peptide increases the amphipathic character of the peptide by introducing higher 
levels of cationic functional groups. According to amphipathic stabilization of 
secondary structures, this should increase the peptides ability to form helical 
conformations under micellar-type environments. However, these amino acids 
structurally resemble the bis(n-alkyl) Ca,Ca-disubstituted amino acids which are known 
to preferentially adopt an extended conformation. Table 6.1 shows proposed variations 
of peptides that could be synthesized to determine the secondary structure promoting 
ability of these amino acids.
Table 6.1. Suggested helical peptides incorporating Bap.
Peptide Sequence Helix
Design
Pi-10* H-Aib-Aib-Bap-Z.ys-Aib-Aib-Bap-Z,ys-Aib-Aib-NH2 a
Ipi-10* H-Bap-Aib-Aib-Lys-Aib-Aib-Iys-Aib-Aib-Bap-N^ 3io
Ach-lOa® H-Ac6C-Aib-Iys-Bap-Aib-Ac6 C-Bap-£ys-Ac6 C-Aib-NH2 a
Ach-10® H-Bap-Aib-Ac6C-£ys-Ac6 C-Aib-Iy$-Aib-Ac6 C-Bap-NH2 3io
Bap-6 H-Ac6c-Ac6c-Bap-Lys-Ac6c-Ac6c-NH2 a
Bap-8 H-Ac6c-Ac6c-Iys-Ac6c-Ac6c-Bap-Ac6c-Ac6c-NH2 3io
Salt-bridge stabilization of secondary structure is also well documented. The 
presence of tetrafunctional amino acids, such as Bglu and Bap should provide several 
interesting opportunity to study highly salt-bride stabilized secondary structures as is 
illustrated in Figure 6.3. These peptides complement the family o f peptides presented
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in Chapter 3 of this dissertation and would greatly increase our understanding of the 
factors that promote and stabilize secondary structures in peptides. In addition to 
determining structures by electronic circular dichroism spectroscopy, vibrational 
circular dichroism spectroscopy (VCD) (10) and NMR will be utilized to gain better 
understanding of helical conformations.618'20
 ^ 0 2C^ ^ C 0 2 HaN ^ ^ N HaOzQ ^  ^ C Oz Ha N ^ ^ N Ha C°2
/W lflA#'
Figure 63. Highly stabilized salt-bridge peptide incorporating Bap and Bglu.
Chapter 4 of this dissertation addresses the bioactivity of the presented peptides 
as selective cytolytic agents towards macrophages infected with intracellular pathogens. 
Due to exponential growth in the use of classical antibiotic therapy, bacterial resistance 
towards antibiotics is becoming an ever-growing problem. This problem is exacerbated 
in the case of intracellular pathogens since they reside within the cellular environment 
of the very immune system which is used to target it, and infection is not associated 
with a significant extracellular component of the pathogen. Because of this resistance
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problem, several new approaches towards antimicrobial defense have been explored 
within the past twenty years. One of the most promising routes toward developing a 
new weapon to battle bacterial agents have been the growing interest in linear 
amphipathic peptides as antimicrobial agents. Amphipathic peptides are highly 
ubiquitous in nature and make up an important part of the natural defenses of several 
species in the animal kingdom. The peptides are characterized by the presence of a 
definable cationic amphipathic helical structure and are usually relatively short (<40 
residues), thus suggesting that considerable biological activity can be exhibited by 
relatively short sequences.6,21 These peptides have been found to be active against a 
wide array of pathogens, including gram-positive and gram-negative bacteria, protozoa, 
and fungi.6,22 Although currently not prevalent as therapeutic agents, some peptides are 
currently under review for use as drugs.
Although no direct bioactivity was observed towards Brucella abortus, MIC 
studies against representative Gram-positive and Gram-negative bacteria support the 
theory that increased hydrophobicity in peptide composition increases cytolytic activity. 
This hydrophobicity-dependent cytolytic character is also observed in mammalian non­
infected peritoneal macrophages from BALB/c mice. Thus, Pi-10 and Ipi-10, which 
contain Aib as their hydrophobic residues, show the lowest cytolytic activity. In 
contrast, Cyh-10 and Ich-10, in which the Aib residues have been substituted with much 
more hydrophobic AC6C, show the highest levels of cytotoxicity. ACh-10 and ACh- 
10a, which contain a mixture of Aib and Acgc residues, show cytolytic activities 
roughly in between those of Pi-10 and Cyh-10. These peptides may be the best suited 
for further study as in vivo therapeutics.
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Studies of the selective bioactivity in vitro against peritoneal macrophages 
infected with an intracellular pathogen, Brucella abortus-GFP, clearly show that the 
peptides show a selective cytolytic activity towards infected macrophages at 
concentrations that are nan-lethal to healthy macrophages. An additional interesting 
feature to note is the higher selectivity of a-helical peptides versus 3io-helical peptides. 
This suggests a strongly structure-dependent mechanism of cell lysis and activity. In 
vitro activation of harvested macrophages with PMA induces peptide-promoted cell 
killing in a similar fashion to Ba infected macrophages. In contrast, PKC inhibition of 
PMA-induced cellular activation suppresses peptide activity completely. This suggests 
a cellular membrane-mediated response by infected macrophages towards the presence 
of a pathogen. This response may increase susceptibility of the infected cells towards 
peptide activity or promote peptide aggregation at the cellular membrane. Further 
studies to promote the understanding of cellular response towards intracellular 
pathogenic infections are required to fully understand the mechanism by which these 
peptides function. These studies include fluorescently labeling peptides to observe 
peptide distribution in infected versus non-infected macrophages, and PKC inhibitor 
treatment of Sa-infected macrophages. In addition, peptide activity at the cellular 
membrane and peptide affinity for infected versus non-infected macrophages must be 
determined. We plan to further test the presented peptides through in vivo studies to 
determine cytotoxicity and efficacy in combination with classical antibiotic therapy. 
These studies are planned to be extended towards the search for potent therapeutic 
approaches to treat bacterial infections of greater current interest, such as 
Mycobacterium tuberculosis.
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Chapter 5 of this dissertation addresses the role of C^C^-disubstituted amino 
acids, such as Aib (2-aminoisobutyric acid), Ac6c (1 -amino-1 -cyclohexy Icarboxy lie 
acid), and Api (4-aminopiperidine-4-carboxylic acid), in solid phase peptide synthesis. 
C^C^-Disubstituted amino acids have become recognized tools for the selective control 
of peptide secondary structure*10,13 and for accentuating physiological properties of 
resulting peptides (see chapters 2,3 and 4). Recently, these derivatives have been 
shown to generate highly helical segments with peptides as short as 10 residues in 
length.*9 In particular, close proximity of these residues causes dramatic increases in 
the helical propensity of resulting peptides, as well as stabilizes these peptides towards 
enzymatic degradation under physiological conditions.*6 These amino acids are of 
current interest in the development of novel amphipathic peptides with high helicity for 
study as in vivo selective weapons against macrophages infected with intracellular 
pathogens (See Chapter 4). As with //-alkylated amino acids, Ca,Ca-disubstituted 
amino acids offer a significant challenge in their ability to couple under solid phase 
peptide synthesis conditions. Couplings generally require large excesses of reagent and 
extended coupling-times. This, in turn, makes peptides rich in C^.C^disubstituted 
amino adds very expensive to synthesize. The inherent difficulty in coupling of several 
residues of C“,C°-disubstituted amino adds in a row stems primarily from the steric 
repulsion that arises between the residue that is being coupled and the residue that is 
already on the resin.
In an attempt to develop a new, faster method for couplings of these difficult 
amino adds, our attention has turned to the higher reactivity of amino add chlorides, 
which have been shown to have very high reaction rates in solution phase couplings.*33,26 
In addition to being of higher reactivity, amino add chlorides are considerably less
174
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
expensive to synthesize in comparison to their corresponding acid fluorides and can be 
prepared by a number of simple reagents such as thionyl chloride, oxalyl chloride and 
phosphorous trichloride. However, pre-formed amino acid chlorides generally do not 
perform as well in solid phase peptide synthesis due to competing oxazolone 
formation.” 4
The sulfonyl oxygens of the o-nitrobenzenesulfonyl (oNBS) group are 
considerably less nucleophilic than the corresponding carbonyl group of a urethanyl 
type protecting group. Thus, the problem of intramolecular cyclization is not of 
concern in the preparation and application of oNBS-amino acid chlorides or other 
activated ester functional groups. This phenomenon may in turn result in lower 
racemization of oNBS protected proteinogenic amino acids, since oxazalone formation 
is the key intermediate in facilitating this process.
Chapter 5 of this dissertation introduces a new scheme for solid-phase peptide 
synthesis based on the oNBS group as the ^-protecting group. The group has been 
shown to be easily introduced into a number of C^C^-disubstituted amino a c i d s , i s  
stable as an amino acid adduct and is readily cleaved to form a UV-active chromophore 
which is quantitatively characterizable during the coupling reaction is in progress.
The oNBS group should allow for the use of highly activated C-terminus 
activating groups, such as acid chlorides and HATU adducts. The lowered 
nucleophilicity of the sulfonamide oxygen of oNBS-amino acid adducts are not prone to 
oxazalone formation and should greatly increase coupling yields and lower reaction 
times. The deprotection of the oNBS group by mercaptoacetic acid is fast, effective and 
quantitative. This coupling scheme should lead to the ability to generate longer, 
difficult sequences in high yields, with lower costs and decreased reaction times.
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APPENDIX. CRYSTAL STRUCTURE ANALYSIS OF o- 
NITROBENZENESULFONYL AMINO ACID DERIVATIVES
A .l. oNBS-Aib-OH
Coordinates
Atom X Y Z
S 0.72056(4) 0.74709(4) 0.66517(4)
01 0.7351(1) 0.6310(1) 0.7369(1)
02 0.6911(1) 0.8615(1) 0.7143(1)
03 0.9857(1) 0.8572(1) 0.9103(1)
04 0.9402(1) 1.0585(1) 0.8421(1)
05 0.7824(1) 0.5380(1) 0.5226(1)
06 0.6262(1) 0.4020(1) 0.4448(1)
N1 0.8494(1) 0.7755(1) 0.6512(2)
N2 0.6668(1) 0.5099(1) 0.4677(2)
Cl 0.9453(2) 0.9467(2) 0.8181(2)
C2 0.9124(2) 0.8995(2) 0.6751(2)
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Coordinates (continued)
C3 0.5912(2) 0.7231(2) 0.4981(2)
C4 0.4957(2) 0.8161(2) 0.4452(2)
H4 0.505 0.891 0.496
C5 0.3871(2) 0.8002(2) 0.3197(2)
H5 0324 0.865 0384
C6 0.3702(2) 0.6904(2) 0.2465(2)
H6 0.296 0.680 0.161
C7 0.4617(2) 0.5946(2) 0.2986(2)
H7 0.449 0.518 0.250
C8 0.5715(2) 0.6127(2) 0.4224(2)
C9 1.0419(2) 0.8788(2) 0.6737(2)
H9A 1.093 0.816 0.742
H9B 1.090 0.958 0.694
H9C 1.026 0.849 0.584
CIO 0.8295(2) 0.9953(2) 0.5664(2)
H10A 0.811 0.963 0.477
H10B 0.876 1.075 0.584
H10C 0.748 1.008 0.570
H30 1.010(3) 0.894(3) 0.991(3)
H1N 0.887(2) 0.716(2) 0.648(3)
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Bond Distances and Bond Angles
Bond_____________Distance__________________ Bond Angle
S - O l 1.434(1) A 0 1 - S - 0 2 120.1(1)°
S - 0 2 1.438(1)A 0 1 - S - N l 109.9(1)°
S -N l 1.610(1)A 01 - S - C3 106.3(1)°
S-C3 1.783(2)A 0 2 - S - N l 106.2(1)°
0 2 - S - C 3 106.3(1)°
N 1-S-C 3 107.5(1)°
01 -S 1.434(1) A
0 2 -S 1.438(1) A
0 3 -Cl 1.314(2) A Cl - 03 - H30 107.3(20)°
0 3 - H 3 0 0.896(30) A
0 4 -Cl 1.224(2) A
0 5 -N 2 1.229(1) A
0 6 -N 2 1.220(2) A
N l - S 1.610(1) A S - N l  -C2 124.1(1)°
N1-C2 1.470(2) A S-N1-H1N 115.0(10)°
N1 -H1N 0.780(18)A C2-N1-H1N 119.3(11)°
N 2 -0 5 1229(1) A 05 - N2 - 06 124.1(1)°
N 2 -0 6 1220(2) A 0 5 -N 2 -C 8 118.0(1)°
N2-C8 1.469(2) A 0 6 -N 2 -C 8 117.8(1)°
C l -0 3 1.314(2) A 0 3 - C l - 0 4 124.6(1)°
C l - 0 4 1224(2) A 0 3 -C 1 - C 2 113.4(1)°
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Bond Distances and Bond Angles (continued)
C1-C2
C2-N1
C2-C1
C2-C9
C2-C10
C 3-S
C3-C4
C3-C8
C4-C3
C4-H4
C4-C5
C5-C4
C5-H5
C5-C6
C6 -C5
C6-H6
C6-C7
C7-C6
C7-H7
C7-C8
1.535(2) A 
1.470(2) A 
1.535(2) A 
1.533(1) A 
1.530(2) A
1.783(2)A 
1.396(2) A 
1.398(2) A 
1.396(2) A 
0.949 A 
1.390(2) A 
1.390(2) A 
0.950 A 
1.382(3) A 
1.382(3) A 
0.950 A 
1.390(2) A 
1.390(2) A 
0.950 A 
1.389(2) A
0 4 - C 1 - C 2  
N1 - C2 - Cl 
N1-C2-C9 
N1-C2-C10 
C1-C2-C9 
Cl -C2-C10 
C9-C2-C10
5 -C 3 - C 4  
S -C 3 -C 8  
C4-C3-C8 
C3-C4-H 4 
C3 - C4 - C5 
H4-C4-C5 
C4-C5-H5 
C4-C5-C6 
H5-C5-C6 
C5 - C6 - H6 
C 5-C6-C7 
H6-C6-C7 
C6 - C7 - H7 
C6-C7-C8 
H7-C7-C8
121.9(1)°
110.0( 1)°
106.4(1)°
111.9(1)°
106.6(1)°
111.2(1)°
110.5(1)°
117.3(1)°
124.6(1)°
117.7(1)°
119.6°
120.8(2)°
119.6°
119.8°
120.5(2)°
119.8°
120.0°
120.0(2)°
120.0°
120.4°
119.1(2)°
120.5°
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Bond Distances and Bond Angles (continued)
C8-N2 1.469(2) A N2-C8-C3 122.1(1)°
C8-C3 1398(2) A N2-C8-C7 116.0(1)°
C8-C7 1389(2) A C3-C8-C7 121.9(1)°
C9-C2 1.533(1) A C 2-C 9-  H9A 109.4°
C9-H9A 0.980 A C 2-C 9-  H9B 109.5°
C9 - H9B 0.980 A C2-C9-H9C 109.5°
C9-H9C 0.980 A H9A-C9-H9B 109.5°
C10-C2 1.530(2) A C2 - CIO - H10A 109.5°
C10-H10A 0.980 A C2 - CIO - H10B 109.5°
C10-H10B 0.980 A C2-C10-H10C 109.5°
C10-H10C 0.980 A H10A-C10-H10B 109.5°
Experimental
Crystal Data
CioH12N20 6S a -  11.665 (3) A D*=1.572 Mgm'J
M r- 28828 b = 10.614 (2) A Mo Ka radiation
Monoclinic c=  11.121 (4) A A = 0.71073 A
Space Group; P2\!c 0=117.80(2)° T= 100 K
Data collection
3536 independent reflections
6 U  = 30.0°
R(F) = 0.042 (183 parameters)
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A.2. 0NBS-Ac*c-OH
C3B
C2B 05B
C4BC12A H2BO l A
04B U1B 06BC11A 02B
C8A 03ASlA C1BC10A C6AC9A C9BC7BC7A
,C5A 03B C6B SIB C8B02A C10BH2A 04A
H1A CIA OIB CUB06A
C4A
C13B05A CI2BC2A
C3A
Coordinates
Atom X Y Z
SI 0.09596(3) 0.97588(3) 0.32063(4)
01 0.07698(10) 0.95375(10) 02103(1)
02 0.06725(10) 0.91675(10) 0.3854(1)
03 0.2461(1) 0.81592(10) 0.4065(1)
H30 0.241(2) 0.760(2) 0.413(2)
04 0.24094(10) 0.81240(9) 0.5707(1)
05 0.14870(10) 1.1214(1) 0.1952(1)
06 0.0177(1) 1.1534(2) 0.0649(1)
N1 02041(1) 0.9921(1) 03861(1)
H1N 0230(2) 1.003(2) 0.345(2)
N2 0.0665(1) 1.1387(1) 0.1599(1)
Cl 02458(1) 0.8540(1) 0.4949(2)
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Coordinates (continued)
C2 02565(1) 0.9556(1) 0.4958(2)
C3 0.0400(1) 1.0790(1) 0.3179(2)
C4 0.0017(1) 1.0927(2) 0.3932(2)
H4 0.011 1.050 0.449
C5 -0.0502(1) 1.1680(2) 0.3893(2)
H5 -0.075 1.177 0.443
C6 -0.0664(1) 1.2302(1) 0.3079(2)
H6 -0.103 1.281 0.304
C7 -0.0290(1) 1.2184(1) 0.2318(2)
H7 -0.040 1.261 0.176
C8 0.0245(1) 1.1443(1) 02386(2)
C9 0.3585(1) 0.9748(1) 0.5226(2)
H9A 0.397 0.945 0.592
H9B 0.375 0.950 0.465
CIO 0.2294(1) 0.9995(1) 0.5820(2)
H10A 0.164 0.989 0.563
H10B 0264 0.971 0.654
C ll 0.3792(1) 1.0750(1) 0.5333(2)
H11A 0.446 1.084 0.556
H11B 0.348 1.104 0.462
C12 0.3490(2) 1.1189(2) 0.6155(2)
H12A 0.358 1.184 0.615
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Coordinates (continued)
H12B 0.387 1.096 0.689
C13 0.2488(2) 1.0999(1) 0.5899(2)
H13A 0210 1.129 0.520
H13B 0.233 1.126 0.647
s r 0.39312(3) 0.48665(3) 0.68607(4)
01 ' 0.3976(1) 0.49706(10) 0.7938(1)
02’ 0.42115(10) 0.55820(10) 0.6352(1)
03’ 0.2330(1) 0.63264(10) 0.5829(1)
H30' 0.231(2) 0.691(2) 0.573(2)
04’ 023567(10) 0.64204(9) 0.4180(1)
05* 0.34019(10) 0.3166(1) 0.7739(1)
06’ 0.4629(1) 0.2774(1) 0.9117(1)
NV 0.2909(1) 0.4609(1) 0.6055(1)
H1N' 0.260(2) 0.433(2) 0.632(2)
N2' 0.4230(1) 0.3043(1) 0.8187(1)
C l' 0.2384(1) 0.5980(1) 0.4959(2)
C2' 0.2447(1) 0.4959(1) 0.4948(2)
C3’ 0.4653(1) 0.3952(1) 0.6891(2)
C4' 0.5174(1) 0.4014(2) 0.6278(2)
H4’ 0.512 0.453 0.584
C5' 0.5775(2) 0.3341(2) 0.6293(2)
H5' 0.611 0339 0.585
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Coordinates (continued)
C6' 0.5890(1) 0.2599(2) 0.6956(2)
H6' 0.630 0214 0.697
CT 0.5399(1) 02535(1) 0.7599(2)
H7' 0.549 0204 0.807
C8' 0.4778(1) 0.3197(1) 0.7547(2)
C9' 0.1459(1) 0.4597(1) 0.4502(2)
H9'l 0.118 0.474 0.502
H9*2 0.110 0.490 0.380
CIO’ 02909(1) 0.4666(1) 0.4192(2)
H10C 0.260 0.496 0.348
H10D 0.355 0.486 0.450
c i r 0.1424(1) 0.3588(1) 0.4324(2)
H11C 0.172 0.329 0.504
H11D 0.078 0.339 0.400
C12' 0.1897(2) 0.3313(2) 0.3586(2)
H12C 0.190 0265 0.353
HI 2D 0.156 0.356 0285
C13' 0.2877(1) 0.3656(1) 0.4029(2)
H13C 0.316 0.350 0.352
H13D 0.323 0.336 0.473
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Bond Distances and Bond Angles
Bond Distance Bond Angle
SI -O l 1.429(2) A 0 1 - S I - 0 2 119.9(1)°
S I - 0 2 1.440(1) A 0 1 -S 1 -N 1 109.7(1)°
SI -N1 1.613(1) A 0 1 -S 1 -C 3 106.5(1)°
S1-C3 1.778(2)A 0 2 -S 1 -N 1 107.1(1)°
02  - SI - C3 105.5(1)°
N l - S l - C 3 107.5(1)°
0 1 -S I 1.429(2) A
0 2 -SI 1.440(1) A
03 - H30 0.850(30)A H30 - 03-C1 107.5(16)°
0 3 -Cl 1.319(2) A
0 4 -C l 1.224(2) A
0 S -N 2 1.232(2) A
0 6 -N 2 1.221(2) A
N l - S l 1.613(1) A S1-N1-H1N 112.3(16)°
N1-H1N 0.829(21)A S1-N 1-C2 123.0(1)°
N1-C2 1.478(3) A H1N-N1-C2 119.9(16)°
N 2 -0 5 1.232(2) A 05 - N2 - 06 125.3(2)°
N 2 - 0 6 1.221(2) A 0 5 - N 2 - C 8 117.3(2)°
N2-C8 1.465(2) A 0 6 - N 2 - C 8 117.3(1)°
C l -0 3 1.319(2) A 0 3 - C l - 0 4 123.6(2)°
C l - 0 4 1224(2) A 03 - Cl - C2 113.4(2)°
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Bond Distances and Bond Angles (continued)
C1-C2
C2-N1
C2-C1
C2-C9
C2-C10
C3-S1
C3-C4
C3-C8
C4-C3
C4-H4
C4-C5
C5-C4
C5-H5
C5-C6
C6-C5
C6-H6
C6-C7
C7-C6
C7-H7
C7-C8
1331(3) A 
1.478(3) A 
1.531(3) A 
1.548(2) A 
1.538(3) A
1.778(2) A 
1.391(2) A 
1.394(3) A 
1.391(2) A 
0.950 A 
1.389(3) A 
1.389(3) A 
0.950 A 
1.381(3)A 
1.381(3) A 
0.951 A 
1.386(2) A 
1.386(2) A 
0.950 A 
1.382(2) A
0 4 -C l - C2
N 1-C 2-C 1
N 1-C 2-C 9
N1 -C 2-C 10
Cl - C2 - C9
Cl -C 2-C 10
C9-C 2-C 10
S1-C 3-C 4
S1-C 3-C 8
C 4-C 3-C 8
C 3-C 4-H 4
C 3-C 4-C 5
H 4-C 4-C 5
C4 - C5 - H5
C 4-C 5-C 6
H 5-C 5-C 6
C 5-C 6-H 6
C 5-C 6-C 7
H 6-C 6-C 7
C 6-C 7-H 7
C 6-C 7-C 8
H 7-C 7-C 8
123.0(2)°
110.1(2)°
106.7(1)°
112.0( 1)°
106.9(1)°
111.5(1)°
109.4(1)°
118.5(2)°
124.1(1)°
117.2(2)°
119.3°
121.5(2)°
119.2°
120. 1°
119.9(2)°
120.0°
120. 1°
119.9(2)°
120.1°
120.3°
119.4(2)°
120.3°
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Bond Distances and Bond Angles (continued)
C8-N2 1.465(2) A N 2-C 8-C 3 1213(1)°
C8-C3 1.394(3) A N 2-C 8-C 7 116.7(2)°
C8-C7 1.382(2) A C 3-C 8-C 7 122.1(1)°
C9-C2 1.548(2) A C2-C9-H9A 109.3°
C9 - H9A 0.990 A C2-C9-H9B 1092°
C9 - H9B 0.989 A C2-C9-C11 111.8(1)°
C9-C11 1.532(3) A H9A-C9-H9B 108.0°
H9A-C9-C11 109.2°
H9B-C9-C11 109.3°
C10-C2 1.538(3) A C2-C10-H10A 109.4°
C10-H10A 0.989 A C2-C10-H10B 109.5°
C10-H10B 0.990 A C2-C10-C13 111.2(1)°
C10-C13 1.531(3) A H10A-C10-H10B 108.0°
H10A-C10-C13 109.4°
H10B-C10-C13 109.4°
C11-C9 1.532(3) A C9-C11 -H11A 109.2°
C ll -H11A 0.989 A C9-C11 -H11B 109.2°
C11-H11B 0.990 A C9-C11-C12 111.9(2)°
C11-C12 1.521(3) A H11A-C11 -H11B 107.9°
H11A-C11 -C12 1092°
H11B-Cll -C12 109.3°
C12-C11 1.521(3) A C ll -C12-H12A 109.4°
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Bond Distances and Bond Angles (continued)
C12-H12A 0.990 A C ll -C12- H12B 109.4°
C12 - H12B 0.990 A C ll -C12-C13 111.4(2)°
C12-C13 1.524(2) A H12A-C12 - H12B 108.0°
H12A-C12-C13 109.4°
H12B-C12-C13 109.3°
C13-C10 1.531(3) A C10-C13 -C12 111.4(2)°
C13-C12 1.524(2) A C10-C13 -H13A 109.4°
C13-H13A 0.990 A CIO -C13 - H13B 109.4°
C13-H13B 0.990 A C12-C13-H13A 109.3°
C12-C13 -H13B 109.3° H13A-C13-H13B 108.0°
s r - o r 1.429(2) A 0 1 '- S I '-0 2 ’ 120.1(1)°
8
I
a> 1.436(1)A O l '- S l '-N l ' 109.6(1)°
S l’ -N l’ 1.604(1) A 0 1 '-S 1 ’-C3' 106.9(1)°
S l’ -C3’ 1.781(2) A 02’-S l’-N l' 106.6(1)°
02’- S l ’-C3’ 105.3(1)°
N 1'-S1 '-C 3’ 107.8(1)°
o r - s r 1.429(2) A
0 2 ’ - s r 1.436(1)A
03' - H30' 0.883(30)A H 3 0 '-0 3 ’-C l' 105.6(16)°
0 3 '-C l ' 1.314(2) A
f—
4
U18 1223(2) A
05' - N2' 1.228(2) A
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Bond Distances and Bond Angies (continued)
06' - N2' 1222(2) A
N r - s r 1.604(1) A S I'-N l'-H IN ' 117.0(16)°
N l'-H IN ' 0.828(22) A S1'-N 1'-C2' 1243(1)°
N l' - C2* 1.468(2) A H1N'-N1'-C2' 118.0(16)°
N2* - 05’ 1.228(2) A 05' - N2' - 06' 124.7(1)°
N2' - 06' 1.222(2) A 05’-N 2'-C 8’ 117.9(2)°
N2’-C8’ 1.471(2) A 06’-N 2'-C 8' 117.4(1)°
C1‘ -0 3 ’ 1.314(2) A 03’-C l’-0 4 ' 123.7(2)°
C l '-0 4 ' 1.223(2) A 0 3 '-C l'-C 2 ' 115.5(2)°
C l' - C2' 1.532(3) A 04’-C l’-C2’ 120.7(2)°
C2'-N1' 1.468(2) A N l'-C 2 '-C l’ 110.8(2)°
C 2 '- c r 1.532(3) A N l’-C 2 '-C 9’ 106.9(1)°
C2’-C9' 1.546(2) A N l'-C 2 '-C 10 ' 112.7(1)°
C2' - CIO' 1.540(2) A C l'-C 2 '-C 9 ' 107.1(1)°
C l’-C2'-C10' 110.0(1)°
C9'-C2'-C10' 1092(1)°
C3* - SI' 1.781(2) A S l'-C 3 '-C 4 ’ 118.1(2)°
C3’-C4’ 1.389(2) A S l'-C 3 '-C 8 ' 124.5(1)°
C3'-C8’ 1.398(3) A C4’-C3’-C8' 117.3(2)°
C4'-C3' 1.389(2) A C3'-C4’-H4’ 119.4°
C4' - H4' 0.951 A C3* - C4' - C5' 1212(2)°
C4'-C5' 1387(3) A H4'-C4’-C5' 119.4°
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Bond Distances and Bond Angles (continued)
C5'-C4’ 1.387(3) A C4’-C 5'-H 5' 119.9°
C5' - H5' 0.949 A C4’-C5’-C6’ 120.3(2)°
C5’-C6’ 1.390(3) A H5’-C5’-C6’ 119.9°
C6'-C5' 1.390(3) A C5’-C6’-H6’ 120.2°
C6' - H6' 0.950 A C5’-C6’-C7’ 119.6(2)°
C6'-C7' 1.384(2) A H6' - C6’ - C7' 120.2°
CT-C& 1.384(2) A C6'-C7'-H 7' 120.3°
C7'-H7’ 0.949 A C6'-C7'-C 8' 119.4(2)°
C 7-C 8’ 1.384(2) A H7' - C7' - C8' 120.3°
C8'-N2’ 1.471(2) A N2’-C8’-C3* 121.7(1)°
0
 
00 1 O OJ 1.398(3) A N2’-C8’-C7’ 116.1(2)°
C8' - C7' 1.384(2) A C3' - C8' - C7' 122.1(1)°
C9'-C2' 1.546(2) A C2' - C9' - H9'l 109.2°
C9' - H9'l 0.990 A C2' - C9' - H9'2 109.2°
C9' - H9'2 0.990 A C 2 '-C 9 '-C ll ' 112.0(1)°
C 9 '-C ir 1.528(3) A H9'l -C9’-H9’2 107.9°
H9'l -C9’-C11’ 109.2°
H O S -C y -C ll' 1092°
C10’-C2' 1.540(2) A C2' - CIO' - H10C 1092°
CIO' - H10C 0.990 A C2'-C10'-H10D 109.1°
CIO’-HIOD 0.990 A C2' - CIO' - C13' 112.4(1)°
CIO' - C13’ 1.527(3) A HIOC-CIO'-HIOD 107.8°
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Bond Distances and Bond Angles (continued)
H io c - c io ' - c n * 109.1°
HIOD-CIO'-CB* 109.1°
c i i ' - c y 1.528(3) A C9'- C ll' -H I 1C 1092°
C ll’ -H I 1C 0.991 A C 9 '-C ll’ -H I ID 1092°
C ll’ -H llD 0.990 A C9’-C11’ -C12’ 111.9(2)°
c i r - c i r 1.525(3) A H llC -C ll ’ -H llD 107.9°
H l lC - C ir - C B ’ 1092°
H 11D -C ir-C 12’ 109.3°
c i z - c i r 1.525(3) A C ll'-C 12'-H 12C 109.5°
C12' - H12C 0.990 A C ir -C 1 2 ’ -H12D 109.5°
C12’ -H12D 0.990 A C ll' -C U '-C B ’ 110.7(2)°
c i r - c u ’ 1.524(2)A H12C-C12'-H12D 108.1°
H12C - C12' - C13' 109.5° H12D-C12'-C13* 109.5°
CB'-CIO1 1.527(3) A CIO’-C B ’-CB* 111.1(1)°
C13’ -C12’ 1.524(2) A C10'-C13’-H13C 109.4°
C13' - H13C 0.990 A C10'-C13'-H13D 109.4°
C13'-H13D 0.990 A C12'-C13'-H13C 109.4°
C12’-C 13'- H13D 109.4°
H13C-C13'-H13D 108.1°
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Experimental
Crystal data
CijHisNzOfiS a = 15.9780 (12) A
Mr = 328.34 b = 14.9840 (11) A
Monoclinic c = 13.4360 (10) A
Space Group: F ljc  j8 = 113.568 (6) °
Data Collection 
7815 independent reflections 
R[F*>2o(F2)] = 0.043 
6 U  = 29.0°
Dx=  1.479 Mg m'J 
Mo Ka radiation 
A = 0.71073 A 
T -  100 fC
194
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A J. oNBS-Api(Boc)-OH
06 C9
N2 CIO
05
C17
C8 C l l
C16
C3C7 07N3
Cl 4C12
C2 Cl 502 Cl 3
C4N1 08
Cl
01
C5
C6
04
03
Coordinates
Atom X Y Z
S 0.40527(8) 0.15956(2) 0.93612(5)
01 0.5100(2) 0.13887(5) 1.04800(10)
02 0.2038(2) 0.17126(5) 0.9391(2)
03 0.6663(2) 0.02447(5) 0.9209(2)
04 0.3601(2) 0.04815(5) 0.9285(2)
05 0.2524(3) 0.20772(6) 0.6689(2)
06 0.1454(3) 0.26927(7) 0.7482(3)
07 0.8907(2) 0.08623(6) 0.41070(10)
08 1.1248(2) 0.11205(5) 0.5641(2)
195
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Coordinates (continued)
N1 0.4260(2)
N2 02692(3)
N3 0.8018(2)
Cl 0.5716(3)
C2 0.5404(3)
C3 0.5994(3)
C4 0.8353(3)
C5 0.7825(3)
C6 0.5367(3)
C7 0.5302(3)
C8 0.4530(3)
C9 0.5494(4)
CIO 0.7278(4)
C ll 0.8077(4)
C12 0.7087(4)
C13 0.9540(3)
C14 1.0210(3)
CIS 1.1620(5)
C16 0.8829(5)
C17 1.1285(6)
H1N 0.340(3)
H40 0.358(4)
0.12758(5) 0.8108(2)
0.23997(6) 0.7425(2)
0.12037(6) 0.5896(2)
0.09143(6) 0.8013(2)
0.07291(7) 0.6596(2)
0.10653(8) 0.5574(2)
0.14132(7) 0.7190(2)
0.10889(7) 0.8263(2)
0.05204(7) 0.8925(2)
0.21103(7) 0.9088(2)
0.24542(7) 0.8264(2)
0.28608(8) 0.8136(3)
0.29226(9) 0.8827(3)
0.25951(9) 0.9655(3)
0.21879(8) 0.9802(2)
0.10617(7) 0.5241(2)
0.07312(8) 03102(2)
0.03750(10) 03628(3)
0.05520(10) 0.2018(3)
0.11400(10) 02665(3)
0.1287(6) 0.756(2)
0.0218(9) 0.980(3)
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Coordinates (continued)
H2a 0.4060
H2b 0.6162
H3a 0.5869
H3b 0.5169
H4a 0.7571
H4b 0.9693
H5a 0.8693
H5b 0.7959
H9 0.4930
H10 0.7969
H ll 0.9310
H12 0.7636
H15a 1.2450
H15b 1.2384
H15c 1.0919
H16a 0.9539
H16b 0.8133
H16c 0.7934
H17a 1.2126
H17b 1.0372
H17c 12035
0.0658 0.6409
0.0462 0.6537
0.0928 0.4725
0.1323 0.5572
0.1678 0.7215
0.1493 0.7342
0.0838 0.8288
0.1241 0.9089
0.3093 0.7580
0.3197 0.8729
02644 1.0133
0.1963 1.0391
0.0295 02965
0.0490 0.4379
0.0116 0.3874
0.0456 0.1305
0.0303 0.2335
0.0783 0.1721
0.1053 02015
0.1357 02302
0.1267 0.3403
197
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Bond Distances and Bond Angles
Bond_____________Distance__________________ Bond Angle
S -O l 1.429(1) A 01 - S - 02 120.6(1)°
S -0 2 1.430(1) A O l- S - N l 107.8(1)°
S -N l 1.602(2) A 01 - S - C7 105.8(1)°
S-C 7 1.781(2) A 0 2 -S -N 1 108.2(1)°
0 2 -S -C 7 106.1(1)°
N 1 -S -C 7 107.7(1)°
0 1 - s 1.429(1) A
0 2 -S 1.430(1) A
0 3 -C6 1.223(2) A
0 4 -C 6 1.303(2) A C 6 -0 4 -H 4 0 106.8(15)°
0 4 -H 4 0 0.939(28) A
0 5 -N 2 1211(3) A
0 6 -N 2 1.219(3) A
07 - C13 1.333(2) A C 13-07-C 14 123.0(1)°
07  - C14 1.467(2) A
08 - C13 1221(2) A
N l- S 1.602(2)A S -N l - Cl 126.0(1)°
N l-C l 1.473(2)A S-N 1-H 1N 115.5(14)°
N1-H1N 0.777(20) A C1-N 1-H 1N 117.6(14)°
N 2 -0 5 1211(3) A 05 - N2 - 06 124.0(2)°
N 2 -0 6 1219(3) A 0 5 -N 2 -C 8 118.4(2)°
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Bond Distances and Bond Angles (continued)
N2-C8 1.470(3) A 0 6 -N 2 -C 8 117.6(2)°
N3-C3 1.460(2) A C 3-N 3-C 4 113.3(2)°
N 3-C4 1.453(3)A C3-N 3-C13 124.4(2)°
N3-C13 1.354(2) A C4-N 3-C13 120.5(1)°
C l-N l 1.473(2) A N l - C l - C2 106.2(2)°
C1-C2 1.537(3) A N 1-C 1-C 5 112.4(1)°
C1-C5 1.539(3) A N 1 -C l-C 6 111.9(2)°
Cl -C6 1.520(3) A C 2-C 1-C 5 109.1(2)°
C2 - Cl - C6 106.3(2)°
C5 - Cl - C6 110.6(2)°
C2-C1 1.537(3) A C l-C 2 -C 3 112.5(2)°
C2-C3 1.517(3) A Cl -C 2-H 2a 108.7°
C2-H2a 0.950 A Cl - C2 - H2b 108.8°
C2 - H2b 0.951 A C3 - C2 - H2a 108.7°
C3 - C2 - H2b 108.7°
H2a - C2 - H2b 109.4°
C3-N3 1.460(2) A N 3-C 3-C 2 109.6(2)°
C3-C2 1.517(3) A N3 - C3 - H3a 109.4°
C3 -H3a 0.950 A N3 - C3 - H3b 109.4°
C3-H3b 0.950 A C2 - C3 - H3a 109.4°
C2 - C3 - H3b 109.4°
H3a - C3 - H3b 109.5°
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Bond Distances and Bond Angies (continued)
C4-N3 1.453(3) A N 3-C 4-C 5 110.5(2)°
C4-C5 1.519(3) A N 3-C 4-H 4a 109.2°
C4-H4a 0.951 A N3 - C4 - H4b 1092°
C4 - H4b 0.950 A C5 - C4 - H4a 109.3°
C 5-C4-H 4b 1092°
H4a - C4 - H4b 109.5°
C5-C1 1.539(3) A C 1-C 5-C 4 111.9(2)°
C5-C4 1.519(3) A Cl - C5 - H5a 108.8°
C5 - H5a 0.951 A Cl - C5 - H5b 108.8°
C5 - H5b 0.949 A C 4-C 5-H 5a 108.9°
C4 - C5 - H5b 108.9°
H5a - C5 - H5b 109.5°
C 6-03 1.223(2) A 03 - C6 - 04 123.5(2)°
C 6 -0 4 1.303(2) A 0 3 -C 6 -C 1 120.3(2)°
C6-C1 1.520(3) A 04-C 6 -C 1 116.0(2)°
C 7-S 1.781(2) A S -C 7-C 8 123.6(1)°
C7-C8 1.392(3) A S-C 7-C 12 118.4(2)°
C7-C12 1.389(3) A C8-C 7-C 12 117.8(2)°
C8-N2 1.470(3) A N 2-C 8-C 7 122.1(2)°
C8-C7 1.392(3) A N 2-C 8-C 9 115.8(2)°
C8-C9 1.384(3) A C 7-C 8-C 9 122.0(2)°
C9-C8 1.384(3) A C8-C 9-C 10 118.8(2)°
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Bond Distances and Bond Angles (continued)
C9-C10 1.371(4) A C 8-C 9-H 9 120.6°
C9-H9 0.950 A C10-C9-H 9 120.6°
C10-C9 1371(4) A C 9-C IO -C ll 121.0(2)°
C IO -C ll 1.366(4) A C9-C10-H10 119.6°
C10-H10 0.950 A C ll -C10-H10 119.5°
C ll-C IO 1.366(4) A C IO -C ll -C12 1203(2)°
C11-C12 1.397(4) A C10-C11 -H ll 120.0°
C l l - H l l 0.951 A C12-C11 -H ll 119.8°
C12-C7 1.389(3) A C7-C12-C11 120.2(2)°
C12-C11 1.397(4) A C7-C12-H12 119.9°
C12-H12 0.950 A C ll -C12-H12 120.0°
C 13-07 1.333(2) A 07-C13 -0 8 125.7(2)°
C I3 -0 8 1.221(2) A 07-C 13-N 3 110.7(2)°
C13-N3 1.354(2) A 08-C 13-N 3 123.6(2)°
C 14-07 1.467(2) A 07-C 14-C 15 110.7(2)°
C14-C15 1.498(4) A 07 -C14-C16 102.7(2)°
C14-C16 1.488(4) A 07 -C14-C17 109.8(2)°
C14-C17 1.503(4) A C15 -C14-C16 111.4(2)°
C15 -C14-C17 110.6(2)°
C16-C14-C17 111.5(2)°
C15-C14 1.498(4) A C14-C15 -H15a 109.4°
C15 -H15a 0.949 A C14-C15 -H15b 109.3°
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Bond Distances and Bond Angles (continued)
C15 -H15b 0.951 A C14-C15 -H15c 109.5°
C15-H15c 0.950 A H15a-C15 - H15b 109.5°
H15a-C15 - Hl5c 109.6°
C16-C14 1.488(4) A C14-C16-H16a 109.5°
C16 -H16a 0.951 A C14-C16-H16b 109.5°
C16-H16b 0.949 A C14-C16 - H16c 109.5°
C16-H16c 0.951 A H16a-C16 - H16b 109.5°
H16a-C16 - H16c 109.5°
C17-C14 1.503(4) A C14 - C17 - HI7a 109.4°
C17 - H17a 0.950 A C14-C17-H17b 109.4°
C17 - H17b 0.949 A C14-C17 - H17c 109.4°
C17 - H17c 0.950 A H17a-C17 - H17b 109.6°
H17a-C17-H17c 109.5°
Crystal data 
C 1 7 H 2 3 N 3 O 8 S  
Mr = 429.45 
Monoclinic 
Space Group: P2\lc 
Data Collection
a = 6.8729 (2) A 
b = 29.564 (2) A 
c =  10.1549 (7) A 
0  = 94.946(4)°
4239 independent reflections 
A = 0.044 6 U  = 75.0°
Dx= 1.386 Mgm" 
Cu-Ka radiation 
A =1.54184 A 
r=294K
202
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A.4. oNBS-Lys(Z)-OH
Coordinates
Atom X Y Z
S 0.44587(7) 0.67712(2) 0.46520(10)
01 0.4531(2) 0.68197(6) 0.7285(4)
02 0.5378(2) 0.68989(6) 0.3148(4)
03 0.2694(2) 0.58453(7) 0.2571(5)
04 0.3539(2) 0.57244(6) -0.1043(5)
05 0.8200(2) 0.47620(6) 0.8214(5)
06 0.9475(2) 0.45421(6) 0.5450(4)
07 0.1068(2) 0.68812(9) 0.8071(6)
08 02359(2) 0.64832(7) 0.7029(5)
N1 0.4293(2) 0.63241(6) 0.4098(4)
N2 0.8168(2) 0.49479(7) 0.4197(5)
N3 0.1852(2) 0.67845(8) 0.6774(6)
Cl 0.4419(3) 0.61719(8) 0.1570(5)
C2 0.3451(3) 0.58965(8) 0.1150(7)
C3 0.5575(3) 0.59816(8) 0.1208(6)
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Coordinates (continued)
C4 0.5763(3)
C5 0.6926(3)
C6 0.7085(3)
C l 0.8582(2)
C8 0.3251(3)
C9 0.2178(3)
CIO 0.1358(3)
C ll 0.1598(4)
C12 0.2634(4)
C13 0.3464(3)
C14 0.9931(3)
C15 1.0614(3)
C16 1.1617(3)
C17 1.2246(3)
C18 1.1872(3)
C19 1.0859(3)
C20 1.0236(3)
H40H 0.300(3)
H1N 0.378(3)
H2N 0.850(3)
HI 0.4392
H3a 0.6148
0.56441(9) 0.2916(7)
0.54563(9) 0.2592(6)
0.51490(9) 0.4496(8)
0.47533(8) 0.6128(7)
0.70409(8) 0.3652(6)
0.70464(9) 0.4745(7)
0.72990(10) 0.3948(9)
0.75480(10) 0.2063(9)
0.75470(10) 0.0963(8)
0.72966(9) 0.1770(7)
0.42960(10) 0.7356(7)
0.39888(8) 0.6157(6)
0.38783(9) 0.7161(7)
0.35840(10) 0.6177(7)
0.33990(10) 0.4125(8)
0.35010(10) 0.3057(7)
0.37970(10) 0.4082(7)
0.5537(9) -0.097(6)
0.6235(8) 0.472(6)
0.496(1) 0.273(5)
0.6373 0.0384
0.6167 0.1511
2 0 4
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Coordinates (continued)
H3b 0.5629
H4a 0.5197
H4b 0.5697
H5a 0.7500
H5b 0.6975
H6a 0.7063
H6b 0.6487
H10 0.0632
H ll 0.1035
H12 02m
H13 0.4190
HI 4a 0.9329
H14b 1.0398
HI6 1.1892
H17 1.2939
H18 1.2313
H19 1.0590
H20 0.9537
0.5894 -0.0454
0.5457 0.2594
0.5731 0.4577
0.5645 03781
0.5346 0.0987
0.5263 0.6093
0.4968 0.4347
0.7301 0.4703
0.7723 0.1513
0.7718 -0.0361
0.7301 0.1014
0.4185 0.8274
0.4442 0.8435
0.4009 0.8584
0.3510 0.6931
0.3199 0.3421
0.3369 0.1634
03870 0.3345
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Bond Distances and Bond Angles
Bond_____________Distance Bond Angle
S -O l 1.435(2) A 01 - S - 02 118.8(1)°
S -0 2 1.427(2) A O l- S - N l 107.9(1)°
S -N l 1.598(2) A 0 1 -S -C 8 106.5(1)°
S-C 8 1.791(3) A 0 2 - S - N l 106.9(1)°
0 2 -S -C 8 105.7(1)°
N 1-S -C 8 110.9(1)°
0 1 -S 1.435(2)A
0 2 -S 1.427(2) A
0 3 -C2 1.192(4) A
0 4 -C2 1.332(4) A C 2 -04 -H 40H 103.2(21)°
04-H 40H 0.913(33)A
0 5 -C7 1.214(4) A
0 6 - C l 1.337(3) A C 7 -06 -C 14 1152(3)°
06-C 14 1.444(4) A
07-N 3 1209(4) A
08-N 3 1216(4) A
N l-S 1.598(2) A S -N 1-C 1 120.8(2)°
N l-C l 1.473(3)A S-N 1-H 1N 114.4(22)°
N1-H1N 0.759(34) A C1-N 1-H 1N 110.1(24)°
N2-C6 1.467(4) A C 6-N 2-C 7 118.4(3)°
N2-C7 1.337(4) A C6-N 2-H 2N 117.5(22)°
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Bond Distances and Bond Angles (continued)
N2-H2N 0.885(29) A C7-N2-H 2N 124.1(22)'
N 3 -0 7 1209(4) A 07 - N3 - 08 123.5(3)°
N 3 -0 8 1.216(4) A 0 7 -N 3 -C 9 1172(3)°
N 3-C9 1.477(5) A 0 8 -N 3 -C 9 119.3(3)°
C l-N l 1.473(3) A N 1-C 1-C 2 107.0(3)°
C1-C2 1.509(5) A N 1-C 1-C 3 111.4(2)°
C1-C3 1.530(5) A N1 - Cl - HI 110.9°
C l-H I 0.950 A C2-C1 -C3 112.4(2)°
C2-C1-H 1 110.0°
C3 - Cl - HI 105.3°
C 2 -0 3 1.192(4) A 03 - C2 - 04 124.4(3)°
C 2 -0 4 1.332(4) A 03 -C2-C1 124.5(3)°
C2-C1 1.509(5) A 04 -C 2-C 1 111.1(3)°
C3-C1 1.530(5) A Cl - C3 - C4 113.0(3)°
C3-C4 1.511(5) A Cl - C3 - H3a 108.6°
C3 - H3a 0.950 A Cl - C3 - H3b 108.6°
C3 - H3b 0.951 A C4 - C3 - H3a 108.6°
C4 - C3 - H3b 108.5°
H3a - C3 - H3b 109.5°
C4-C3 1.511(5) A C 3-C 4-C 5 1132(3)°
C4-C5 1.531(5) A C3 - C4 - H4a 108.6°
C4-H4a 0.950 A C3 - C4 - H4b 108.5°
2 0 7
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Bond Distances and Bond Angles (continued)
C4-H4b 0.950 A C 5-C 4-H 4a 108.5°
C5 - C4 - H4b 108.5°
H4a - C4 - H4b 109.5°
C 5-C4 1.531(5) A C 4-C 5-C 6 109.8(3)°
C5-C6 1.496(5) A C4 - C5 - H5a 109.4°
C5 - H5a 0.950 A C4 - C5 - H5b 109.4°
C5 - H5b 0.950 A C6 - C5 - H5a 109.4°
C6 - C5 - H5b 109.3°
H5a - C5 - H5b 109.5°
C 6-N 2 1.467(4) A N 2-C 6-C 5 112.0(3)°
C6-C5 1.496(5) A N2 - C6 - H6a 108.9°
C6 - H6a 0.950 A N2 - C6 - H6b 108.8°
C6 - H6b 0.950 A C 5-C 6-  H6a 108.8°
C 5-C 6-H 6b 108.9°
H6a - C6 - H6b 109.5°
C 7 -0 5 1.214(4) A 0 5 -C 7 -0 6 124.1(3)°
C 7 -0 6 1.337(3) A 0 5 -C 7 -N 2 1253(3)°
C 7-N 2 1.337(4) A 0 6 -C 7 -N 2 110.7(3)°
C 8-S 1.791(3) A S -C 8 -C 9 127.0(2)°
C8-C9 1.398(5) A S-C 8-C 13 114.7(3)°
C8-C13 1375(5) A C9-C8-C13 118.0(3)°
C9-N3 1.477(5) A N 3-C 9-C 8 122.8(3)°
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Bond Distances and Bond Angles (continued)
C9-C8 1.398(5) A N 3-C 9-C 10 116.3(3)°
C9 - CIO 1.377(5) A C 8-C9-C10 120.9(3)°
CIO - C9 1.377(5) A C9-C10-C11 119.5(4)°
CIO -Cl 1 1.367(6) A C9-C10-H10 120.3°
C10-H10 0.949 A C11-C10-H10 120.2°
C11-C10 1.367(6) A C10-C11-C12 120.7(4)°
C11-C12 1.360(7) A C10-C11 - H ll 119.7°
C l l - H l l 0.950 A C12-C11 -H ll 119.6°
C12-C11 1.360(7) A C ll -C12-C13 120.1(4)°
C12-C13 1.383(5) A C ll -C12-H12 120.0°
C12-H12 0.948 A C13 -C12-H12 119.9°
C13 - C8 1.375(5) A C8-C13-C12 120.8(3)°
C13-C12 1.383(5) A C8-C13-H13 119.6°
C13-H13 0.950 A C12-C13 -H13 119.6°
C 14-06 1.444(4) A 06-C 14-C 15 108.6(3)°
C14-C15 1.488(5) A 06 - C14 - H14a 109.6°
C14-H14a 0.949 A 06 - C14 - H14b 109.7°
$SB1TfrHu 0.950 A C15 -C 14- H14a 109.9°
C15-C14 1.488(5) A C14-C15-C16 1202(3)°
C15-C20 1.379(5) A C16-C15-C20 118.0(3)°
C16-C15 1.358(5) A C15 -C16-C17 121.9(3)°
2 0 9
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Bond Distances and Bond Angles (continued)
C16-C17 1.373(5) A C15 -C16-H16 119.0°
C16-H16 0.951 A C17 -C16-H16 119.1°
C17-C16 1.373(5) A C16-C17-C18 119.7(3)°
C17-C18 1.356(5) A C16-C17-H17 1 2 0 2 °
C17-H17 0.950 A C18-C17-H17 1 2 0 2 °
C18-C17 1.356(5) A C17-C18-C19 120.2(3)°
C18-C19 1.375(5) A C17-C18-H18 119.8°
C18-H18 0.949 A C19-C18-H18 119.9°
C19-C18 1.375(5) A C18-C19-C20 1192(3)°
C19-C20 1.382(5) A C18-C19-H19 120.4°
C19-H19 0.951 A C20-C19-H19 120.5°
C20-C19 1.382(5) A C15-C20-H20 119.5°
C20-H20 0.951 A C19-C20-H20 119.6°
Crystal data
C2 0H2 3N3O8S a = 11.8092 (13) A Dx = 1.391 Mg m 3
M r- 465.49 b = 34.832 (4) A Cu-Aa radiation
Orthorhombic c = 5.4033 (6 ) A A = 1.54184 A
Space Group: P2{2\2 V - 2 2 2 2 . 6  (7) A T - 296 K
Data Collection
2680 independent reflections
R = 0.039 flU* = 75.0°
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A3. oNBS-Aib-NCA
04
C40 3
N2 C5
C8
C7
C9
C6 C2 0 602 C3
0 5C11C10
0 7
Coordinates
Atom X Y Z
S 0.38287(3) 1.00000 022477(3)
01 026310(10) 1.0866(2) 0.14078(9)
02 0.55330(10) 1.0747(2) 0.25570(10)
03 0.0169(2) 0.7683(3) 0.1517(2)
04 0.0698(2) 0.7896(3) -0.02220(10)
05 0.2661(2) 0.9594(2) 0.52552(9)
06 0.0771(2) 1.1794(3) 0.55930(10)
07 0.4541(2) 0.7813(2) 0.44240(10)
N1 027750(10) 0.9938(2) 0.34001(9)
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Coordinates (continued)
N2 0.1103(2)
Cl 0.1524(2)
C2 0.1565(2)
C3 0.3461(2)
C4 -0.0350(2)
C5 0.2160(2)
C6 0.4124(2)
C7 0.2888(2)
C8 0.3284(2)
C9 0.4936(3)
CIO 0.6181(2)
C ll 0.5782(2)
H4a -0.0689
H4b -0.1137
H4c -0.0386
H5a 0.3324
H5b 0.2152
H5c 0.1401
H8 0.2429
H9 0.5222
H10 0.7313
H ll 0.6648
0.7518(3) 0.07750(10)
1.1395(2) 036710(10)
1.1025(3) 0.49300(10)
0.9003(3) 0.43430(10)
1.1062(3) 0.3096(2)
1.3324(3) 0.3487(2)
0.7722(2) 0.18340(10)
0.6795(2) 0.10970(10)
0.5143(3) 0.06310(10)
0.4408(3) 0.0912(2)
0.5306(3) 0.1647(2)
0.6967(3) 0.2101(2)
0.9843 0.3234
1.1884 0.3393
1.1251 03304
13467 0.3857
1.3540 02699
1.4172 0.3788
0.4522 0.0124
0.3272 0.0596
0.4781 0.1841
0.7594 02597
2 1 2
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Bond Distances and Bond Angles
Bond_____________Distance Bond Angle
S - O l 1.421(1) A 01 - S - 02 1203(1)°
S -0 2 1.420(1) A O l - S - N l 104.8(0)°
S - N l 1.674(1) A 0 1 - S - C 6 108.7(1)°
S-C6 1.763(1)A 0 2 - S - N 1 108.4(1)°
0 2 - S - C 6 107.0(1)°
N1 - S - C6 107.1(1)°
0 1 -S 1.421(1) A
0 2 -S 1.420(1) A
0 3 -N 2 1.208(2) A
0 4 -N 2 1.222(2) A
0 5 -C2 1369(2) A C 2-0 5 -C 3 109.4(1)°
0 5 -C3 1.379(2) A
0 6 -C2 1.194(2) A
07 -C3 1.197(2) A
N l - S 1.674(1) A S -N l  -Cl 122.8(1)°
N l - C l 1.495(2) A S-N 1-C 3 120.8(1)°
N1-C3 1.365(2) A C1-N1-C3 111.9(1)°
N 2 -0 3 1.208(2) A 03 - N2 - 04 125.8(2)°
N 2 - 0 4 1322(2) A 0 3 - N 2 - C 7 1173(1)°
N2-C7 1.471(2) A 0 4 -N 2 -C 7 116.9(1)°
C l - N l 1.495(2)A N 1-C1-C2 98.5(1)°
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Bond Distances and Bond Angies (continued)
C1-C2 1.520(2) A N l - C l - C4 1122(1)°
C1-C4 1.531(2) A N1-C1-C 5 1142(1)°
C1-C5 1.520(3) A C 2-C 1-C 4 108.6(1)°
C2-C1-C5 109.8(1)°
C4-C1-C5 112.5(1)°
C 2 -0 5 1.369(2) A 05 - C2 - 06 121.2(1)°
C 2 -0 6 1.194(2) A 0 5 -C 2 -C 1 110.8(1)°
C2-C1 1.520(2) A 0 6 -C 2 -C 1 128.1(2)°
C 3 -0 5 1.379(2) A 0 5 - C 3 - 0 7 122.2(1)°
C 3 -0 7 1.197(2) A 05 - C3 - N1 109.1(1)°
C3-N1 1.365(2) A 07 - C3 - N1 128.7(1)°
C4-C1 1.531(2) A Cl -C4-H4a 109.4°
C4 - H4a 0.950 A Cl -C4-H4b 109.5°
C4 - H4b 0.950 A Cl - C4 - H4c 109.5°
C4-H4c 0.950 A H4a - C4 - H4b 109.5°
H4a - C4 - H4c 109.5°
H4b - C4 - H4c 109.5°
C5-C1 1.520(3) A Cl - C5 - H5a 109.5°
C5 - H5a 0.950 A Cl -C5-H5b 109.5°
C5 -H5b 0.951 A Cl - C5 - H5c 109.5°
C5-H5c 0.950 A H5a - C5 - H5b 109.4°
H5a - C5 - H5c 109.5°
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Bond Distances and Bond Angles (continued)
C6-S 1.763(1) A
C6-C7 1.387(2) A
C6-C11 1.385(2) A
C7-N2 1.471(2) A
C7-C6 1.387(2) A
C7-C8 1.381(2) A
C8-C7 1.381(2) A
C8-C9 1.377(3) A
C8-H8 0.950 A
C9-C8 1.377(3) A
C9-C10 1.380(3) A
C9-H9 0.950 A
C10-C9 1.380(3) A
CIO-Cll 1.381(3) A
C10-H10 0.950 A
C11-C6 1.385(2) A
Cll-C IO 1.381(3) A
C l l - H l l 0.951 A
H5b - C5 - H5c 109.4°
S -C 6 -C 7 122.7(1)°
S-C6-C11 117.3(1)°
C7-C6-C11 119.0(1)°
N2-C7-C6 121.9(1)°
N2-C7-C8 116.9(1)°
C6 - C7 - C8 121.2(1)°
C7-C8-C9 119.0(2)°
C7-C8-H8 120.5°
C9-C8-H8 120.5°
C8-C9-C10 120.6(2)°
C8-C9-H9 119.7°
C10-C9-H9 119.7°
C9-C10-C11 120.0(2)°
C9-C10-H10 120.0°
C ll -C10-H10 120.0°
C6-C11 - CIO 120.1(2)°
C6-C11-H11 119.9°
C10-C11 - H l l 119.9°
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Crystal data
CuHwNaOrS a = 7.6466 (5) A
Mr = 31428 b = 7.3302 (3) A
Monoclinic c — 11.9056 (5) A
Space Group: P2\ j8 = 96.966 (4) °
Data Collection
2703 independent reflections
R = 0.028 6 U  = 75.0°
Dx= 1.58Mgm*J 
Cu-A'a radiation 
X-  1.54184 A 
r=298K
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